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Abstract 
 
Colorectal cancer (CRC) is one of the most prevalent malignancies in the 
Western world with a 5 year survival rate of patients with metastatic disease 
of less than 10%. As such, there remains a pressing need for novel treatment 
strategies and modalities. Established treatments including anti-EGFR 
antibodies, for example cetuximab, have improved survival although 
disappointingly only 10-20% of patients obtain an objective clinical response. 
Advancing treatment modalities include oncolytic viruses (Reovirus, Vaccinia 
Virus (JX-594)), which preferentially replicate in cancer cells causing cell 
death and stimulate anti-tumour immunity, and BH3-mimetic inhibitors (ABT-
263), which antagonise the BCL-2 family of pro-survival proteins, may 
enhance CRC patient survival.  Harnessing the potential immune and anti-
cancer effects of these treatment modalities, alone and in combination, at 
primary tumour and sites of metastatic and micrometastatic (for example 
lymph nodes) disease could form the basis of successful clinical adjuvant 
strategies. 
This MD thesis aims to investigate the efficacy of two OV, Reovirus and JX-
594 vaccinia virus against CRC.  In particular, the work outlined in this thesis 
has examined whether i) Reovirus directly kills CRC cell lines with differential 
mutational status, alone or in combination with BH3-mimetics and ii) can 
activate immune effector cells to enhance killing of EGFR targeted cells in 
order to optimise the use of anti-EGFR therapy; iii) delineate the mechanism 
of cell death induced by JX-594 treated CRC cells, and iv) test the ability of 
JX-594 to activate and induce an innate immune response in the blood and 
lymph nodes. 
Studies investigating Reovirus in combination with ABT-263 and Cetuximab 
were performed. ABT-263 in combination with Reovirus demonstrated that 
this strategy did not yield enhanced killing over either agent alone, with only 
additive effects observed in a single cell line, SW620.  However, initial studies 
combining Cetuximab with OV did reveal the potential of Reovirus to increase 
EGFR-mediated ADCC against a KRAS mutant cell line, SW480, 
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demonstrating the importance of OV immune activation in combination 
therapeutic approaches.  To date, the immune potential of reovirus is well 
recognised however, less is known about the immune potential of JX-594, an 
OV currently in clinical testing at Leeds Teaching Hospitals NHS Trust.  To 
test the ability of JX594 to activate immune cell populations, healthy donor 
blood, along with blood and lymph nodes from CRC patients, were collected 
and treated with JX-594.  JX-594 treated NK cells from patient blood and 
lymph nodes demonstrated CD69 activation, enhanced degranulation and 
increased cytotoxicity against CRC cell line targets. In blood, NK cell 
activation was dependent on IFN production and the presence of CD14+ve 
monocytes however in lymph node mononuclear cells this was IFN 
independent and the mechanism remains to be elucidated.  Importantly, OV 
activation of immune effector cells known to reside in LN is encouraging for 
targeting distant micrometastatic disease. 
OV hold promise as a novel treatment modality. Direct tumour-specific lysis, 
transgene expression and the induction of tumour specific innate immunity in 
isolation, or in combination with adjunct antitumour treatment modalities, 
means that they may provide a two-pronged attack against the tumour at 
different disease sites. 
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Chapter 1  
Introduction 
1.1 Colorectal Cancer 
1.1.1 Epidemiology 
After breast and lung cancer, colorectal cancer is the third most prevalent 
cancer in the UK. However despite this it remains the second leading cause 
of cancer death1,2. Globally there were 1.36 million new cases diagnosed in 
2012 with incidence rates being reported to have increased by up to 29% since 
1975. By 2030, the burden of colorectal cancer is expected to increase to 
more than 2.2 million new cases and 1.1 million deaths.3 Bowel cancer is more 
prevalent in males than females with a lifetime risk of developing bowel cancer 
in the UK quoted as 1 in 14 in men and 1 in 19 in women4. Increasing age is 
a prominent risk factor with approximately 75% of bowel cancer cases 
occurring in patients over 65 years of age5. 
 
1.1.2 Staging 
In 1932, Cuthert Dukes (1890-1977) published his seminal paper describing 
a staging system for rectal cancer. With the addition of some small modern 
additions, his work continues to this day to provide a simple and reproducible 
method of staging colorectal malignancy providing the bedrock for prognostic 
and therapeutic strategies in the field. The four stages, are summarised in 
Table 1.1. 
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Dukes A Confined to the mucosa and submucosa 
Dukes B Invasion through the muscularis without lymph node 
involvement 
Dukes C Invasion through the muscularis with regional node 
metastasis 
Dukes D Tumour metastasis to distant sites 
Table 1.1 Dukes staging of Colorectal Cancer. 6 
 
As Dukes originally observed, there continues to be a strong association 
between disease staging and patients expected five-year survival rate. The 
overall five-year relative survival of colorectal cancer patients in England is 
50.7%, however, 93.2% of patients diagnosed with Dukes A disease survived 
five-years from diagnosis compared to only 6.6% of those with advanced 
disease (Dukes D). Whilst Dukes A cancer therefore represents a good 
prognostic outcome, currently only approximately 13% of those patients 
diagnosed with a colorectal cancer are Dukes A. With the implementation of 
national bowel screening in December 2009 this figure is set to increase 
however there remains a pressing need for novel treatment modalities to 
increase the therapeutic armamentarium to treat late stage metastatic 
colorectal cancer 5. 
 
1.1.3 Metastatic Colorectal Cancer 
The word ‘metastasis’ has its derivation in the Greek words ‘meta’ meaning 
next to and ‘stasis’ meaning placement, which translates together into change 
of place or displacement. Simplistically, the process of metastasis can be 
summarised as ‘a complex process in which a specific population of cancer 
cells within the primary can adapt to selective pressure which allow those cells 
to spread, invade and flourish in hostile, non-native environments’ 7. 
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1.1.4 Metastatic Dissemination 
In 1889, a British Surgeon by the name of Stephen Paget proposed one of the 
early theories of metastatic dissemination. His theory was based on the 
observation and analysis of 735-autopsy records of women with metastatic 
breast cancer. Paget observed that there was a non-random involvement of 
organs by associated metastatic disease that did not occur by chance and a 
result hypothesised the seed and soil theory. In this model, certain favoured 
tumour cells with metastatic activity (‘seeds’) will have a special affinity for the 
growth-enhancing milieau within specific organs (‘soil’) and therefore the site 
of metastasis will depend on the affinity of the tumour for the 
microenvironment 8. 
There has been a great body of work since then focussing on the mechanistic 
aspects of tumour spread involving tumour biology, lymphangiogenesis,  
immunology and simply the anatomical proximity of primary tumours to 
drainage systems, a good example being colon cancer metastasising to the 
liver via the portal system. It is beyond the scope of this work to review all the 
mechanistic literature, however, Ribatti and colleagues8 provide a useful 
summary of the principle components required for tumour spread. These are: 
• Neoplasms are biologically heterogeneous and contain subpopulations 
of cells with different angiogenic, invasive and metastatic properties.  
• The process of metastasis is selective for cells that succeed in 
invasion, embolisation, survival in the circulation, arrest in distant 
capillary beds and extravasation into and multiplication within distant 
organ parenchyma.  
• Metastatic outcome depends on multiple interactions of the metastastic 
cells within host homestatic mechanisms of which the tumour cells can 
escape. 
 
1.1.5 Lymph Nodes 
Cancer related mortality associated with colorectal neoplasia is inextricably 
linked to the stage of disease at diagnosis with those patients with lymph node 
metastasis found at the time of surgery demonstrating an adverse prognosis. 
Accurate radiological and histological lymph node staging is therefore crucial 
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not only for risk stratification but also to guide targeted therapeutic strategies. 
Other factors conferring a worse prognosis include peritoneal invasion, 
perforation, extramural venous invasion, incomplete resection and extensive 
extramural spread.9,10 
Of note, there is a 25% recurrence rate in patients reported to have tumour 
negative lymph nodes suggesting that nodal staging may often be inadequate 
by traditional hematoxylin and eosin (H&E) staining or alternatively other 
factors are at play.11 Focussing on lymph nodes, surgical resection 
undoubtedly plays a pivotal role on patient outcomes with a study in 2006 of 
80,000 colorectal cancer patients in the United States demonstrating that 
resection of at least 15 lymph nodes during colectomies was associated with 
a 54-month increase in the median survival of patients with node negative 
disease.12 
Treatment strategies are discussed in more detail later in this chapter. 
Typically node positive colon cancer patients (Dukes C) will receive adjuvant 
chemotherapy, the evidence for which is largely undisputed with adjuvant 
treatment in this patient cohort proving to be cost effective, while 
demonstrating a reduction in recurrence and mortality and increasing disease 
free survival.13 The role of adjuvant therapy in those patients with node 
negative disease (Dukes B) remains less clear and is based on individuals 
risk stratification. Factors that are considered may include surgical and histo-
pathological lymph node yields, levels of primary tumour extramural spread 
and most relevant to this work, the detection of occult tumour cells in the 
surrounding lymph nodes, commonly referred to as micrometastasis.14,15 
Micrometastasis are defined by the American Joint Committee on Cancer 
(AJCC) as cohesive deposits of tumour cells of 2mm or less but larger than 
0.2mm. Since the first reports regarding micrometastasis were published there 
has been fierce debate as to the prognostic impact of these cells on patient 
outcomes. Indeed, it is estimated that only 0.05% of circulating tumour cells 
may survive to initiate a metastatic focus 16. However, a recent meta-analysis 
by Sloothak and colleagues 15 concluded that the detection of micrometastasis 
was associated with an increased risk of cancer recurrence in patients with 
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stage II colorectal cancer and recommended adjuvant therapies be initiated in 
these patients. 
There is an increasing drive to use enhanced methods to increase the rate of 
detection of these cells. Serial sectioning, immunhistochemistry (IHC) using 
cytokeratin markers, reverse transcriptase polymerase chain reaction (RT-
PCR) and more recently sentinel lymph node mapping have all increased 
diagnostic yields.  Combined data from 16 studies reviewed by Sirop et al. 
(2011)17 revealed an overall micrometastasis prevalence rate of 26.5% 
(24.7% with IHC, 36.6% with RT-PCR) with most studies in the analysis 
suggesting that the presence of micrometastasis carried a worse prognostic 
outcome when compared with node negative disease. These finding are 
supported by Ueda et al. (2013) who analysed thirteen clinicopathological 
variable and 5 biological markers in stage II colorectal cancer and identified 
lymph node micrometastasis and lymphatic invasion to be independent 
prognostic factors with respect to 5 year survival in patients diagnosed with 
stage II colorectal cancer.18 
Limited data exist with regards to the benefit of treating patients with proven 
micrometastatic disease with regards to survival benefit. Interestingly, a pilot 
study of 106 patients who underwent sentinel lymph node mapping at the time 
of surgery concluded that patients diagnosed with micrometastasis, and 
treated with chemotherapy as a result of being considered as having ‘high-
risk’ disease showed improved outcomes.17 Conversely, a recent study of 
2000 colorectal cancer patients in the United States demonstrated no benefits 
of adjuvant chemotherapy in patients with stage II disease regardless of the 
presence or absence of poor prognostic features.19 
Despite mixed reports in the literature, it seems clear that traditional staging 
procedures provide insufficient information to identify those high-risk patients 
who may or may not benefit from adjuvant therapy. Minimal residual disease 
certainly acts as a strong prognostic predictor of patient survival and could be 
a used to guide and stratify individualised treatment strategies for these 
patients. Further clinical trials are certainly needed, however it is clear that the 
presence of occult disease in the form of micrometastasis in lymph nodes or 
- 6 - 
simply circulating tumour cells could provide exciting new targets for novel 
treatment strategies.20 
1.2 The Immune System 
1.2.1 General Principles 
The immune system is an organisms primary defence system and comprises 
of an array of biological processes and structures that allow an organism to 
protect itself against disease. Fundamentally the immune system works by 
distinguishing ‘self’ from ‘non-self’. The immune system consists of two basic 
arms, the innate and adaptive immune response. Functioning as ‘the first line 
of defence’, the innate immune response is non-specific with no immune 
memory and responds to foreign stimuli in a generic fashion. Adaptive 
(acquired) immunity creates immunological memory following an initial 
response to a specific pathogen. Accordingly, subsequent encounters with the 
same pathogen are met with an enhanced or primed host response. Adaptive 
immunity is the basis of vaccination, whereby a low volume pathogenic trigger 
primes immunological memory and lasting immunity.21 
Broadly speaking the innate immune system initiates an acute primary 
inflammatory response stimulated and regulated by a range of cytokines, 
prostaglandins and complement proteins. Inflammation acts as a physical 
barrier against the spread of infection and promotes healing of damaged 
tissues following pathogenic clearance. Antigen presenting cells including 
dendritic cells (DC’s) and macrophages, express pattern recognition receptors 
(PRR’s) such as Toll-like Receptors (TLR) or RIG-1 like receptors (RLR) on 
their cell surface, in endosomes and within their cytoplasm. PRR’s recognise 
specific small molecular motifs expressed by foreign pathogens known as 
pathogen associated molecular patterns (PAMPS) and/or biomolecules 
(nuclear or cytosolic proteins, tumour DNA, HMGB-1) released outside cells 
or exposed on the surface of cells following tissue damage, known as 
damage-associated molecular patterns (DAMPS). Receptor activation by a 
PAMP/DAMP triggers a plethora of signalling cascades leading to gene 
transcription, release of inflammatory mediators and immune cell recruitment 
and activation.22 
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The adaptive immune response is highly pathogen specific, creates 
immunological memory and provides long lasting cell protection. The adaptive 
system uses specialised leukocytes derived from multipotent haematopoetic 
stem cells of the bone marrow called lymphocytes. Two broad classes are 
responsible for the antibody (humoral) response and the cell-mediated 
response, B cells and T cells, respectively. Adaptive immunity relies on the 
capacity of immune cells to distinguish between so called ‘self’ and foreign 
antigens. Antigens, are recognised by major histocompatibility complex 
(MHC) and professional APC’s such as DC, B-cells and Macrophages. MHC 
class I and II molecules found on the surface of APCs mediate the process of 
antigen presentation. MHC class I and class II are similar in function and act 
to deliver short peptides to the cell surface for recognition by cytotoxic CD8+ 
and helper CD4+ T cells respectively. Endogenous (intracellular) peptides bind 
to MHC-I and exogenous (extracellular) peptides bind to MHC-II. APC’s 
express antigen MHC complexes, along with co-stimulatory ligands on their 
cell surface which are recognised by specific T-cell receptors (TCR) to activate 
specialist T-cell subgroups as described above.  
Virus infection triggers an endogenous antigen response secondary to 
intracellular viral replication. After virus destruction, viral antigens are 
presented to naïve cytotoxic T cells by coupling of their TCR with a peptide 
bound MHC class I leading to activation of cytotoxic CD8+ T lymphocytes 
(CTL). Effector CTL release perforin and granzyme leading to apoptosis and 
cell death. 
Exogenous antigens (bacteria and toxins) are engulfed by DC which migrate 
via chemotactic signals to lymph nodes rich in T cells. Following a process of 
maturation and pathogenic destruction, DC’s display the non-self antigen on 
their surface and form an MHC:antigen complex (MHC-class II for exogenous 
antigens) which activates a CD4+ T Helper 1 (TH1) or T Helper 2 (Th2) cell 
response depending on the antigen (Figure 1.1).  Helper T cells release 
interleukins amongst other cytokines, which stimulate B cells to  produce 
antibodies.   
Humoral, adaptive immunity is governed by B cells which are the major cell 
type involved in the creation of immunoglobulins. B cells express a unique B 
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cell receptor (BCR) which recognise antigens in their native form and trigger 
a series of events leading to antibody production by terminally differentiated 
plasma cells. Antibodies recognise unique antigens and form antigen-
antibody complexes which coordinate the induction of several cell death 
mechanisms. Mechanisms include agglutination, activation of the complement 
cascade causing inflammation and cell lysis, opsonisation which enhances 
phagocytosis, ADCC (see section 1.2.3.2) and neutralisation.23 
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Figure 1.1 The Innate and Adaptive Immune Response; An Overview. 
Innate immune mechanisms include the production of cytokines and the activation of 
antigen-presenting cells (macrophages and dendritic cells) and natural killer (NK) 
cells. Antigens are degraded into smaller peptides in endosomes/lysosomes in the 
APCs and are subsequently expressed on the cell surface in MHC class II peptide 
complexes, which can be recognized by CD4+ T helper lymphocyte cells. T helpers 
assist B cells to proliferate and mature into antibody-producing plasma cells. DCs 
can also present epitopes to CD8+ T cells. This is also known as cross-presentation. 
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1.2.2 Cancer and the Immune System 
The role of the immune system in cancer has been the subject of debate for 
many years after it was first highlighted by Virchow et al. over 150 year ago. 
In his studies, Virchow made the crucial observation that certain cancers 
resulted in inflammation that were inherently associated with white blood cells. 
Thereafter, numerous reports of spontaneous tumour regression relating to 
acute concomitant infections (influenza, smallpox, tuberculosis, hepatitis and 
gonorrhoea) were published.24,25 Following the observation of tumour 
regression in a patient with streptococcal infection in an ulcerated tumour, 
William Coley, the ‘Father of Immunotherapy’ embraced the potential 
relationship between cancer and the immune system. His experiments 
involved directly injecting tumours or metastatic deposits with a so called 
‘vaccine’ containing a mixture of Gram negative (Serratia marcescens) and 
Gram-positive (Streptococcus pyogenes) bacteria. Coley’s Toxin was 
reported to cause spontaneous regression in several tumours including 
lymphoma and sarcoma, however despite some positive results, treatment 
related deaths, reporting inconsistencies, and poorly controlled experimental 
design led to general criticism and disbelief from the wider scientific 
community.25,26 In the last 30 years rapid advances in the understanding of 
immunooncology has validated many of Coley’s initial observations with 
respect to the interplay between cancer pathogenesis and immune activation.  
With regard to cancer, for the immune system to discriminate between self 
and non-self and mount an appropriate response it must be able to recognise 
differences in the antigenic make-up between transformed cells such as 
tumours, and normal cells. As such the underlying relationship between 
cancer and immunity, is for the immune system to survey for the development 
of malignancy and eliminate tumour cells when they arise. The three principals 
involved include detection of non-self-antigens from malignant cells, effector 
functions to target and destroy the malignant cell whilst protecting the host, 
and the development of immunological memory via the adaptive immune 
response. However, cancer cells arise from normal host cells and as such are 
recognised by the immune system as self or altered self-antigens. 
- 11 - 
As a direct result, the immune system is now thought to play a dual role in 
cancer, the paradigm known as immunoediting, which provides a positive and 
negative balance of immune surveillance, encompassing the recognition of 
altered self and tumour elimination with cancer progression.27 The multi-
faceted mechanism consists of three phases, elimination, equilibrium and 
escape where the immune system can suppress tumour growth by destroying 
or inhibiting tumour cell development, and promote tumour progression either 
by selecting for tumour cells with acquired resistance or genetic modification, 
or enhancing conditions within the tumour microenvironment that facilitate 
tumour growth.28 
One of the hallmarks of cancer is the ability of cancer to evade or escape 
immune response embodied by both host and tumour related mechanisms. 
Failure to mount an effective anti-tumour immune response has obvious 
sequelae for the patient in the form of tumour progression but also, 
significantly presents one of the key factors which limits the efficacy of anti-
cancer immunotherapies. Several important mechanisms exist by which 
tumours evade an immune response and are summarised below. 
 
1.2.2.1 Reduction in expression of cell surface antigens 
Loss of antigen expression and resultant reduction in overall immunogenicity 
results from tumour cell genome instability. Genetic mutations lead to a 
passive loss of MHC-1 expression resulting in tumours avoiding recognition 
by specific TCR and reduced sensitivity to cytotoxic T cell mediated lysis. 
Interestingly, Rees et al. (1999)29 described the loss of all MHC-1 molecules 
in some colorectal and prostate malignancies, render tumour cells completely 
unrecognisable by CTL’s, but instead make the tumour more susceptible to 
NK-cell mediated killing. Complete loss of MHC-1 expression is rare and more 
commonly human tumours downregulate their expression to approximately 
50% conferring an overall tumour cell survival benefit.30 
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1.2.2.2 Modulation of immune cell killing mechanisms 
Three distinct processes ultimately induce immune cell killing of tumour cells 
which include i) formation of death-inducing signalling complexes leading to 
apoptosis (eg binding of Fas Ligand (FasL) to Fas Receptor (FasR); ii) binding 
of tumour necrosis factor related apoptosis inducing ligand (TRAIL) to tumour 
necrosis factor related apoptosis inducing ligand receptor (TRAIL-R) and iii) 
the release of perforin and granzyme from cytotoxic granules.31 
Metastatic CRC cells amongst others have been reported to show decreased 
and/or mutated levels of FasR and TRAIL-R on their cell surface resulting in 
tumour cell protection.31 Interestingly, recent data has demonstrated 
upregulation of FasR in various tumour types which whilst making tumours 
more susceptible to Fas-mediated apoptosis is conversely thought to 
upregulate cell proliferation and differentiation, chemokine production and 
inflammatory responses through a series of non-cytotoxic, non-apoptotic 
signalling cascades leading to the promotion of tumour growth.31 
Furthermore, with respect to Fas-mediated tumour immune protection, 
O’Connell et al. (1997) first described the so call ‘Fas Counterattack’ 
mechanism of immune escape in colon, melanoma, and liver cancer cells 
which relates to the active killing of Fas-sensitive tumour infiltrating 
lymphocytes (TIL) by tumour derived FasL thereby imparting an ‘immune 
privilege’ on the tumour.32 Several findings support this theory including i) 
various cancer cell lines have been shown to express FasL and kill 
lymphocytes through Fas-mediated apoptosis in vitro; ii) human cancers are 
known to express variable amounts of Fas-L, and iii) inducing FasR-mediated 
apoptosis of activated leukocytes results in immune tolerance and gives 
immunological protection to the tumour as demonstrated in animal allograft 
transplantation models.32–34 
 
1.2.2.3 Modification of the tumour microenvironment 
Tumour can evade NK cell-mediated innate immune cell death by shedding 
NK ligands (e.g. NKG2D ligands; MICA, MICB and RAET/ULBP proteins) into 
the tumour microenvironment and as such avoiding NK cell recognition 
pathways. Salih et al. (2008)35 reported that in a variety of tumours, release of 
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NKG2DL had been observed to interfere with NKG2D-mediated tumour 
immunity. Mechanisms of NK cell escape utilised by tumours include a 
reduction of ligand density on the tumour cell surface, decreased expression 
of NK receptors (described below) and blocking of the NKG2D-binding site.36 
 
1.2.3 Components of the immune system 
There are multiple vital components of the immune system which fall beyond 
the scope of this study. However, to understand this work it is important to 
explore the function of natural killer cells and immunoglobulins in more detail. 
 
1.2.3.1 Natural Killer Cells 
Natural killer cells are a specialized population of granular lymphocytes that 
are highly cytotoxic to both tumour cells and virus-infected cells. NK cells act 
as the first line of defense against viral infections preceding the development 
of an antibody response and produce significant levels of cytokines and 
chemokines (IFN-α, IFN-β, IL-12, IL-18).37 Activation is dependent on cytokine 
production with IFN-α and β acting as potent inducers of NK-cell mediated 
cytotoxicity, and IL-12 resulting in production IFN-γ which induces an antiviral 
state.  The response is regulated by a selection of activating (CD16, NKG2D, 
NKp30, NKp44, NKp46) and inhibitory receptors, which recognise MHC class 
I and MHC-like molecules on the surface of target cells. Tumour cells, and 
virus infected cells therefore become a natural target for NK cells as a result 
of them down-regulating MHC in order to evade the host adaptive immune 
response.38–40 
Given the early activation of NK cells in response to a virus challenge, one 
would expect NK cell inhibition or depletion to enhance intratumoural spread 
of an oncolytic virus and enhance tumour killing though lytic pathways. 
Several studies have indeed validated this theory. Replication, tumour 
necrosis and animal survival was significantly enhanced following VSV 
infection in an in vivo model of rats bearing intrahepatic multifocal 
hepatocellular carcinoma (HCC) after antibody mediated depletion of NK 
cells.41 A second study showed that HSV activated NK cells preferentially 
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lysed HSV-infected glioblastoma cells, a process that was dependent on NK 
cell natural cytotoxicity receptors (NCRs) such as NKp30 and NKp46. In the 
absence of these receptors (NCR(-/-) knockout mice) HSV titres and efficacy 
increased.42  
Conversely, other studies have reported an anti-tumoural effect of NK cells 
after oncolytic viral treatment. Prestwich et al. (2009) compared the direct 
oncolytic effect of Reovirus in the resistant murine melanoma cell line, 
B16ova, compared with the parental cell line, B16. Resistance of B16ova was 
thought to be due to the absence of the Reovirus receptor, JAM-1, and 
unsurprisingly Reovirus replication was not detectable after subcutaneous 
injection of B16ova tumours in mice. Despite this, B16ova tumours regressed 
in vivo, in an NK cell dependent fashion. Further in vitro studies by the same 
group, loaded dendritic cells (DC) with Reovirus infected Mel888 cells known 
to secrete a broad range of chemokines, causing NK cell migration. The 
resultant secretion of IFN-β stimulated NK cell-mediated cytotoxicity of the 
Mel888 cells and concurrent NK cell recruitment caused DC maturation. Both 
studies together reinforce the role of NK cells in an innate anti-tumoural 
response.43,44  
The complex interplay of NK cells in response to viruses serves to adequately 
highlight just some of the challenges faced in optimising potential oncolytic 
therapies. On one hand the innate immune response is seen as inhibitory to 
therapeutic efficacy acting to quash desired viral replication and cell lysis. 
However counter-intuitively an ever-increasing body of data exists highlighting 
the important role of oncolytic viruses to induce innate and adaptive immune 
responses against the tumour thereby increasing their overall therapeutic 
effect. 
 
1.2.3.2 Antibody-Dependent Cell Cytotoxicity (ADCC) 
ADCC is a mechanism of cell-mediated immune defence in which immune 
effector cells (NK cells, monocytes/macrophages, neutrophils, dendritic cells) 
actively lyse target cells (tumour cells, cells infected with intracellular 
pathogen) whose membrane antigens have been bound by specific antibodies 
(belonging to IgG, IgA or IgE classes). ADCC contributes to the clearance of 
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infected or foreign cells via the innate and acquired immune system.45 ADCC 
mechanisms vary depending on the effector cells that are recruited by 
antibodies but broadly follow a similar path.  Initially, the Fab region of an 
antibody recognises and binds to a specific antigen found on the surface of a 
target cell and the Fc region of the antibody binds to Fc𝛾 receptors (Fc𝛾R) on 
effector cells. The target cell-antibody-effector cell complex activates effector 
cells and results in the release of preformed cytotoxic factors, such as perforin 
and granzyme, which destroy target cells. Synchronous immunoregulatory 
cytokine and chemokine release from the activated effector cell further 
mediates the development of an immune response. 
The majority of ADCC research has involved the use of peripheral blood 
mononuclear cells (PBMC’s) in which NK cells are the main effector. The most 
common Fc𝛾R expressed by NK cells is CD16 (Fc𝛾RIII) which binds to IgG 
bound to the surface of target cells (infected with pathogen or Ab-targeted 
cancer cells). Antibody-dependent NK-mediated killing occurs via several 
complimentary pathways: 1) exocytosis of cytotoxic granules; 2) TNF family 
death receptor signalling leading to apoptosis and 3) pro-inflammatory 
cytokine release, for example IFN-𝛾. IFN-𝛾 release is reported to inhibit cell 
proliferation, promotes antigen presentation, increase angiogenesis, increase 
MHC surface expression and contribute to the upregulation of TRAIL 
expression on NK cells which work synergistically to promote tumour/infected 
cell death.46,47 Less is known about ADCC by non NK-cell populations in 
peripheral blood and mucosal compartments. However, antibody-dependent 
cell phagocytosis (ADCP) has been described for phagocytic immune cell 
populations such as DC, monocytes and macrophages.48,49 
ADCC is a rapid effector pathway whose efficacy is strongly dependent on a 
number of variables including the density and stability of the antigen and both 
antibody affinity and FcR-binding affinity. For example, ADCC involving 
human IgG1 (the most utilised class by therapeutic antibodies) is highly 
dependent on the glycosylation profile of the antibody Fc portion and efficacy 
is effected by Fc𝛾RIIa and Fc𝛾RIIIa polymorphisms. This variant ADCC 
activity allows scientists to modulate, enhance and mimic the effects of ADCC 
in order to develop potential novel therapeutics. Recombinant antibody 
engineering of the Fc region of IgG can optimise IgG1 antibodies for NK 
- 16 - 
binding and enhance ADCC. Similarly the use of bispecific antibodies that are 
able to bind activating molecules expressed by both tumour cells and cytotoxic 
cells can mimic classical ADCC in experimental studies.50  Also see section 
1.3. for antibody-induced ADCC. 
 
1.2.3.3 Interferons (IFNs) 
Interferons (IFNs) are secreted glycoproteins discovered by Isaacs et al. in 
1957,51 so called because they ‘interfere’ with viral replication within cells. 
They are a species-specific class of cytokine and have a potent antiviral effect, 
by allowing communication between cells to trigger the immune system to 
attack tumour and pathogens. There are three classes of IFN described; Type 
I, Type II and Type III summarised in Table 1.2. For the purposes of this thesis, 
this summary focusses largely on type I IFNs as they provide a pivotal 
component of the innate anti-viral immune response. 
 
 
Type	 Interferon	
Type	I	 IFN-α,	IFN-β,	IFN-δ	IFN-ω	IFN-κ	
Type	II	 IFN-γ	
Type	III	 IFN-λ	
Table 1.2 The three classes of IFNs. 
 
 
Type I and III interferons are secreted in response to virus infection and exert 
their effects via Type I IFN and Type III IFN receptors respectively. Type I IFN 
receptor is expressed ubiquitously whereas Type III IFN receptor has a more 
limited distribution within tissues with receptor expression limited to cells of 
epithelial origin. Type II IFN’s are secreted by activated immune cells for 
example natural killer cells (NK) and/or T-cells. Type II IFN’s role is to activate 
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macrophages and promote a cell-mediated adaptive immune response via T-
helper 1 (Th1) cells. 52 
The type I IFN response is initiated after host cell PRR such as membrane-
associated TLR and RIG-1-like receptors identify viral PAMPs, for example 
foreign cytoplasmic RNA. Activation of the PRR stimulate a signalling cascade 
that initially activates transcription factors such as activator protein-1, NF-κB 
and IFN-regulatory factor 7 before these proteins are translocated into the 
nucleus and trigger the transcription of genes encoding type I IFNs, cytokines 
and chemokines. Initial responses are driven mainly by IFN-β but switch to 
IFN-α during a subsequent amplification phase of the overall response.53 
Following secretion of the Type I IFNs, they bind to their respective receptors 
either on the same cell or neighbouring cells and trigger a Janus kinase 
(JAK)/signal transducer and activator of transcription (STAT) signalling 
cascade leading to the production of IFN-stimulated genes (ISG) which act to 
confer an antiviral state. ISGs produced include protein kinase R (PKR) which 
inhibits protein synthesis, 2’-5’-oligoadenylates synthase (OAS) which works 
to degrade cellular and viral mRNA and ISG15 which conjugates a range of 
proteins involved in the IFN response stabilising them against degradation.  
Ultimately the expression of hundreds of ISGs therefore results in a 
coordinated antiviral response leading to an antiviral state within the cell. 54 A 
schematic diagram of the IFN response is shown in Figure 1.2. 
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Figure 1.2 Schematic diagram to illustrate antiviral cell IFN response 
signalling pathway and areas in which oncolytic virus can antagonise 
the pathway.  
Virus infection is sensed by PRRs which trigger signalling cascades leading to 
activation of transcription factors NF-κB, IRF3 and AP-1. On entering the nucleus 
they stimulate transcription of the IFN-β gene. IFN-β is secreted from the cell where 
it binds to the type I IFNR on the same or adjacent cells triggering activation of the 
JAK/STAT pathway.  This leads to the assembly of the ISGF3 complex in the nucleus 
and the transcription of hundreds of ISGs. The positions where viral proteins can 
inhibit the production and/or action of IFN are denoted by red stars. This figure is 
adapted from a review by Haller et al. (2006).54 
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Whilst it is clear viruses stimulate a potent host cell innate immune response 
via the IFN pathway for successful infection to take place viruses must multiply 
extensively. Therefore, it is now evident that most viruses have developed 
means to down-regulate the host IFN response. Using Vaccinia Virus (VV) to 
illustrate this for the purposes of this report, inhibition of the IFN response is 
not only multi-mechanistic but also occurs at multiple levels with each 
individual VV protein potentially antagonising multiple pathways. Some 
mechanisms utilised by VV to evade immune clearance and allow replication 
are summarised below. 
1. Reduced production and recognition of PAMPs 
VV acts to minimise production of PAMPS primarily by minimising the 
production of dsRNA as a result of structural arrangements within the terminal 
regions of the genome. Similarly by blocking host cell protein synthesis there 
is a reduction and loss of IFN transcription. An example of this is the numerous 
intracellular proteins (A49, B14, C4, K7, M2, N1) that inhibit NF-κB activation. 
Finally the virus actively expresses proteins such as E3, which sequesters 
dsRNA via a C-terminal dsRNA binding domain thereby preventing activation 
of the dsRNA-binding PRR-induced protein signalling cascade.55,56  
2. Secretion of IFN capture proteins (Decoy receptors). 
B18R is an IFN-binding protein that acts both in solution and via 
glycosaminoglycans (GAG) at the cell surface to sequester and bind type I 
IFNs, preventing them from activating IFNR in both infected and uninfected 
cells. B18R targets IFN-α and not IFN-β which relies on more intracellular 
mechanisms. IFN-α is produced in large quantities by dendritic cells, which 
are recruited to the site of infection or inflammation and therefore requires 
neutralisation outside the infected cell.57 
3. Signal transduction inhibition 
VV blocks and antagonises signalling cascades induced by the binding of type 
I IFNs to their respective receptor complexes. An example of this is the protein 
VH1, which rapidly dephosphorylates STAT1 and STAT2 after concordant 
entry into the cell along with infecting virion.58 
4. Blocks action of intracellular ISGs 
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Within the infected cell, VV encoded proteins inhibit the actions of protein 
transcribed ISGs. Examples include the E3 protein which binds ISG15 
preventing its antiviral activity and similarly the E3 binds dsRNA to prevent the 
activation of PKR and OAS.59 
The relationship between an oncolytic virus and the innate immune response 
is complex given scientists desire for the innate immune system to mediate 
part of the viruses therapeutic efficacy. Inhibition of this innate response could 
theoretically impair potential treatment function. Indeed in VV genetically 
engineered to express IFN-β (JX-795), Kirn et al. (2007) reported that the 
generation of anti-tumour immunity resulted in improved tumour selectivity 
and efficacy when compared with controls. Similarly, engineering IFN-β into 
Vesicular Stomatitis Virus (VSV) is reported to enhance NK cell activation and 
increase inflammatory cytokine production.60,61 
Importantly, there is an active and intact antiviral innate immune response 
within normal cells but not tumour which prevents toxicity of virus 
administration. Indeed evidence suggests that severe toxicity is seen from 
both Reovirus and VSV in normal tissues when administered to IFN-α and 
IFN-β knockout mice.62 Balancing the generation of anti-tumour efficacy with 
potentially unacceptable toxicity is therefore vital to the generation of 
successful oncolytic viral agents. 
 
1.3 Epidermal Growth Factor Receptor (EGFR)  
EGFR is a cell membrane growth factor receptor tyrosine kinase which plays 
a critical role in the control of key cellular transduction pathways including 
promoting cell proliferation and opposing apoptosis in both normal and 
cancerous cells. EGFR is commonly upregulated in various cancers including 
metastatic colorectal cancer.63 Overexpression of EGFR is linked to the 
promotion of cancer progression with EGFR levels being shown to predict 
tumour grade, relapse rates and patient prognosis.64,65 
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EGFR mediated signal transduction is complex and beyond the scope of this 
work to detail in full, however Figure 1.3 shows a summary of EGFR induced 
and KRAS mediated signalling pathways.  
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Figure 1.3 EGFR-induced and KRAS-mediated signalling pathways.  
A) Activation of EGFR by ligand binding and receptor auto-phosphorylation create a 
docking site for the SOS/GRB2 complex, resulting in KRAS activation. KRAS then 
signals through the RAF/MEK/ERK and PI3K/AKT cascades to promote cell growth 
and suppress apoptosis. B) Cetuximab and Panitumumab, bind to EGFR preventing 
ligand binding and KRAS activation leading to growth suppression and cell death by 
inhibition of RAF/MEK/ERK and PI3K/AKT pathways. Mutant KRAS and BRAF cause 
constitutive activation of the  pathway, leading to anti-EGFR antibodies resistance,  
cell growth and survival. (Adapted from Knickelbein et al. (2015)66) 
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EGFR downstream signalling pathway are relevant given their interaction with 
anti-EGFR receptor inhibitors (discussed in section 1.3.1) used for the 
treatment of CRC and the constitutional activation of the pathway in various 
tumour cell types, making them an obvious target for cancer-related research. 
Following EGFR activation, RAS stimulation is triggered. Activated RAS 
promotes membrane recruitment and activation of its downstream effectors. 
Over 18 effectors have been reported to be controlled by activated RAS, which 
provides the common upstream molecule of several pathways. These include 
RAF/Mek/ERK and PI3k/Akt. Four RAS proteins have been reported (NRAS, 
HRAS, KRASa and KRASb) which show varying potencies to activate the 
different cascade pathways. KRAS is considered the stronger inducer of the 
RAF/MEK/ERK pathway while HRAS induces the PI3k/Akt pathway 
preferentially.67 Importantly in human cancer, RAS demonstrates different 
mutational frequencies with KRAS reported as the most frequently mutated 
RAS isoform.68 These mutations result in constitutive activation of the proteins 
and therefore no longer require ligand binding to EGFR for activation. 
Downstream in the RAS-RAF-MEK pathway is the serine/threonine (S/T) 
kinase Raf family. Activation occurs in a complex series of events mediated 
by its interaction with RAS. As with RAS, mutation rates in RAF are high in 
certain cancers for example the BRAF mutation rates are documented as 30% 
in ovarian cancer, 27-70% in melanoma and 5-22% in colorectal cancer.69–72 
Mutations can occur at different locations in the BRAF protein but the most 
commonly reported mutation (V600E) occurs at residue number 600 and 
replaces valine with glutamic acid. The V600E mutation is present in almost 
60% of all melanoma patients73 and interestingly has recently been reported 
to be responsible for the pre-malignant transformation of benign colorectal 
polyps into serrated adenomas defining it as a marker and risk factor for the 
progression of colorectal cancer.74 
RAF phosphorylation ultimately regulates the activity of mitogen-activated 
protein kinase/ERK kinase (MEK1). Once activated, the cascade is reported 
to play a critical role in apoptosis by phosphorylating various apoptotic 
regulatory factors such as Bas, Bim, Mcl-1, caspase 9 and BCL-2. 
Furthermore the pathway also influences cell cycle regulation, cell 
differentiation, migration, metabolism and proliferation.75 
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PI3K can also be activated as a result of ligand binding to EGFR. The 
signalling cascade induced ultimately recruits Akt, the primary mediator of 
PI3K-initiated signalling. Akt acts to mediate both the activation of certain 
substrates (CREB) or the inactivation of others (BRAF, Bim, BAD and 
Procaspase 9). Interestingly, the pathway also includes several phosphatases 
which inhibit the growth-promoting effect of PI3k by removing phosphates 
from PIP2 and PIP3 as such the genes encoding them (e.g. PTEN) are 
referred to as tumour suppressor genes. 
 
1.3.1 Anti- EGFR Receptor Inhibitors 
Two pharmacological approaches have been delineated to target and inhibit 
EGFR functions for cancer treatment, which include anti-EGFR monoclonal 
antibodies and small molecule tyrosine kinase inhibitors (not discussed 
further). Anti-EGFR antibodies are competitive antagonists against EGFR 
which act by occluding the ligand binding region of the extracellular binding 
domain. Anti-EGFR monoclonal antibodies are highly selective, recognising 
EGFR exclusively, however resistance to these agents is well documented 
and is thought to relate to constitutive activation of downstream mediators as 
a result of mutational variations. In an unselected patient cohort only 10% will 
be responsive with mutations in the KRAS gene, causing constitutive pathway 
activation and treatment failure accounting for up to 40% of resistant 
patients.76 
To date two anti-EGFR monoclonal antibodies, cetuximab and panitumumab 
are in mainstream use for metastatic CRC therapy.  
 
1.3.1.1 Cetuximab 
Cetuximab (Erbitux™) is a chimeric monoclonal IgG1 antibody composed of 
variable regions (Fv) of a murine anti-EGFR antibody, which displays high 
affinity for EGFR, and a constant region (Fc) of a human IgG1 kappa 
immunoglobulin. Cetuximab is now in widespread clinical use with evidence 
supporting the first and second line use of Cetuximab as an option for 
previously untreated epidermal growth factor receptor (EGFR)-expressing, 
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RAS wild-type, metastatic colorectal cancer in adults in combination with 
either FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) or FOLFIRI (5 
fluorouracil, folinic acid and irinotecan) and third-line as a monotherapy.77 
Importantly in this patient cohort, retrospective biomarker analysis confirmed 
KRAS mutation status as an effective predictive biomarker although 
disappointingly the authors were unable to draw any definitive conclusions 
with respect to BRAF mutation status due to the small numbers of BRAF 
mutant genotypes found in the cohort (11 of 309 patients).78,79 However, 
analysis of an alternative treated patient cohort comparing objective tumour 
responses, progression free survival and overall survival following Cetuximab 
or Panitumumab treatment by Nicolantonio et al. (2009) showed that in the 
presence of BRAF V600E mutations there was no response. The authors 
hypothesised that combination strategies to target both EGFR and BRAF may 
yield interesting outcomes.80 
Cetuximab’s principle mode of action is to inhibit EGFR signalling and by 
doing so reduce cell proliferation, angiogenesis and cell survival, however in 
addition Cetuximab is reported to induce ADCC (see section 1.2.3.2) by 
recruiting immune effector cells and also acts to induce apoptosis by 
increasing the expression of pro-apoptotic proteins such as Bax and caspase 
3 or by inactivating anti-apoptotic proteins for example BCL-2.81 
ADCC is triggered by the binding of the Fc region of Cetuximab, which is 
already bound via Fv regions to the target cell, to any of the Fc𝛾 receptors 
expressed by cells of the innate immune system (for example CD16 on NK 
cells). The role of specific immune cell types to the anti-tumour ADCC 
response exerted by anti-EGFR monoclonal antibodies remains unclear.  
General consensus points to NK cells being the primary immune effector with 
in vitro experiments demonstrating that Cetuximab is able to mediate NK-
dependent ADCC with the magnitude of response directly related to CD16 
(Fc𝛾RIII) polymorphism.82,83 Conflicting evidence however exists with respect 
to whether high affinity or low affinity Fc𝛾R polymorphisms are required to 
improve clinical outcomes. Studies by Bibeau et al. (2009)84 and Lopez-
Albaitero et al. (2009)83 reported longer progression free survival in patients 
with higher affinity Fc𝛾R polymorphisms in metastatic colorectal patients 
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treated with cetuximab and irinotecan. Conversely, the opposite association 
was found by Zhang et al. (2007)85 and Dahan et al. (2011)86 with better 
outcomes reported in patients with low affinity polymorphisms. Direct 
comparison, however, is limited given significant study variation in the 
underlying number of patients expressing KRAS mutations and other studies 
incorporating concurrent alternative antibody treatments alongside cetuximab. 
The impact of these variations is unknown but could arguably account for 
some of the differences seen in evaluating the impact of Fc𝛾R polymorphisms 
on Cetuximab efficacy.87 
 
1.3.1.2 Panitumumab 
Panitumumab (Vectibix™) is a humanized IgG2 kappa monoclonal antibody. 
Like Cetuximab, in the United Kingdom its use is recommended by NICE and 
the European Medicines agency for use in untreated, RAS wild-type 
metastatic colorectal cancer in adults as a monotherapy (third-line) or in 
combination with FOLFOX or FOLFIRI. There is also good evidence that the 
response to Panitmumab is also limited to only those patients with wild-type 
KRAS tumours.88 
Like Cetuximub, Panitumumab works prinicipally via competitive inhibition of 
the EGFR thus blocking downstream signalling cascades, however it also has 
been shown to activate an immune response. As an IgG2 anti EGFR antibody, 
ADCC is induced via cells of myeloid lineage (neutrophil and monocytes). 
Panitumumab  is less effective at inducing NK-dependent ADCC which is 
likely related to reduced avidity/preference of IgG2 immunoglobulins for CD16 
when compared with IgG1.89,90 
 
1.3.1.3 GA201 
GA201 is a novel anti-EGFR monoclonal antibody designed to have enhanced 
ADCC properties. GA201 was developed from the humanisation of the rat 
ICR62 antibody with the Fc region glycoengineered to contain afuscosylated 
carbohydrates to encourage enhanced binding to Fc𝛾RIIIA. Initial in vitro 
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demonstrated that GA201 had a similar efficacy to Cetuximab, inhibiting EGF 
ligand binding, downstream signalling and cell proliferation. 
Interestingly, GA201 exhibited superior binding to both high and low affinity 
variants of Fc𝛾RIIIA, which when compared with Cetuximab, resulted in 
enhanced induction of ADCC against both wild-type KRAS and mutant KRAS 
tumour cell lines. In vivo  experiments using a variety of immunocompetent 
mouse xenograft models (pancreas, colorectal and breast) also showed a 
significant therapeutic benefit of GA201 compared with Cetuximab in both 
KRAS wild-type and KRAS mutant tumours with variable EGFR expression. 
Furthermore the efficacy of GA201 was potentiated further when combined 
with Irinotecan chemotherapy.91 
With clinical responses of approximately 15% across all sub classes of anti-
EGFR monocloncal antibodies, only modest overall survival benefits when 
compared with best supportive care, and increasingly robust cost-benefit 
analysis of novel therapies being undertaken by many countries, the 
challenges are clear. The future of monoclonal antibody therapy is to identify 
biomarkers and individualise treatment strategies to allow clinicians to predict 
and target only eligible patients. Strategies should incorporate not only the 
mechanistic effects of targeting EGFR and downstream signalling pathways 
but also the potential benefit of exploiting  antibody immune potential.92 
 
1.4 Oncolytic Viruses 
1.4.1 Background 
In the late nineteenth century and into the early twentieth century cancer 
therapy as a field of medicine was wholly reliant on surgical excision with a 
clear push towards alternative treatments. Viruses as an option for the 
treatment of cancer therefore developed in a somewhat innocuous fashion 
under the observational premise that in some cases cancer patients who 
contracted an infectious disease went into brief periods of clinical remission. 
Particular examples included cases of leukaemia where it became well 
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recognised that the contraction of influenza virus could in some cases 
demonstrate beneficial effects93. 
Thereafter, throughout the 20th century viruses have been the focus of 
fluctuating attention in the quest to find novel experimental agents for the 
treatment of cancer. Interest initially peaked in the 1950’s and 60’s with the 
evaluation of the oncolytic properties of numerous viruses including 
Bunyamera, Ilheus, West Nile Virus, Semliki Forest Virus and adenovirus to 
name a few being explored in human tumour cell lines and then 
immunosuppressed rats. Proof of concept of the ‘oncolytic virus’ was driven 
by Moore et al.94 who using a novel in vivo tumour model in mice 
demonstrated that the virus, Russian Far East Encephalitis Virus, could 
selectively target and kill cancer cells (Sarcoma 180), and in some cases 
completely destroy it. Unsurprisingly, however, infection did eventually cause 
fatal encephalitis in the treated mice94,95. 
Over the next two decades little to no research progress was made, however 
in the last fifteen years developments in virology, genetic manipulation and 
molecular biology have enabled there to be a resurgence in the field. 
Recombinant technology has allowed researchers to genetically engineer 
viruses to enhance their safety profile by selectively targeting tumours cells, 
an approach first published by Martuza et al. (1991) using a herpes simplex 
virus type one (HSV-1) in an experimental glioma model96. Thereafter, a huge 
wave of interest has driven both pre-clinical and clinical research. 
Investigation of viruses for oncolytic and/or anti-tumour properties, and the 
potential interactions between viruses and the immune system, continues 
unabated with clinical grade viruses now reaching phase III trials 97. 
 
1.4.2 Vaccinia Virus 
1.4.2.1 History 
Variola Virus (Variola major) is a member of the poxvirus family and for 
thousands of years was responsible for devastating epidemic outbreaks of 
smallpox and millions of deaths worldwide. The origin of smallpox as a natural 
disease has been lost in history but is believed to date back to 10,000BC. 
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Colloquially, known as ‘speckled monster’ the disease was non selective, 
affecting all levels of society and in Europe alone in the 18th century was 
responsible for 400,000 deaths annually and a fatality rate of up to 60% in 
adults and 98% in children.98,99 
Throughout time it was well established that survivors of smallpox became 
immune to the disease and the practice of variolation or inoculation, by which 
a small of amount of fresh matter from an infected pustule was injected 
subcutaneously into an uninfected individual to impart immunity, became 
widely accepted practice.100 In the late 18-hundreds Edward Jenner 
discovered the protective effects of cowpox to variola virus (VARV) after 
overhearing tales of dairymaids being protected from smallpox naturally after 
having suffered from cowpox and established a vaccination against the 
disease. Based on his work, and following a worldwide vaccination campaign 
the World Health Organisation (WHO) declared smallpox to be eradicated in 
1980.101,102 The agent used for the vaccination programme was not the same 
and its exact origins are unclear. It was called vaccinia virus (VV) and 
demonstrates a close relationship to the cowpox virus suggesting that it may 
be a hybrid of cowpox and VARV.103,104 
By the 1980’s, VV had emerged as an increasingly useful adjunct for use in 
alternative biological and medical applications. Several factors enabled the 
virus to develop in this way including VV’s large double-stranded DNA 
genome, which enables insertion of up to 25 kb of foreign DNA without any 
loss of infectivity. As a direct result of its historical importance as a smallpox 
vaccine, the biology and pathogenesis of VV has been investigated 
extensively and there is a large and established safety profile for the virus. 
Finally, and importantly, VV continues to demonstrate high infection efficiency 
making them important in the field of oncolytic virotherapy.105 
A variety of recombinant viruses now exist derived from various vaccinia 
strains and continue to be heavily investigated in the laboratory, these include 
Modified Vaccinia Ankara (MVA), Western Reserve (WR), Lister (LIVP), New 
York Vaccinia Virus (NYVAC) and Copenhagen (COP). There use in a wide 
variety of solid tumours continues to show promise in a pre-clinical setting with 
several forms progressing into clinical trials. 
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1.4.2.2 Structure, Replication and Life Cycle of VV 
1.4.2.2.1 Structure 
Vaccinia virus remains one of the largest viruses to replicate within humans 
and as a result of its success as a live viral vaccine it is also one of the most 
extensively studied members of the poxviridae family.  
The vaccinia virion is a single membrane barrel-like structure measuring 320-
380nm in the long axis by 260-340nm in the short.106,107 The virion has a 
complex internal structure featuring a bioconcave core flanked by lateral 
bodies (Figure 1.4).108 The core is made up of a proteinaceous wall with pore-
like structures throughout enclosing a nucleocapsid, while the lateral bodies 
surrounding this structure are comprised of amorphous protein structures that 
to date have no known function (Figure 1.5).109,110  
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Figure 1.4 Electron micrograph of thin-sectioned vaccinia virus particles 
demonstrating an outer membrane surrounding a bioconcave core. 
(reproduced from swissinfo.ch) 
 
 
 
 
 
 
 
 
- 32 - 
DNA sequencing has confirmed that the genome consists of 191,636 base 
pairs with a basic composition of 66.6% A & T within which there are 198 
‘major’ protein-coding regions and 65 overlapping minor regions encoding a 
potential 263 genes.111 Mass spectrometry has analysed the protein 
composition of the mature virions and identified at least 70 virus proteins 
although the localization of many of these virion proteins within the genome 
remains unknown. 
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Figure 1.5 Illustrative representation of two vaccinia virion structures, 
IMV (a) and EEV (b).  
The Intracellular mature virion (a) is the most abundant form and is the first virus 
particle transcribed in the host cell. The single membrane structure has a bioconcave 
core flanked by lateral bodies. IMV’s are responsible for local cell-cell spread. The 
extracellular enveloped virion (b), develops from the IMV form and gains a second 
membrane as a result of a wrapping process undertaken in the golgi apparatus. The 
EEV’s are responsible for distant virus dissemination and the extra membrane 
covering allows the EEV’s to play a role in evasion of host innate immunity (ds; double 
stranded). 
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1.4.2.2.2 Morphogenesis and Replication 
Virion morphogenesis is a complex process ultimately leading to the 
production of two major classes of mature virion differentiated from one 
another by their number of membranes. Intracellular mature virus (IMV) has a 
single membrane and remains within the cytoplasm of the infected cell until 
cell lysis. The IMV’s are thought to be responsible for the horizontal spread of 
poxvirus and remain largely intracellular until cell lysis. The second set of 
mature virions acquire an additional wrapping from the host trans-golgi 
network, resulting in a second membrane. The so-called extracellular 
enveloped viruses, (EEV) are exported from the cell, prior to cell death by 
fusing with the plasma membrane before being released via exocytosis. The 
EEV’s are thought to be responsible for the distant spread of the virus within 
the host.112,113 Importantly, in addition to their role in dissemination, and as a 
direct result of being wrapped in a host derived membrane they play a pivotal 
role in enabling VV to evade host antibody and complement responses.114 
Unique to the poxvirus family, the entire life cycle including transcription, 
replication and virus assembly occurs within the host cell cytoplasm. Virus 
replication is initiated by the binding and entry of virions into susceptible cells. 
After direct fusion of cellular and viral membranes, the inner viral core is 
delivered by microtubules into the cytoplasmic compartment where it remains 
intact for several hours. Fusion of both types of virion is facilitated by the 
interaction of a group of virion entry/fusion proteins (A21, A28, H2 and 
L5)115,116 within the virus membrane with either glucosoaminoglycans (GAGS) 
or laminins on the cell surface.117,118 These proteins enable fusion of the virus 
to the host cell but also facilitate cell to cell spread. 
The core contains structural proteins, a tightly compacted viral DNA genome 
and various transcriptional enzymes necessary to initiate replication. Within 
several minutes of infection, the virus genome is transcribed into early 
messenger RNA (mRNA) by the virus associated DNA-dependent RNA 
polymerase. Translated proteins from these mRNA’s allow replication of virus 
DNA, and modification of the cell microenvironment to the advantage of the 
virus, enabling the virus to escape from the host innate immune response.  
Later gene transcription follows, with genes encoding for new virus particles 
and enzymes packaged into virions that initiate transcription in the next 
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infected cell.119 The immature virion (IV) is released upon cell lysis and a 
minority of virions are transported for ‘wrapping’, the addition of a second 
cellular membrane to form the EEV population.114 Host cells undergo lysis 7-
24 hours after initial infection releasing both infectious EEV and IMV forms 
with each individual infected cell yielding approximately 10,000 new viral 
particles. A summary of the life cycle is shown in Figure 1.6. 
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Figure 1.6 Illustrative overview of Vaccinia virus replication and 
lifecycle. 
There are 18 steps in the VV lifestyle which are described below: (1) Entry of EEV’s. 
(2) Core released and early mRNA synthesis. (3) Protein synthesis. (4) Secretion of 
early proteins including proliferation stimulators and immune evasion factors. (5) Viral 
DNA genome release. (6,7) Viral DNA synthesis. (8,9)Intermediate phase gene 
transcription. (10,11) Late phase gene transcription. (12,13) Formation and assembly 
of the immature virion. (14) Maturation into IMV. (15) Cell lysis and release of IMV. 
(16) Proportion of IMV’s undergo wrapping with second membrane to form 
intracellular enveloped virion (IEV). (17) IEV transported to the cell surface by 
microtubules and released via exocytosis in the form of mature EEV’s. (18) 
Membrane fusion and infection of neighbouring cells. (Figure adapted from Boyle et 
al. 2009).120 
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1.4.2.3 Vaccinia as an Oncolytic Virus 
As a result of vaccinia’s role as a vaccine in the treatment of smallpox, it has 
become the most extensively researched and understood virus for use in 
humans. A wealth of literature existed examining virus biology and 
pathogenesis in both pre-clinical and clinical settings, making it a very 
attractive proposition for developing into a potential biotherapeutic cancer 
agent. 
Vaccinia virus has several unique features that make it an ideal candidate for 
use as a potential oncolytic or immunotherapeutic agent and consequently 
there are a range of recombinant VV viruses being investigated with promising 
results. Some of these features are discussed below: 
1. VV rapidly infects, replicates and lyses target cells when compared with 
other virus species with the first viral particles reportedly released before 
8 hours of infection and cell death seen at between 48 and 72 hours.121 
 
2. VV possesses a broad tumour tropism which inherently targets tumour 
cells in a multi-mechanistic fashion. Primarily this occurs as a result of VV 
utilization of membrane fusion pathways to infect target cells.122 In addition 
tumour cell targeting is also increased by the infrastructure of the cancer 
cell mimicking that of a virally infected host cells with deregulated cell 
cycles, defective apoptotic pathways and immune evasion pathways.123 
Finally, cancer cells typically demonstrate activation of the 
EGFR/RAS/MAPK signal transduction pathway and defective anti-viral 
type I IFN responses, which support VV replication and spread. In fact, 
evidence suggests that VV targets these pathways by secretion of an EGF 
homologue, vaccinia growth factor (VGF), to activate the 
EGFR/RAS/MAPK pathway and secrete B18R to inhibit type I IFN’s.124 
 
3. VACV possesses an intrinsic ability to evade host cell defenses by utilising 
the EEV antigenic virion, therefore making it incredibly attractive for 
potential intravenous delivery. EEV cloaks itself in a host derived cell 
membrane containing various host complement proteins. This allows 
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efficient and protected virus dissemination to distant sites and also allows 
the virus to be transported unharmed in the bloodstream.125 
 
4. As a result of the size of the genome, VACV is easily amenable to genetic 
manipulation and can be armed with multiple large transgenes to enhance 
various functional aspects of the chosen therapeutic design. 
 
5. Due to the extensive historical clinical utilization of the poxviridae family 
they are considered safe in a clinical setting and do not integrate into host 
DNA due to their replication pathway. Importantly, in the event of an 
adverse outcome several antiviral agents already exist that could be 
utilised to treat patients.126 		
1.4.2.4 Virus modification strategies to enhance tumour specificity 
While Vaccinia virus has a high natural tropism for tumour cells, research has 
continued to explore different strategies to enhance tumour specific replication 
in bioengineered viruses. In JX-594, utilised in this study and discussed later, 
the genetic modifications are specifically designed to augment its natural 
intrinsic targeting, enhance tumour specific replication and potentiate the 
oncolytic potential of vaccinia virus, whilst enhancing anti-tumour immunity 
through the expression of transgenes.127 Some of the genetic modifications 
are discussed in more detail in this section. 
 
1.4.2.4.1 Deletion of Thymidine Kinase 
Thymidine kinase (TK) is an E2F-responsive gene involved in 
deoxyribonucleotide synthesis in dividing cells. Normal cells intrinsically have 
low nucleotide concentrations and therefore require TK to allow replication, 
however cancer cells constitutively express high levels of nucleotides 
rendering TK redundant in cancer cell proliferation cycle. By deleting the TK 
gene in JX-594, the virus is forced to preferentially replicate in cancer cells, 
relying on adequate concentrations of nucleotides present in host tumour 
cells. The TK-deleted virus is quickly cleared from healthy tissue which acts 
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as an additional protective mechanism against viral toxicity.128 Various models 
have validated tumour selective replication as a result of TK deletion, and 
demonstrated anti-tumour efficacy (positive results) in various animal models 
(including mouse and rabbit) including melanoma, colon cancer, sarcoma and 
liver metastasis.129–132 
 
1.4.2.4.2 Deletion of Vaccinia Growth Factor (double deleted vaccinia virus). 
Vaccinia growth factor (VGF) is a secreted 77 amino acid glycoprotein, which 
is expressed as an early phase protein in the vaccinia virus lifecycle. It is an 
epidermal growth factor (EGF) homologue that stimulates cell proliferation by 
binding to the EGF receptor (EGFR) found on both infected and surrounding 
non-infected cells. Vaccinia virus relies on the proliferation of cells for efficient 
virus production and therefore stimulates normal cells to divide using VGF. In 
contrast, cancer cells naturally proliferate making expression of VGF, to 
enhance this process, superfluous in this setting. Deletion of VGF from the 
vaccinia genome therefore enhances tumour selectivity.133 Studies of a double 
deleted vaccinia virus (ddVV), involving the combination of TK deletion with 
VGF deletion have confirmed that this is a promising tumour selective gene 
therapy vector. In vitro, resting and dividing NIH3T3 cells were infected with 
ddVV-GFP. In resting cells (those requiring VGF to divide) a reduced viral 
yield was seen when compared with control virus. In contrast, in the freely 
dividing cells (mimicking cancer cells) virus recovery was equivalent to wild 
type or single deletion variants. In vivo similar results were gained with 
improved survival and tumour specific replication observed in nude mice 
following intraperitoneal (i.p.) injection.  
 
1.4.2.4.3 Arming Vaccinia Virus with immune-stimulatory molecules 
The fact that oncolytic viruses can amplify in tumour tissue with accompanying 
transgene expression makes ‘arming’ viruses with therapeutic proteins or 
immunomodulatory molecules a potential way of enhancing anti-tumour 
efficacy and/or immunity. Various strategies have been investigated to 
enhance virus oncolytic activity. For example, secreted transgene products 
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such as the cytosine deaminase/5-fluorocytosine (CD/5-FC) have been used 
to stimulate a cytotoxic effect on neighboring non-infected cells and is 
described as so-called suicide gene system.134 An alternative strategy utilised 
is to inhibit tumour angiogenesis; in renal cell cancer models enhanced splenic 
extramedullary hamatopoieis was seen after systemic treatment with a ddVV 
armed with vascular endothelial growth factor (VEGF) receptor 1 to sequester 
VEGF and promote an antiangiogenic effect.135 Similarly, VACV encoding 
GLAF-1, a single chain antibody targeting human and murine VEGF, exhibited 
significantly enhanced therapeutic efficacy in vitro and in human xenograft 
models in nude mice.136 
 
1.4.2.5 JX-594 
There are a wide variety of recombinant viruses derived from various vaccinia 
backbones in pre-clinical and clinical testing, however for the remainder of this 
report we will focus on the experimental virus utilised, JX-594. JX-594, 
commercially known as Pexa-Vec, was initially designed and manufactured 
by Jennerex & Partners, however in 2014 the company and product was taken 
over by Sillajen Biotherapeutics Inc.  
JX-594 is an engineered targeted poxvirus with transgene ‘arming’ developed 
from the Wyeth vaccine strain (Dryvax; Wyeth Laboratories, Madison, NJ). 
The virus backbone is genetically modified to disrupt TK to enhance tumour 
selectivity and attenuation. Immune stimulation is driven by insertion of human 
granulocyte-macrophage colony-stimulating factor (GMCSF) under the 
control of an engineered early-late promoter. Finally, a lacZ transgene 
encoding β-Galactosidase (β-Gal) controlled by the p7.5 early/late promoter 
aids virus tracking.127,137 (Figure 1.7) 
To date, JX-594 is the most advanced vaccinia based oncolytic virus in the 
clinical setting, entering phase III trials with promising results. The virus has 
been given safely to over 250 patients in a selection of advanced tumour types 
and was the first virus to induce partial and complete tumour responses, be 
recovered from tumours after systemic intravenous delivery and demonstrate 
improved survival rates in randomized trials.138–140 
- 41 - 
JX-594 is highly cancer selective, although the mechanisms behind this still 
remain poorly understood. It is clear however, that it is multi-mechanistic in 
nature involving EGFR/RAS pathway signaling, cellular TK levels and cancer 
cell resistance to type I interferons.124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 42 - 
 
 
 
 
 
Figure 1.7 Schematic diagram to show modification of Wyeth strain 
vaccinia virus to construct JX-594. 
The top fragment shown represents the virus J segment, a 5.1kb section in which the 
TK gene is found. A pSC65 vector with a GM-CSF insert is inserted by homologous 
recombination into the TK gene area and results in TK gene disruption. In addition, 
the LacZ gene is inserted encoding for β-galactosidase. For experimental JX-594 
subtypes this area can be replaced with green fluorescent protein (GFP) or 
Luciferase (fLUC) to aid virus recognition in experimental models (Adapted from 
Mastrangelo et al. (1998)).137 
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1.4.3 Reovirus 
1.4.3.1 Background 
Reovirus (Respiratory Enteric Orphan Virus) is a member of the Reoviridae 
family. The virus was first isolated in 1953 from a rectal swab taken from a 
healthy human child and thereafter three serotypes were identified and 
designated into the Reoviridae family. The name Reovirus was coined later in 
1959 by Sabin et al. (1959)141 as an acronym reflecting the fact that the viruses 
in this group had been found in both the Respiratory and Enteric tracts with 
no associated disease, and as such were described as Orphan in nature.  
As mentioned, three serotypes of Reovirus have been reported based on their 
activity and are designated Type 1 Lang, Type 2 Jones, Type 3 Abney and 
Type 3 Dearing. The serotypes are all ubiquitous in both their ability to infect 
nearly every known mammalian species and their geographical distribution, 
being largely found in stagnant water and sewerage. Exposure is common, 
with anywhere between 70-100% of those investigated demonstrating 
seropositivity and 50% of adults aged 20-30 years demonstrating exposure by 
carrying antibodies against the virus.142,143 Despite these high exposure 
levels, symptoms remain very mild, with reported cases largely limited to the 
very young and are often subclinical in nature.144 Interestingly, the non-
pathogenic nature of the virus was demonstrated by Rosen et al. (1963)145 
who inoculated (intranasally) 27 volunteers in a correctional institution with 
serotypes 1,2 and 3; only 30% of those patients developed minor symptoms. 
 
1.4.3.2 Structure, Function and Lifecycle 
Reovirus is a non-enveloped virus composed of a genome of 10 segments of 
double stranded-DNA enclosed in two inner and outer concentric isosahedral 
protein capsid shells.146 The virus replicates within the cell cytoplasm and the 
10 segments of dsRNA range in length from 1.2 to 3.9 kilobases and are 
named accordingly (3 x lambda (long), 3 x mu (medium) and 4 x sigma (small) 
segments). The ten segments encode twelve viral proteins in total, eight 
structural and four non-structural (Figure 1.8).147  
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Figure 1.8 Reovirus structure 
Reovirus is a non-enveloped dsRNA virus approximately 80nm in diameter. The viral 
genome consists of 10 segments of dsRNA contained within an outer and inner 
capsid which encode for structural and non-structural proteins. Sigma-1 has been 
identified as the viral attachment protein and alongside Sigma-3 is reported to play a 
role in virulence. Mu-1, Mu-2 and Lambda-3 have roles in viral replication. Figure 
adapted from Gong and Mita (2014)148 
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Reovirus infection is initiated by the binding of the viral protein sigma 1 (𝜎1), 
a filamentous attachment protein, to junctional adhesion molecule-A (JAM-A), 
a serotype-independent, cell surface receptor.149 𝜎1 also binds to cell-surface 
carbohydrate in a serotype dependent fashion, for example, sialic acid in 
serotype 3 strains. Following attachment to the cell surface, Reovirus 
internalisation is initiated via 𝛽1 integrins which promote a clathrin-dependent 
endocytotic process.147 Within the endosome,  the virus undergoes proteolytic 
disassembly to form sub virion particles (ISVP) in the host cytoplasm and 
replication proceeds. In addition, cleavage fragment particles escape into the 
cytoplasm where they activate NF-𝜅B and modulate apoptotic cell death 
pathways. Interestingly, inhibition of these pathways using either 
pharmacological agents or via expression of transdominant forms of I𝜅B result 
in complete cessation of Reovirus-induced apoptosis suggesting a critical role 
for NF-𝜅B activation in Reovirus cell death.150 
 
1.4.3.3 Reovirus as an Oncolytic Agent 
Initial experimentation using Reovirus focused on its relatively non-pathogenic 
nature and therefore it represented a useful model to investigate viral 
replication and pathogenesis. However, in 1977 Hashiro et al.151 described 
the susceptibility of certain tumour cells and spontaneously transformed cell 
lines of human and murine origin to ‘cytotoxic Reovirus induction’.  
Furthermore, the authors also found that ‘normal’ cells were resistant to the 
virus and as such the potential for Reovirus to be used as an oncolytic agent 
was ignited. These early findings were further validated by Duncan et al 
(1978)152 who reported a differential sensitivity to infection with type 3 
Reovirus in normal and SV40-tranformed WI-38 cells. The authors reported 
complete lysis of transformed cells at 96 hours post infection compared with 
no detectable cell death in normal cells.  
 
1.4.3.4 Reovirus and Clinical Trials 
The first reported clinical use of Reovirus was in 1963 in a study to ascertain 
the clinical manifestations of the virus. All 3 serotypes were given as an 
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intranasal inoculation to healthy adult volunteers after which they were 
followed up for 23 days. There was some evidence of minor upper respiratory 
tract illness and diarrhoea but no significant clinical manifestations.145    
Following the development of Reolysin by Oncolytics Biotech Inc. (Calgary, 
Canada) a clinical grade product developed from the type-3 Dearing strain, 
Reovirus has demonstrated activity in clinical trials across a range of cancer 
types, including but not limited to breast, prostate malignant glioma, 
pancreatic, head and neck and ovarian cancers.153  Various administrative 
strategies have been explored and similarly trials have examined the virus 
when given alone and in combination with other cancer therapies.154 
The first phase 1 cancer related study (REO-001) undertaken was an open-
label study to determine the safety and tolerability of Reolysin. 19 patients with 
clinically accessible and evaluable disease of varying cancer types (head and 
neck, sarcoma, breast), who had failed to improve on standard treatment 
regimens, were given escalating doses of intratumoural virus. At the end of 
six weeks, there was a 37% local target tumour response with one patient 
exhibiting complete remission. Significantly, it was also noted that three 
patients had responses recorded in synchronous lesions distant from the site 
of primary treatment.155 
Thereafter, Reovirus has been the subject of intense investigation in the 
clinical setting with 32 clinical trials completed or ongoing. Reovirus is safe to 
use via both intralesional/intratumoural and systemic routes of administration 
in Phase I trials. In Phase II trials it has successfully reduced tumour size and 
burden and promoted tissue necrosis, validating pre-clinical data. The first 
phase III trial continues to explore the overall survival and progression free 
survival benefit of intravenous administration of Reolysin in combination with 
paclitaxel and carboplatin versus chemotherapy alone, in patients with 
metastatic or recurrent squamous cell carcinoma of the head and neck; initial 
reports are keenly awaited.  
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1.5 Oncolytic Virus and the immune system, friend or foe? 
Oncolytic viruses have emerged as attractive tools in the development of 
novel anti-cancer therapies. Historical research has focused on the direct 
cytotoxic effects of these agents and only recently has the potential role of the 
immune system in viral therapy been highlighted and become the focus of 
attention.  Understandably, initial hypothesis revolved around the immune 
system being detrimental and inhibitory to the success of virotherapy with the 
host immune system lacking the sophistication to identify the difference 
between malevolent pathogens and therapeutic agents, ultimately leading to 
viral clearance, neutralization and the negation of direct tumour cell killing. 
However, it is now a widely accepted and increasingly understood 
phenomenon that the efficacy of these therapies relies on a three-way 
interaction between the oncolytic viruses, the immune system and the tumour 
microenvironment.  Acting as an immunotherapy, viruses can prime anti-
tumour immunity, generating both innate and adaptive immune responses, 
and ultimately resulting in tumour regression. 60  
 
1.5.1 Vaccinia, JX-594 and the immune system 
The historical use of vaccinia virus during the eradication of smallpox, has 
meant that its immune activating potential is well understood and documented. 
Furthermore, the clinical progress of clinical grade vaccinia virus, such as 
GMCSF expressing JX-594, has allowed the potential for this virus to target 
the immune response and enhance virotherapy to be well explored.  
The first significant report of vaccinia eliciting an anti-tumour immune 
response was by Mastrangelo et al. (1999)137 who conducted a phase 1 trial 
in seven immunocompetent, revaccinated patients with surgically incurable 
cutaneous melanoma. For six weeks, the group administered a twice weekly 
intra-tumoural injection of JX-594 in an escalating dose protocol.  An anti-
vaccinia humoral response was identified in all seven treated patients with 
injected tumours becoming inflamed and infiltrated with a number of immune 
cell types. The clinical outcomes were mixed, however, importantly five of the 
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seven patients demonstrated tumour regression at both treatment site and 
distant untreated disease loci, indicative a systemic anti-tumour response.  
Regardless of the immune potential elicited by an oncolytic virus, if the virus 
is not delivered directly into tumour it is important to establish that viral 
infection is targeted and tumour cell specific. Studies using systemic delivery 
methods have demonstrated that vaccinia virus can be delivered to tumour in 
mouse models, however insufficient tumour cell killing and infection of normal 
tissues remained an issue.   Hung et al. (2007),156 for example, used a non-
invasive luminescence imaging system to monitor ovarian tumours treated 
with intraperitoneal vaccinia in a mouse model. They reported that vaccinia 
virus was able to selectively target, control and illicit a potent anti-tumour 
immune response when delivered intraperitoneally but intravenous delivery 
methods did not yield successful therapy. 
One strategy considered to improve tumour selectivity, undertaken by Kirn et 
al. (2007)61, was to clone IFN-	𝛽 gene into a B18R deletion vaccinia mutant. 
IFN-	𝛽 in normal tissues is known to inhibit viral replication, however tumour 
cells are often resistant to the antiviral effects of type I IFNs and as such viral 
replication should not be inhibited in tumour cells. Using this virus the authors 
were able to show a complete tumour response following systemic delivery; 
moreover the response was associated with protection from tumour re-
challenge in a CMT93 murine tumour model indicating a systemic and 
continued anti-tumour immune response.  
 
1.5.2 Reovirus and the immune system 
Despite Reovirus progressing to clinical trials for the treatment of various 
localized and disseminated malignancies, the first study to examine the 
potential immune contribution to Reovirus efficacy was performed by Errington 
et al. (2008).157 The authors examined the ability of Reovirus to activate 
human dendritic cells (DC), important regulators in both the innate and 
adaptive immune response, and reported that Reovirus could induce DC 
maturation and stimulate the production of various inflammatory cytokines 
including IFN-𝛼, TNF-𝛼, IL-12 and IL-6. Furthermore, Reovirus-activated DC 
upregulated IFN-𝛾 production and increased NK cell cytolytic activity when co-
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cultured with autologous NK cells. Similarly, when Reovirus-activated DC 
were co-cultured with autologous T cells Reovirus augmented T cell cytokine 
production and the induction of CTL-mediated tumour cell killing.  
In a separate study examining the use of Reovirus in Melanoma, Errington et 
al. (2008)158 showed that Reovirus could replicate in and lyse human 
melanoma cell lines and freshly resected melanoma samples. The study 
demonstrated that virus-induced cell death was associated with the release of 
a range of pro-inflammatory cytokines and chemokines along with abrogation 
of the immunosuppressive cytokine, IL-10.  The authors reported that 
Reovirus-induced cell death may act to reverse the immunosuppressive milieu 
of the tumour microenvironment, actively recruiting immune effector cells and 
leading to the generation of an innate anti-tumour immune response.  
These data were further supported by Prestwich et al. (2009)44 who 
demonstrated that DC’s loaded with Reovirus infected melanoma cells and 
co-cultured with PBMC induced IFN-	𝛾 production within the NK cell 
population in a cell to cell contact dependent manner. Importantly, they also 
showed that DC loaded with infected melanoma cells induced NK cell 
cytotoxicity towards tumour cells via an IFN-dependent mechanism. Murine 
melanoma cell lines (B16ova) were resistant to direct Reovirus oncolysis in 
vitro, however C57BL/6 mice bearing B16ova lymph node and splenic 
metastasis were cleared of their disease burden when treated intravenously 
(i.v.) with Reovirus loaded T-cells. In the same in vivo model using immuno-
deficient mice Reovirus had no effect. These results clearly demonstrated the 
importance of the immune system for the efficacy of Reovirus.43 
 
1.6 Apoptosis, Necrosis and Autophagy 
1.6.1 Cell death mechanisms and OV 
Oncolytic virus mediated cell death traditionally does not follow the classic 
pathways of apoptosis, necrosis or autophagy but instead typically will display 
features of all three modalities with some variation seen between different 
virus types. In an effort to explain the mixed cell death pathways alternative 
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definitions have emerged including programmed apoptosis, necroptosis and 
necrosis-like programmed cell death. 
In Vaccinia infection the classical pathways have all been implicated to varying 
degrees with cell lysis considered the common endpoint of infection.  
Apoptosis has been reported in some cancer cell lines and immune cells, 
autophagy is disrupted in fibroblasts following infection and necroptosis has 
also been shown to have a role in the death of vaccinia infected T cells.159 
Reovirus-induced cell death is widely reported to primarily occur by an 
apoptotic mechanism, however it has also been to shown to activate a 
caspase independent cell death pathway, inducing features consistent with 
necroptosis.160 However, understanding the mechanism of virus-induced cell 
death will enable complimentary combination strategies to be defined.  
 
1.6.2 Apoptosis 
Apoptosis is an essential process to maintain normal development and tissue 
homeostasis. It is characterised by defined morphological changes such as 
the formation of apoptotic bodies, caspase activation and loss of integrity from 
mitochondrial membranes. Apoptotic bodies are removed by phagocytosis 
after a process of flipping of phosphatidylserines to the outer membrane 
surface and at the same time anti-inflammatory cytokines are released to 
minimise immune activation. The process is considered non-immunogenic.161 
Vaccinia virus is known to encode various inhibitors of apoptosis including 
F1L, N1L and SPI-2 which combine to prevent premature cell death and may 
inhibit viral replication and spread. However, apoptosis has been observed 
following infection with VV.  In response to infection with VV, Greiner et al. 
(2006)162 demonstrated a time dependent increase in apoptosis but no 
evidence of necrosis in Mel526 cells as discriminated by annexin-V and 7-
AAD staining. Similarly, Humlova et al (2002)163 suggested VV stimulated 
apoptosis in a murine macrophage line (J774.G8) using various techniques 
including mitochondrial membrane potential and annexin-V positivity. 
Interestingly the study reported that VV-induced apoptosis was dependent on 
early gene expression and was associated with reduced levels of Bcl-x(L), an 
anti-apoptotic member of the Bcl-2 family.  
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Reovirus is reported to induce apoptosis in a wide variety of in vitro and in vivo 
experimental models including cancer cells and tumours. Reovirus-induced 
apoptosis  involves the release of TRAIL from infected cells and the activation 
of TRAIL-associated death receptors (DR), DR4 and DR5. A subsequent 
activation cascade results in caspase 8 activation, cleavage of Bid and the 
release of pro-apoptotic mitochondrial factors.164,165 The combined activation 
of death receptor and mitochondrial pathways leads to downstream activation 
of effector caspases, such as caspase-3, the role of which is considered 
critical to Reovirus-induced apoptosis.166   
 
1.6.2.1 The Bcl-2 Family; Proapoptotic versus Prosurvival 
One of the hallmarks of cancer is the evasion of apoptosis.167 Cancer cells 
demonstrate attrition against a plethora of cellular stresses that would almost 
certainly result in normal cells undergoing apoptosis. Examples include 
unfavourable microenvironments, aberrant cell cycle progression and 
oncogene activation. However, cancer cells have evolved multiple strategies 
in order to evade these normal cell cycling processes, one of which being the 
upregulation of the pro-survival BCL-2 family proteins. BCL-2 family members 
have either pro-apoptotic (BH3-only proteins; Bax, Bak, Bad, Bim, Noxa) or 
anti-apoptotic (BCL-2, Bcl-XL, Bcl-w, Mcl-1) functions. The so called BH3-only 
proteins are pro-apoptotic in nature and principally act to control mitochondrial 
death signalling via the release of cytochrome C, a potent catalyst of 
apoptosis. On activation by stimuli such as intracellular damage, Bim, Bad and 
Noxa sequester anti-apoptotic targets and initiate apoptosis by permeabilising 
the mitochondrial outer membrane and inducing the release of pro-apoptotic 
enzymes, such as cytochrome C. Cytochrome C then activates the caspase 
pathway ultimately leading to cell death. Various danger signals can induce 
the pathway to initiate cell death, for example following DNA damage, the p53 
tumour suppressor gene upregulates the expression of Bax, which in turn 
stimulates mitochondrial release of cytochrome C.168 In many tumours, 
apoptosis is dysregulated by upregulation of pro-survival family members or 
mutations in the p53 pathway which abrogate the normal activation pathways 
apoptosis triggers.  
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A summary of the intrinsic and extrinsic apoptotic pathways along with the 
interaction of BCL-2 family proteins, is presented is in Figure 1.9.  
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Figure 1.9 Apoptosis and BCL-2 family protein. 
A) A summary of the extrinsic and intrinsic signalling cascade leading to activation of 
caspase 3/7,  caspase 8/10 and cell death. B) BCL-2 inhibits apoptosis by interacting 
with BAK and BAX. BH3-only proteins (BAD, BIM, NOXA) activate apoptosis by 
inhibiting BCL-2. Specific BH3-only proteins (BID, PUMA) can also induce apoptosis 
by directly activating BAK and BAX. ABT-263 is a ‘BAD-like’ mimetic that can bind 
BCL-2, BCL-XL and BCL-W selectively inhibiting their action. 
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1.6.3 Necrosis  
Necrosis is a less coordinated, studied and defined method of cell death. Cells 
undergoing necrosis characteristically demonstrate swelling of the cytoplasm 
and organelles, which is followed by rupture of the plasma membrane and 
release of the cytoplasmic contents. Necrosis is thought to be immunogenic 
in nature and is accompanied by the release of various pro-inflammatory 
cytokines including tumour necrosis factor-α (TNF-α).169 Necrosis was 
traditionally thought to be unregulated in nature, with no set pathways or 
cellular regulation. However, more recent evidence has shown that necrosis 
can be a controlled mechanism with defined pathways and molecular 
regulation and as such has been aptly called programmed necrosis or 
necroptosis.170 
Necroptosis has been reported in response to vaccinia virus (Lister-dTK 
strain) in ovarian cancer cell lines although features more consistent with 
apoptosis and autophagy, such as LC3 lipidation and phosphatidylserine 
exposure, were also seen.  In response to Lister dTK swollen nuclei, ruptured 
membranes, cytoplasmic vacuolation and HMGB-1 release were observed all 
of which are associated with necrosis. In addition, the authors reported a 
significant increase in glycolysis and mitochondrial respiration 24 hours post 
infection consistent with active necrosis and confirmed this modality as the 
principle causative process for the cell death observed.159 
Similarly, Berger et al. (2013)160 described Reovirus-induced necroptosis cell 
death in L929 cells treated with Type 3 Dearing  Reovirus (T3D). T3D was 
shown to activate NF-kB and initiate caspases consistent with virus-induced 
apoptosis. However, interestingly blockade of NF-kB and/or caspases (using 
ZVAD-FMK) did not affect T3D-induced cell death. The alternative cell death 
pathway was further defined to be RIP-1 kinase dependent, reduce cellular 
ATP levels and was associated with cell membrane destruction consistent 
with necroptosis.  
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1.6.4 Autophagy 
Autophagy is described as a catabolic process designed to protect and ensure 
an organisms well-being. Autophagy involves the sequestering of a wide array 
of undesired intracellular constituents into double-membrane vesicles known 
as autophagosomes which then undergo lysosomal degradation.171 
Autophagy is a reversible process particularly in the context of nutrient 
starvation. It is not completely clear therefore if autophagy represents a 
complete cell death mechanism or a trigger to alternative cell death 
phenomena.  Autophagy also represents an important innate immune 
response against viral infection by enhancing viral antigen presentation on 
MHC-I, although it is also known that some viruses utilise host cell autophagy 
to enhance  survival and replication.  
Vaccinia virus actively disrupts cellular autophagy through a poorly 
understood novel mechanism involving abnormal LC3 lipidation and direct 
conjugation of ATG12 and ATG3. Despite this it is clear that there is no 
general activation of autophagic processes and cell death is not thought to be 
dependent upon the induction of autophagy. 159,172 
Evidence for Reovirus-induced autophagy remains limited with no conclusive 
experimental evidence in the literature. Thirukkumaran et al. (2012)173 studied 
Reovirus-induced cell death mechanisms in human multiple myeloma cell 
lines. Apoptosis was the principle mechanism of cell death, however, in 
addition at 24-48hours post-infection there was formation of autophagosome 
puncta containing LC3-II, consistent with the activation of autophagy. 
Interestingly, formation of the autophagosome, was abrogated by the 
autophagy inhibitor, 3-methyladenine (3-MA). It remains unclear, however to 
what extent autophagy plays a role in Reovirus-induced cell death with 
conflicting reports suggesting that the mechanisms behind Reovirus induced-
apoptosis might in fact shift the cell away from autophagy like death.174 
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1.7 Agents which may potentiate OV direct killing 
1.7.1 BH3 Mimetics 
As discussed previously, the antiapoptotic proteins Bcl-2 and Bcl-XL play a 
critical role in the maintenance of normal cell homeostasis. These proteins are 
however often overexpressed in solid tumours, and have been implicated in 
therapy resistance making these proteins attractive targets for the 
development of novel anticancer drugs.175  Selective inhibition of these anti-
apoptotic proteins was therefore designed to normalise cell death machinery 
and overcome chemoresistance and may prove useful in potentiating OV 
therapy.168 
 
1.7.1.1 ABT-737 
ABT-737 was developed in the mid-2000’s by Abbott Laboratories as a novel 
Bcl-2, Bcl-XL and Bcl-W but not Mcl-1 mimetic. ABT-737 demonstrated higher 
affinity for its targets than previous molecules and enhanced intrinsic apoptotic 
signals rather than directly initiating apoptosis. 
Oltersdorf et al. (2005)176 reported ‘single agent mechanism based killing’ in a 
variety of cancer cell lines and primary patient derived cells including small-
cell lung carcinoma (SCLC) and lymphoma. Hann et al. (2008) also examined 
the therapeutic efficacy of ABT-737 in de novo human primary SCLC tumour 
xenograft models and standard cell line xenograft models. In the cell line 
models, ABT-737 induced dramatic tumour regression, however the authors 
described more mixed results in the primary xenograft models with only one 
of three SCLC showing a significant response. Variable BCL-2 family protein 
expression in the primary tumours, in particular increased Mcl-1 (not targeted 
by ABT-737) and decreased Noxa were suggested as the  most likely 
explanation for ABT-737 resistance. The hypothesis was further supported by 
multiple in vitro experiments demonstrating a reduction in Mcl-1 could 
overcome ABT-737 resistance.168,177–179 The findings opened the door to 
potential combination strategies using alternative agents such as Sorafenib 
and Cisplatin which have been shown to downregulate Mcl-1 in renal tubular 
epithelial cells and acute myeloid leukaemia (AML).180,181 
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1.7.1.2 ABT-263 (Navitoclax) 
A major limitation of ABT-737 is that it is not orally bioavailable and as such 
provides a limited ability to translate from the laboratory to the clinic given the 
inability to perform dose escalation trials. To resolve this issue, ABT-263 a 
structurally related but orally bioavailable Bad-like BH3 mimetic was designed. 
Initial studies performed by Tse et al. (2008)182 demonstrated ABT-263 could 
induce Bax translocation, cytochrome C release and apoptosis in in vitro 
models. Faber et al. (2015)183 examined the efficacy of ABT-263 across a 
panel of greater than 500 cancer cell lines and using gene expression data 
were able to demonstrate that high expression of BIM and low MCL-1 
predicted ABT-263 sensitivity.  Further in vivo studies of oral administration of 
ABT-263 alone induced almost complete tumour cell regression in mouse 
xenograft models of acute lymphoblastic leukaemia and SCLC.184,185 In 
xenograft models of multiple myeloma and B-cell lymphoma only a modest 
response was seen, however in combination with standard of care treatment 
regimes, ABT-263 was able to significantly enhance treatment efficacy.182 
ABT-263 has now been the subject of various Phase I and Phase II clinical 
trials. The latest phase I trials have explored combination strategies in 
advanced solid tumours with erlotinib186, irinotecan187 and gemcitabine188 and 
in refractory lymphoid malignancies with rituximab189. Mixed response rates 
have been reported however the combinations do offer a favourable safety 
profile. Two recent phase 2 studies have examined the use of navitoclax as a 
single agent in patients with relapsed SCLC and in combination with or without 
rituximab in treatment naïve B cell chronic lymphocytic leukaemia (CLL). 
Limited single agent activity in advanced and recurrent SCLC was reported by 
Rudin et al. (2012)190, however its use in combination with rituximab in B-cell 
CLL resulted in higher response rates and prolonged progression free 
survival.191 
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Aims of the Study 
 
This thesis covers a broad range of oncolytic virus activity including 
mechanistic and immunologic function. Significant volumes of work in the field 
of oncolytic virotherapy exist in the literature and as such this study aimed to 
focus on some outstanding areas of interest and gaps in knowledge in order 
to investigate strategies that may increase the therapeutic efficacy of two 
distinct viruses, Reovirus and Vaccinia Virus.  
While the immune potential of Reovirus is well recognised, less is known 
about JX-594, an OV currently in clinical testing at Leeds Teaching Hospitals 
NHS Trust. Access to fresh human tissue samples from CRC patients allowed 
this study to explore the immune potential of JX-594 and furthermore examine 
for the potential immune effects it may have at distant disease harbouring 
sites, such as lymph nodes.  
The thesis is divided into 3 results chapters with separate stratified aims and 
include the following:  
Chapter 3 – Combination strategies with Reovirus  
• Examines Reovirus cytotoxicity in a range of colorectal cell lines with 
varying EGFR expression and KRAS/BRAF/PI3K mutational variations. 
• Explores the ability of ABT-263 (Navitoclax), an orally administered BH3 
mimetic, to act synergistically with Reovirus and enhance OV direct 
cytotoxicity.  
• Investigates the ability of Reovirus to enhance the effects of anti-EGFR 
monoclonal antibody therapy by promoting ADCC/ADCP. 
Chapter 4 – Vaccinia Virus (JX-594) mechanism of action. 
• Evaluates the mechanism of JX-594 direct oncolysis and cell death 
mechanisms including apoptosis, necroptosis and autophagy. 
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Chapter 5 - JX-594-induced innate immune response 
• Phenotypes fresh human tissue ex-vivo lymph node samples. 
• Examines the effects of JX-594 treatment on the innate immune system in 
blood and lymph nodes, with particular focus on NK cell activation as a 
marker for innate immune activity. 
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Chapter 2  
Materials and Methods 
2.1 General Tissue Culture 
Tissue culture was all performed under aseptic conditions in laminar flow 
NuAire Class II Microbiological Safety Cabinets (NuAire Inc, Plymouth, USA). 
Cabinets were cleaned routinely pre and post procedures with 2% (w/v) Virkon 
(Scientific Laboratory Supplies, (SLS), Nottingham, UK) followed by 70% (v/v) 
ethanol (Sigma-Aldrich Ltd., Dorset, UK) to maintain sterility throughout. 
Plastic ware used was bought in pre-sterilised sealed packages from Corning 
Costar (High Wycombe, UK) or BD Biosciences (Oxford, UK). All pipettes 
used were produced by Gilson Inc. (supplied by Anachem Ltd., Bedfordshire, 
UK). All centrifugation was carried out for 5 minutes at 400g at room 
temperature (RT), using an Eppendorf 5810R centrifuge (Eppendorf, 
Leicestershire, UK) unless otherwise stated. Routine cell observation and cell 
counts were undertaken with an Olympus CKX41 light microscope (Olympus 
UK Ltd., South-End-On-Sea, UK ) using 0.2% (v/v) Tryphan Blue (Sigma-
Aldrich) and a haemocytometer (Weber Scientific International, West Sussex, 
UK). 
 
2.2 Cell Lines 
All cell lines were purchased from American Type Culture Collection (ATCC), 
the European Collection of Cell Cultures (ECACC) or acquired from 
collaborative working groups. All cell lines were cryopreserved in liquid 
nitrogen in 90% foetal calf serum (FCS) supplemented with 10% (v/v) dimethyl 
sulphoxide (DMSO) (Sigma-Aldrich Company Ltd, Dorset, UK) in 1.2ml 
cryotubes (Nunc, NY, USA). A summary of cell lines used and there derivation 
is shown in Table 2.1. 
Prior to testing all cell lines were authenticated using short tandem repeat 
(STR) profiling and direct comparison with Leibniz-Institut Deutsche 
Sammiung von Mikroorganismen und Zellkulturen (DSMZ) databases. 
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Cell lines were recovered from frozen by rapid thawing in a water bath at 37°C 
followed by further dilution in fresh media (x10) and centrifugation to remove 
any residual, potentially toxic, DMSO. Thereafter cells were re-suspended in 
fresh media, either Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma) or 
Roswell Park Memorial Institute (RPMI) 1640 (Sigma) (Table 2.1) 
supplemented with 10% (v/v) heat inactivated FCS (56°C, 30 minutes) and 
maintained in either a 75cm3 or 150 cm3 vented plastic tissue culture flasks 
(Corning Costar, Amsterdam, The Netherlands) in a Sanyo CO2 incubator at 
37°C. Adherent cell lines were routinely passaged or harvested at or near 
confluence by washing with phosphate buffered saline (PBS) (Sigma, Dorset, 
UK ), with or without the additional supplementation of 
Ethylenediaminetetraacetic acid (EDTA) where required (Table 2.1), followed 
by Trypsin-EDTA (10x stock solution diluted in Hanks Buffered Salt Solution 
(HBSS) (Sigma)).  Non-adherent cell lines were washed in PBS and 
centrifuged before being re-suspended in fresh media. 
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Cell Lines Culture Properties 
Culture 
Medium Wash Purchased 
Colorectal cell Lines 
SW480 Adherent DMEM + 10% 
FCS 
PBS + EDTA  ATCC 
SW620 Adherent DMEM + 10% 
FCS 
PBS + EDTA ATCC 
HCT116 Adherent DMEM + 10% 
FCS 
PBS + EDTA ATCC 
Colo320 Suspension, multi 
cell aggregates 
DMEM + 10% 
FCS  
PBS ATCC 
HT29 Adherent DMEM + 10% 
FCS 
PBS + EDTA ATCC 
LoVo Adherent DMEM + 10% 
FCS 
PBS + EDTA ATCC 
LIM 1215 Adherent RPMI + 10% 
FCS 
PBS + EDTA Donated 
LIM1899 Adherent RPMI + 10% 
FCS 
PBS + EDTA Donated 
LIM 2408 Adherent RPMI + 10% 
FCS 
PBS + EDTA Donated 
Normal Kidney Cell Lines 
VERO Adherent DMEM + 10% 
FCS 
PBS + EDTA ATCC 
Osteosarcoma Cell lines 
U20S Adherent DMEM + 10% 
FCS 
PBS + EDTA Donated 
Miscellaneous 
PBMC Suspension RPMI + 10% 
FCS 
PBS Fresh 
LNMNC Suspension RPMI + 10% 
FCS 
PBS Fresh 
Table 2.1 Cell Lines and growing conditions 
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2.3 Measurement of viral titre by Plaque Assay 
2.3.1 Reovirus 
Reovirus Type 3 Dearing Strain was provided by Oncolytics Biotech Inc.  
Stock virus titres were determined using a plaque assay technique. Titred 
aliquots were stored at 4°C for up to 1 month to avoid loss of efficacy through 
repeated freeze-thaw, or at -80°C for longer storage. 
The mouse C3H/An connective tissue cell line, L929, is known to be sensitive 
to Reovirus and was therefore used to determine the plaque forming activity 
of Reovirus stock virus titres and Reovirus treated samples. L929 cells were 
seeded into 6 well plates at a density of 1x106 cells/well in 2mL of DMEM 
containing 10% FCS, and incubated for 4 hours, at 37°C, to allow for cell 
adherence. Stock virus and sample dilutions were prepared by serial dilutions 
in DMEM to give a logarithmic dilution ranging from 10-2-10-11. 
At 4 hours, culture media was removed carefully from the adherent cells with 
special care taken not disturb the monolayer and replaced in either duplicate 
or triplicate with 500μL of the prepared virus samples. Plates were incubated 
for a further 4 hours at 37°C. The virus dilutions were then removed from the 
wells and replaced with 2mL of overlay medium (2:1 ratio of DMEM containing 
10% FCS and 1.6% (w/v) of carboxymethylcellulose (CMC)). Cells were then 
incubated for a further 3 days at 37°C. After 3 days the media:CMC solution 
was removed and the wells washed with PBS before being fixed with 0.5mL 
1% glutaradehyde for 10 minutes at RT. Glutaradehyde was then removed 
prior to the addition of 0.5mL 1% methylene blue (in 50% ETOH) for 3 minutes 
in order to stain the cells and visualise the plaques. Areas that were clear as 
a result of Reovirus-induced lysis (plaques) were counted using a lightbox to 
enhance visualization and the following formula used to calculate viral titre. 
 
Plaque forming units/mL =   average no. of plaques   x   2 
    dilution 			
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2.3.2 JX-594 
JX-594 was provided by John Bell and Colleagues (Ottawa Hospital Research 
Institute, Ottawa, Canada) on behalf of Jennerex Biotherapeutics Inc (recently 
acquired by Sillajen Inc, Korea). Several genetically modified strains were 
provided for use in different experimental models with the principle form used 
in these studies being JX-594-GMCSF-eGFP (referred to as JX-594 if not 
further clarified from this point forward). The insertion of the genes encoding 
for granulocyte macrophage colony stimulating factor (GMCSF) and green 
fluorescent protein (GFP) under an early/late promoter is useful not only due 
to its clinical relevance but because they can also be used as surrogate 
markers for the assessment of viral replication in experimental models.  Other 
versions included in these studies were JX-594-GMCSF-fLuc (Luciferase) and 
JX-594-YFP (Yellow Fluorescent Protein) which does not express GMCSF.  
Titred aliquots were stored at -80°C and thawed when required. The JX-594 
viral backbone is understood to tolerate repeated freeze-thawing with regards 
to maintaining viral titre levels. However where possible this was minimized 
and when in use virus was stored at 4°C for no longer than 72 hours. 
The human bone osteosarcoma epithelial cell line U2OS (originally known as 
2T) were seeded into 6-well plates at a density of approximately 8.4x105 
cells/well in 2mLs DMEM containing 10% FCS, and incubated overnight at 
37°C. 
Stock virus and virus-treated samples for viral quantification underwent serial 
dilutions in serum free DMEM with a dilution factor range of 10-1 to 10-8 in a 
96-well plate.  Media was then carefully removed from the cells and 1mL of 
virus dilution added to appropriate wells, virus was incubated for a further 2hr 
incubation at 37°C. After 2 hours, the media was replaced with 2mL of over 
lay medium (1:1 ratio CMC mix with 3% CMC and 2 x DMEM + 20% FBS) and 
plates incubated for 96 hours at 37°C.  Thereafter the overlay medium was 
aspirated and a single PBS wash of the cell monolayer undertaken. Plaques 
were fixed and stained with 0.5mL 1% glutaradehyde for 10 minutes followed 
by 0.5mL 1% methylene blue (in 50% ETOH) for 3 minutes. Plaque counting 
and calculations were undertaken as previously described to attain virus titres. 
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2.4 Flow Cytometry – Fluorescence-Activated Cell Sorter  
(FACS) 
Flow cytometry was used to analyse the physical and chemical characteristics 
of all experimental cell types. Multiple fluorochoromes were utilised to allow 
for the identification of different subset populations within the mixed-cell 
sample population. Flow cytometry antibodies are outlined in Table 2.2.  All 
flow cytometry outlined in the materials and methods was performed using the 
Attune® NxT Acoustic Focusing Cytometer (Life Technologies, Paisley, UK; 
Thermo Fisher Scientific, Loughborough, UK) and data analysed using the 
Attune® Cytometric Software. (v2.1.0) (Life Technologies, Paisley, UK; 
Thermo Fisher Scientific, Loughborough, UK) 
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TARGET 
MOLECULE 
FLUOROCHROME VOLUME 
ADDED 
MANUFACTURER INDICATION 
CONTROLS     
Triple 
Isotype 
FITC/PE/PErCP 2 μL Dako Cytomation Control Antibody 
Isotype 
IgG1 
FITC/ 
PE 
10 μL 
5 μL 
Dako Cytomation Control Antibody 
Isotype 
IgG2B 
PerCP 5 μL Dako Cytomation Control Antibody 
IMMUNE CHARACTERISATION   
CD3 PerCP 10 μL BD Biosciences T-Cell Marker 
CD4 FITC 5 μL BD Biosciences T-Helper Cell 
marker 
CD8 FITC 5 μL BD Biosciences Cytotoxic T-Cell 
marker 
CD11B PERcP 10 μL BD Biosciences Pan-
Macrophage 
marker 
CD11C PE 5 μL BD Biosciences Dendritic Cell 
(DC) Marker  
CD14 PE 5 μL BD Biosciences Monocytes/ 
Macrophage 
marker 
CD19 PE 5 μL BD Biosciences B-Cell Marker 
CD56 PE 
FITC 
2 μL 
10 μL 
BD Biosciences NK Cell and 
activated T cell 
(NKT) marker 
CD68 FITC Intra-
cellular 
staining 
BD Biosciences Pan-
macrophage 
marker 
CD69 FITC 10 μL BD Biosciences Early activation 
marker 
CD80 PE 2 μL BD Bioscience Activation/ 
Maturation 
marker of 
Mature DC’s 
CD86 PE 2 μL BD Biosciences Early activation/ 
maturation 
marker of DC’s 
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Table 2.2 Flow Cytometry Antibodies 
 
 
 
 
 
CD107a FITC 5 μL BD Biosciences NK Cell 
degranulation 
marker 
CD107b FITC 5 μL BD Biosciences NK Cell 
degranulation 
marker 
CD274 PE 5 μL Sigma-Aldrich Marker for 
Programmed 
Death Ligand -1 
(PDL-1) 
CD279 PE 5 μL Sigma-Aldrich Marker of 
programmed cell 
death protein 1 
(PD-1) 
Class II PE/FITC 2 μL BD Biosciences Cell Surface 
expression on 
antigen 
presenting cells 
(APC’s) 
CELL LINE CHARACTERISATION   
CEA FITC 5 μL BD Biosciences Marker of 
Colorectal 
carcinoma 
EGFR PE 5 μL BD Biosciences  Epidermal 
growth factor 
receptor (EGFR) 
– stimulates cell 
growth and 
differentiation 
BerEp4 
(Anti-
EpCAM) 
FITC 5 μL AbCam Epithelial 
specific antigen. 
Tumour cell 
marker in lymph 
nodes, highly 
conserved 
expression in 
carcinoma 
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2.5 Viability Assays 
2.5.1 Measurement of Cell Viability using Live/Dead™ 	
Cell viability was assessed using the Live/Dead™ reactive dye (Life 
Technologies).  Following experimental conditions, cells were harvested into 
FACS tubes (BD Falcon) and washed in 1mL PBS by centrifugation for 5 
minutes at 400g at RT. The supernatant was discarded and cell pellets were 
re-suspended in 1mL of PBS containing 1μL of PE-conjugated Live/Dead™ 
fluorescent dye (Invitrogen, Paisley, UK). The cell suspension was incubated 
in the dark for 30 minutes at RT. A final PBS wash was performed before the 
cells were fixed in 300μL of 1% Paraformaldehyde (PFA). FACS analysis 
(Section 2.4) was undertaken immediately where possible or alternatively cells 
were stored at 4°C and acquisition was  performed within one week of sample 
preparation. 
 
2.5.2 Methylthiazoyldiphenyl-tetrazolium bromide (MTT) 
metabolic activity. 
Cells were seeded in triplicate at a density of 8 x 103 cells/well (in 200μL) into 
96-cell well plates (Costar) and incubated overnight at 37°C.  After 24 hours 
cells were treated with required virus doses and/or inhibitors and incubated at 
37°C until assay end points.  At the designated time points 20μL MTT  
(5mg/mL diluted in PBS) was added to the existing medium in each well and 
incubated for a further 4 hours at 37°C.  After 4 hours, all media was carefully 
aspirated from the wells, taking particular care not to disrupt the adherent cell 
monolayer, and replaced with 150μL DMSO and left for 5 minutes to allow 
cells to solubilize. Optical density was measured using a multi-well scanning 
spectrophotometer (Multiskan EX plate reader (Thermo Fisher Scientific, 
Northumberland, UK)) at a wavelength  of 550nm and viability calculated by 
direct comparison and normalization against an untreated control. 
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2.6 EGFR expression, Cetuximab and GA201 Binding studies 
Cell lines were harvested as per section 2.2 and divided into FACS tubes at a 
density of 5x105 cells/mL. Cells were washed in 2mL of FACS buffer (PBS + 
1% (v/v) FCS and 0.1% (w/v) sodium azide) and pelleted by centrifugation for 
5 minutes at 400g (RT), with the supernatant discarded. EGFR expression 
was examined using 5μL of stated antibody (Table 2.2) and incubated at 4°C 
for 30mins. To assess efficiency of anti-EGFR antibody drug binding, cell 
pellets were re-suspended in 1mL of media (DMEM, 10% FCS) and 0, 1.25, 
2.5, 5, 10μg/mL of Cetuximab, Panitumumab and GA201 added to the cell 
suspension. The antibodies were incubated for 30 minutes at 37°C before cell 
were washed in 2mL of FACS buffer. Following this, 10μL FITC Mouse anti-
human IgG (Table 2.2) was added to the cell pellets and cells were incubated 
for a further 30 minutes at 4°C. After a final wash in 2mL FACS buffer cells 
were pelleted by centrifugation at 400g for 5 minutes, supernatants discarded 
and cells fixed by the addition of 300μL of 1% PFA. Binding of Cetuximab, 
Panitumumab and GA201 was determined by flow cytometry (section 2.4) 
immediately where possible, or cells were stored at 4°C in the dark for a 
maximum of one week before data acquisition was undertaken. 
 
2.7 51Chromium (51Cr) Cytotoxicity Release Assay 
Tumour target cells (SW480 and SW620) and effector cells (PBMC ± 
overnight pre-treatment with virus) were harvested, washed and centrifuged 
to form a cell pellet as described in section 2.2. Tumour target cells were 
labelled with 50μCi of 51Chromium (Perkin Elmer, Cambridgeshire, UK) per 
one million cells and incubated for 1 hour at 37°C. Radioactive substance 
handling precautions were used at all times and any excess unbound 51Cr was 
removed by three further wash steps using 50mL Hanks Buffered Salt Solution 
(HBSS) (Sigma-Aldrich). Target cells were finally re-suspended in RPMI 
containing 10% FCS at 1x105 cells/mL. Following the harvest of effector cells, 
pellets were also re-suspended in RPMI/10% FCS at a specific cell density to 
enable a known target to effector ratio to be set up. Serial dilutions of the 
effector cell suspension was undertaken to achieve a final volume of 100μl 
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per well, seeded out in triplicate in 96-well round bottomed plates (NUNC, 
Thermo Scientific, Roskilde, Denmark). 50μL of the previously 51Cr-labelled 
target cells were added to each well where required. To control for 
spontaneous release and quantify maximum 51Cr release binding from cell 
targets, two simultaneous control plates were set up containing either target 
cells alone in media or target cells treated with 1% (v/v) Triton-X (Sigma) in 
RPMI (10% FCS) respectively. All plates were incubated for 4 hours at 37°C 
before being centrifuged (5 minutes, 400g, RT) and  harvesting of 50μL of the 
supernatant from each well onto Luma scintillation plates (Perkin Elmer, 
Warrington, Cheshire). Luma plates were allowed to dry overnight at RT and 
levels of 51Cr release determined using a 1450 MicrobetaJet Scintillation 
Counter (Wallac EG & G Ltd., Milton Keynes, UK).  The 51Cr release was 
measured in counts per minute (cpm). Results were converted to and 
expressed as ‘percentage tumour cell lysis’ using the following formula: 
 
% Lysis =  (sample cpm – spontaneous cpm) x 100 
     (max cpm–spontaneous cpm) 
 
2.8 Human primary tissue and blood 
For human tissue and blood experiments written, informed consent was 
obtained from all patients in accordance with local institutional ethics review 
and approval guidelines. (Leeds (East) Research Ethics Committee, 
06/Q1206/106). For healthy donor volunteers, verbal consent was obtained 
and samples collected in accordance with University of Leeds Institute of 
Cancer and Pathology guidelines. 
 
2.8.1 Isolation of peripheral blood mononuclear cells (PBMC) from 
fresh blood using density gradient separation. 
Whole peripheral blood was collected using standard local precautions from 
patients (Leeds Teaching Hospitals NHS Trust) with colorectal cancer 
undergoing colonic surgical resection and/or patients with metastatic 
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colorectal liver cancer undergoing liver resection surgery. Similarly, whole 
peripheral blood was also collected from healthy donor controls. Blood was 
first diluted 1:1 with HBSS and thereafter carefully layered onto Lymphoprep© 
(Axis Shield, Cambridgeshire, UK) at a ratio of two parts blood, one part 
lymphoprep in a 50mL Falcon Tube. Tubes were centrifuged at RT for 25 
minutes at 800g with no brake. Excess plasma was removed and the white 
cell layer collected using a wide-tipped Pasteur pipette (Alpha laboratories Ltd. 
Hampshire, UK). The collected interface PBMC layer was washed in 50mLs 
HBSS and cells pelleted by further 10 minute centrigugation at 400g at RT. 
Cells were washed a second time in 50mLs HBSS and centrifuged at 300g for 
5 minutes at RT. PBMC’s were counted and resuspended in fresh RPMI 
containing 10% FCS culture medium at 2x106 cells/mL. 
 
2.8.2 Primary Tissue Collection 
Fresh tissue samples were acquired from patients undergoing elective, 
planned resection for primary colorectal cancers of any type. The operations 
from which tissue was acquired were wide ranging and tumour location and 
staging at time of operation was variable. Written, informed consent was taken 
from all donors in accordance with institutional ethics review and approval 
(Leeds (East) Research Ethics Committee, 06/Q1206/106).  Whole resection 
specimens were collected under sterile conditions as per the operating 
surgeons preferences and taken fresh, in the absence of formalin, 
immediately to a Consultant Histopathologist for processing. Samples were 
collected at the discretion of the histopathologist to avoid inadequate clinical 
processing, however, tissue considered of primary interest and priority was 
normal and/or tumour draining lymph nodes taken from the specimens 
mesenteric fat. Where possible additional tissue collected included healthy full 
thickness bowel (mucosa to serosa), primary colorectal tumour and in the 
case of concurrent operations to remove liver metastasis, liver tumour and 
hepatic parenchymal samples. As a result of the nature of collection, and 
understandable different disease profiles within donors there was some 
variability to the samples available from each specimen. Samples were 
transported to the laboratory in sterile 150mL screw-topped pots in RPMI 
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containing 10% FCS with the addition of 1% antibiotic, antimycotic solution (A 
combination of 10,000 units Penicillin, 10mg Streptomycin and 25μg 
Amphotericin B (Sigma)), and processed immediately. 
 
2.8.3 Isolation of lymph node mononuclear cells (LNMNC) from 
fresh lymph node specimens using density gradient 
separation 
Fresh lymph node samples were placed in a Petri dish containing 10mL, 
RPMI, 10% FCS and 1% antibiotic and carefully dissected to remove any 
excess fat, necrotic debris or surrounding non-lymph node tissue. Clean 
lymph nodes were then repeatedly injected with media to disaggregate them 
using a 21 gauge, 40mm green needle and 10mL syringe. The remaining cell 
suspension was then passed through a 70μm cell strainer (BD Biosciences) 
and any remaining debris removed using a 50mL large volume wash and 
centrifugation for 5 minutes at 400g, supernatant was discarded leaving a 
single cell suspension of LNMNC’s. 
The remaining single cell suspension of lymph node cells was diluted to a total 
volume of 30mLs in HBSS and layered carefully onto 15mLs of Lymphoprep© 
in a 50mL falcon tube before being centrifuged at 800g for 25 minutes at RT 
with no brake. The plasma containing supernatant was slowly removed with a 
pipette before the remaining LNMNC layer was collected using a wide-tipped 
Pasteur pipette. Cell were washed in 50mLs of HBSS and centrifuged for 10 
minutes at 400g at RT before a second wash again in 50mLs of HBSS with 
centrifugation for 5 minutes at 300g at RT. Cells were counted and 
resuspended in RPMI at 1x106 cells/mL or 2x106 cells/mL depending on cell 
population yields which were variable between samples. 
  
2.8.4 Characterisation of LNMNC’s 
To identify cell populations and the phenotypic appearance cells, LNMNC’s 
cells were harvested and aliquoted into FACS tubes at a density of 5x105-
1x106 cells/tube. Cells were washed in 2mL of FACS buffer, centrifuged 
(Sorvall RT6000B refrigerated centrifuge, Kendro Lab Products, 
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Hertfordshire, UK) at 400g for 5 minutes at 4°C before discarding the 
supernatants. To identify cell populations, a targeted selection of 
fluorescently-conjugated antibodies were added (see Table 2.2) and cells 
incubated for 30 minutes in the dark at 4°C. After 30 minutes cells were 
washed in 2mL of FACS buffer and centrifuged again. The supernatant was 
discarded and the stained cells were fixed in 300μL of 1% PFA. FACS analysis 
(Section 2.4) was undertaken immediately where possible or alternatively cells 
were stored at 4°C and analysis performed within one week of acquisition. 
 
2.8.5 CD14 Positive cell separation of PBMC’s/LNMNC’s using 
magnetic-activated cell sorting (MACS) bead selection. 
Fresh PBMC’s/LNMNC’s were prepared as described in sections 2.8.1 and 
2.8.3, respectively. Cell separation of the CD14 positive and negative fractions 
was then undertaken. The harvested mononuclear cells were washed in 5mL 
of MACS buffer (1% (v/v) FCS + 2mM EDTA in PBS), centrifuged and the cell 
pellet re-suspended in 80μL of MACS buffer per 1x107 total cells in a 15mL 
Falcon tube. 20μL per 1x107 cells of MACS CD14 Microbeads (Miltenyi Biotec 
Ltd., Surrey, UK) were added to the falcon tubes and incubated for 15 minutes 
at 4°C prior to being washed in 2mL of MACS buffer and centrifuged at 300g 
for 5 minutes at RT. The supernatant was again discarded and the remaining 
cell pellet re-suspended in 500 μL/1x108 cells of MACS buffer. A MACS LS 
magnetic separation column was mounted on a magnetic board (both Mltenyi 
Biotec Ltd., Surrey, UK) and washed with 3mLs of MACS buffer prior to use.  
The cell suspension was then loaded and allowed to pass through the column.  
The CD14-ve cell population remained unbound and was collected as the run-
off after 3 further 3mL MACS buffer washes. To collect the bound CD14+ve cell 
population retained in the column, the column was  immediately removed from 
the magnet and flushed using a supplied column plunger. Thereafter 5mL of 
MACS buffer was added to the column and the resultant cell suspension was 
collected into a 50mL Falcon tube. The separated cell populations were then 
counted and utilised as required. 
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2.9 Virus Treatment of Cell Lines, PBMC’S and LNMNC’s 
2.9.1 Cell lines 
Harvested cell lines were seeded into 6 well plates at a density of 2x105 
cells/mL in 3mls of culture medium. Cells were incubated for 4 hours in order 
to allow adherence prior to virus treatment at a range of doses (0, 0.1, 1, 
10pfu/cell).   Plates were further incubated thereafter at 37°C for the required 
experimental time under investigation. 
 
2.9.2 PBMC’s and LNMNC’s 
PBMC’s and LNMNC’s were cultured at 2x106 cells/mL in 24-well plates. Cell 
lines were allowed to settle as required and thereafter were able to be used 
immediately if required. Virus was added at a range of doses (0, 0.1, 1, 
10pfu/cell) and incubated at 37°C for the required experimental time under 
investigation.  
Cell lines, LNMNC and PBMC’s were then utilised where required in further 
experiments described in this chapter: NK cell activation studies such as 
CD69 and CD107 degranulation (section 2.11.2 and 2.11.3 respectively); 
chromium release assays (section 2.7); cell specific phenotyping studies 
(section 2.4) and culture supernatants were collected throughout and 
analysed by ELISA (section 2.12). 
 
2.10 Inhibition of Apoptosis, Necroptosis and Autophagy 
Death Pathways 
SW480 and SW620 cell lines were seeded into a 24-well plate at a density of 
7.5x104 cells in 1mL of culture medium and incubated for a minimum of 4 
hours at 37°C to allow adherence. The apoptotic, necroptosis and autophagy 
inhibitors were then added to the wells at the doses listed in Table 2.3 as 
single agents or in combination and incubated for 1 hour at 37°C. Cells were 
treated with 0 – 10pfu/cell Reovirus or JX-594 for up to 96 hours. At specific 
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time points cells were harvested and cell viability was analysed using 
Live/Dead™ Cell Viability Assay as described in Section 2.5.1. 
 
Inhibitor Inhibits Company Concentration 
Used 
Z-VAD-FMK Apoptosis Calbiochem, Nottingham, UK 50μM 
Necrostatin-1 Necroptosis Tocris Bioscience, Bristol, UK 50μM 
Necrosulphonamide Necroptosis Tocris Bioscience, Brsitol, UK 10μmol/l 
3-Methyladenine     
(3-MA) Autophagy 
Sigma-Aldrich, St 
Louis, MO 50μM 
Table 2.3 Cell death mechanistic inhibitors 
 
2.11 Immune Activation 
2.11.1 NK Cell Activation 
Natural Killer Cells (NK) within both a PBMC and LNMNC population (‘effector 
cells’) were assessed utilising the cell surface expression of CD69 (Section 
2.11.2) and degranulation (section 2.11.3) assessed using CD107a/b. Treated 
effector cell populations were cultured overnight in RPMI containing 10% FCS 
in the presence and absence of virus. Target cell populations (SW480 and 
SW620 cell lines) were harvested as previously described (section 2.2), 
washed in PBS and pelleted by centrifugation. Where appropriate 
supernatants were saved and stored at -80°C for further analysis by ELISA 
(section 2.12). 
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2.11.2 CD69 Expression Assay 
5x105 effector cells in 200μL of RPMI (10% FCS) were added to a FACS tube, 
washed with 2mL of FACS buffer and centrifuged at RT for 5 minutes at 400g. 
The pellet was then stained with the fluorescently-conjugated antibodies CD3 
PerCP, CD56 PE and CD69 FITC (as per Table 2.2) and incubated in the dark 
at RT for 30 minutes. Cells were finally washed in a further 2mL of FACS 
buffer and fixed in 1% PFA before being analysed by flow cytometry (section 
2.4). 
 
2.11.3 CD107 Degranulation Assay 
5x105 effector cells in 200μL of RPMI (10% FCS) were added to FACS tubes 
and 5x104 target cells in 200μL of RPMI (10% FCS) added to give a final 10:1 
effector:target ratio in a total volume of 400μL of media. Cells were co-cultured 
in the FACS tubes for 1 hour at 37°C. After 1 hour an antibody mix containing 
10μL CD3 PerCP, 2μL CD56 PE (for identification of NK cells), 5μL anti-
CD107a FITC, 5μL anti-CD107b FITC and 0.5mL Brefeldin A (Sigma) giving 
a working concentration of 1μL/mL (see Table 2.2) made up to 100μL volume 
with media was added to each tube. Tubes were then incubated at 37°C for a 
further 4 hours before being washed in 2mL of FACS buffer, and fixed in 
300μL of 1% (w/v) PFA. Analysis was undertaken immediately if possible or 
cells were stored in the dark at 4°C for a maximum of a week prior to data 
acquisition by flow cytometry (section 2.4). 
 
 
2.11.4 Interferon Blocking of Natural Killer (NK) cell mediated 
virus activation. 
To assess the pathways involved in virus-induced NK cell activation, type I 
Interferon α/β was blocked and CD69 activation and CD107 degranulation 
assays repeated as described above (sections 2.11.2 and 2.11.3 
respectively). PBMC’s or LNMNC’s cells were seeded at 1x106 cells/mL in a 
12-well plate and incubated for 1 hour at 37°C to allow cells to settle. 30 
minutes prior to the addition of virus 15μL of medium was added to each of 
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the control wells, a combination of 7.5μL anti-IFN α sheep serum (sigma), 
7.5μL anti-IFN β sheep serum and 12.5μL anti-α/β receptor antibodies were 
added to the block interferon and finally 15μL sheep serum and 12.5μL IgG2a 
isotype antibody were added to treatment control wells. Thereafter, cells were 
infected in triplicate (control, interferon block and isotype control) with 0, 0.1 
and 1pfu JX-594 and incubated for 24 hours at 37°C. Cells were harvested as 
detailed in (section 2.8.1 and 2.8.3) and 5x105 effector cells resuspended in 
200μl RPMI/10% FCS before continuing with assays to assess CD69 
expression and CD107 a/b degranulation (section 2.11.2 and 2.11.3 
respectively). 
 
2.12 Enzyme-linked Immunosorbent Assay (ELISA) 
2.12.1 ELISA for IFN-α, IFN-γ, IP-10, GMCSF and TNF- α 
Maxisorp© (96 well, flat-bottomed plates) (Nunc) were coated with pre-
optimised dilutions of capture antibodies (see Table 2.4) diluted in either PBS 
or coating buffer (100mM NAHCO3 in ddH2O) as indicated. Plates were 
wrapped in cling film and stored at 4°C overnight. The following morning plates 
were washed three times with PBS-Tween (0.05% Tween (Sigma) in PBS) 
using a plate washer (Skan Washer 300, Molecular devices, Berkshire, UK) 
and blocked with 200μL of blocking solution (PBS containing 10% FCS) for 2 
hours at RT. Plates then underwent a further 3 washes with PBS-Tween. 
200μL of recombinant protein standards (of known concentration) were added 
in triplicate to the top wells and halving serial dilutions into 100μL of media to 
create a standard curve with halving concentration of recombinant standards; 
the lower most channel only containing media to act as control for background 
optical density readings. Thereafter plates were loaded with sample 
supernatants in triplicate at 100μL/well, wrapped in cling film and stored 
overnight at 4°C. Following the incubation period, plates were washed six 
times in PBS-Tween and 100μL of biotinylated detection antibody diluted in 
blocking solution was added for a further 2 hours at RT. Plates were washed 
again six times in PBS-Tween before 100μL of Extravidin-alkaline 
phosphatase conjugate (Sigma), diluted 1:5000 times with PBS-Tween, was 
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added and incubated for 1 hour at room temperature. Plates were washed 
three times with PBS-Tween and three times with ddH2O. Finally substrate 
solution (p-nitrophenyl phosphate alkaline phosphatase, prepared to 
manufacturers guidelines (Sigma)) was added at 100μL/well and plates left to 
develop in the dark for 15-60 minutes.  
Plates were read using a Multiskan EX plate reader (Thermo Fisher Scientific) 
at a wavelength of 450nM to record optical densities. Using the standard curve 
optical density readings were then used to reveal sample protein quantities 
(pg/mL). 
 
 
Antibody	 Capture	 Detection		 Standard	(Top	
Concentration)	
Type	 Manufacturer	
IFN-α	 1:250	 1:500	 5000pg/ml	 Mouse	Anti-	Human	 Mabtech	
IFN-γ	 1:250	 1:500	 10000pg/ml	 Mouse	Anti-	Human	 BD	Biosciences	
IP-10	 1:500	 1:500	 5000pg/ml	 Mouse	Anti-	Human	 BD	Biosciences	
CXCL-10	 1:180	 1:180	 2000pg/ml	 Goat	Anti-	Human	 R&D	Systems,	Bio-techne.	
GMCSF	 1:500	 1:1000	 2000pg/ml	 Mouse	Anti-human	 Mabtech	
TNF-	α	 1:1000	 1:1000	 2000pg/ml	 Mouse	Anti-human	 BD	Biosciences	
Table 2.4 ELISA antibodies and protein standards 
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2.12.2 ELISA for IFN-β 
ELISA for IFNβ production was undertaken utilizing a Verikine™ Human IFN 
Beta ELISA kit (PBL Interferon Source, NJ, USA). Pre-coated 96-well plates 
provided with the kit were loaded in duplicate with serial dilutions of 
recombinant protein standards as per manufacturer’s instructions before 50μL 
of sample supernatants were added and incubated for 1 hour at RT. Plates 
were washed three times utilizing a supplied wash buffer. 100μL of detection 
antibody, appropriately diluted in a concentrate diluent was then added before 
a further 1 hour incubation at RT. Plates were washed once more 3 times in 
wash buffer prior to addition of 100μL of appropriately diluted Horseradish 
peroxidase (HRP) for a further 1 hour incubation at RT. A final single wash in 
wash buffer was then undertaken before 100μL of TMB substrate (provided 
with kit) was added to each well and allowed to develop for 15 minutes in the 
dark.  Following the addition of 100μL of stop solution, optical densities were 
determined using a Multiskan plate reader at a wavelength of 405nm. Optical 
densities were converted to protein quantities (pg/mL) using the standard 
curve generated. 
 
2.13 Western Blots for HMGB1 
Cell free supernatants were harvested from pre-cultured SW480 and SW620 
cell lines infected with an multiplicity of infection (MOI) of 0, 0.1 or 1 for 24, 48 
and 72 hours. Supernatants were then stored at -80°C until required. 
Alongside this, cell pellets were prepared from harvested DLD-1 cell lines 
cultured in T75 flasks to act as a positive control. 
Running gels and stacking gels were prepared using: ddH2O, 30% acrylamide 
mix; 10% (w/v) SDS, 1.5M Tris pH 8.8 (running gel), 1M Tris pH6.8 (stacking 
gel), 10%  (w/v) ammonium persulphate and Tetramethylethylenediamine 
(TEMED) according to previously described protocols and quantities 
described by Sambrook et al. (1989)192. A 10% running gel was poured into 
prefabricated cassettes (Invitrogen Life Technologies) and allowed to set. The 
cassette was then rinsed with ddH2O, and the stacking gel and comb added. 
20μL of each  of the cell free supernatants diluted 1:1 with Laemmli buffer (4% 
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SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 
0.125 M Tris HCl at pH 6.8) were loaded into the sample lanes alongside 2μL 
of protein molecular marker (Odyssey, LI-COR Biosystems, Lincoln, USA) 
added to the control lane in order to identify the size of the detectable proteins. 
Gels were run at 160-180V for approximately 60 minutes (until dye had run to 
the bottom of the gel) using a XCell SureLock™ Mini Cell system (Invitrogen) 
and a Bio-Rad laboratories PowerPac™ HC. Protein transfer was then 
performed at 25V for 120 minutes onto a Hybond™ C Super nitrocellulose 
membrane (Amersham Biosciences, Little Chalfont, UK). The membrane was 
washed three times in PBS containing 0.1% (v/v) Tween (PBST) and blocked 
overnight in Odysssey blocking buffer (LI-COR Biosciences). 
Staining for HMGB1 was undertaken using a monoclonal mouse anti-human 
HMGB1 antibody (R&D systems, Abingdon, UK) at a 1:500 dilution in a 1:1 
mix of blocking buffer and PBST. The membrane was placed carefully in a 
50mL Falcon tube and 5mL of the antibody mix added and placed on roller 
apparatus for 1 hour at room temperature. The membrane was then washed 
four times for 5 minutes each in PBST. The secondary antibody used was 
goat anti-mouse conjugated with AlexaFluor 680 (Molecular Probes, 
Invitrogen), this was used at a 1:5000 dilution in 5mL of 1:1 ratio mix of 
blocking buffer and PBST. Incubation for 1 hour at RT in the dark was again 
achieved by placing the membrane in a 50mL Falcon and continuously 
rotating on a roller to ensure consistent antibody/membrane coverage. The 
membrane was finally washed four further times for 5 minutes, each in PBST 
before Supersignal™ West Pico Chemiluminescent substrate (Thermo Fisher 
Scientific, Loughborough, UK) was added to the membranes for 5 minutes. 
Excess liquid was removed and the membrane was taken to the dark room 
and exposed to Amersham Hyperfilm™ECL™ film (GE Healthcare Life 
Sciences, Buckinghamshire, UK) and developed using a Kodak X-OMAT 
3000RA Processor. 
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2.14 Statistical Analysis 
Data was represented graphically as mean ± standard error of the mean 
(S.E.M). Statistical analysis was performed using Graphpad Prism for Mac 
(v6.0, Graphpad Software, Inc). p values were calculated by using the one-
way or two-way analysis of variants (ANOVA) with Bonferroni post-hoc test or 
a paired student t-test with two-tailed distribution. p values were considered 
significant at p<0.05. 
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Chapter 3  
Combination Strategies 
3.1 Introduction 
The development of novel targeted therapies for CRC, such as cetuximab and 
Panitumumab, has improved colorectal cancer patient overall survival 
although anti-epidermal growth factor receptor (EGFR) immunotherapy is not 
suitable for all patients, with only 10-20% achieving clinical responses.  KRAS, 
BRAF and PI3KCA mutations (causing constitutively activated EGFR-
signalling) have been implicated in cellular resistance to anti-EGFR therapy.   
Cetuximab (an IgG1 chimeric anti-EGFR antibody) and Panitumumab (an 
IgG2 fully-humanised anti-EGFR antibody) induce their anti-cancer effects by 
two distinct mechanisms; blockade of EGF-receptor binding preventing pro-
survival/proliferation signals, and ADCC/ADCP.  A role for monocytes and NK 
cells has been described for cetuximab-ADCC/ADCP, whereas Panitumumab 
utilises monocytes and neutrophils for its immune-mediated effects; these 
targeted interactions are regulated by Fcγ receptor expression on different 
immune effector cells.193 GA201, a humanised-IgG1 glyco-engineered anti-
EGFR antibody is reported to have increased Fc-gamma binding affinity and 
induction of ADCC in KRAS wild-type and mutant cells, and is also in pre-
clinical development.194 
ADCC should occur irrespective of EGFR-signalling mutations and one would 
expect patients with KRAS-mutations to demonstrate some clinical response 
if ADCC played an important role in vivo. Disappointingly, large clinical studies 
have shown that KRAS-mutant patients do not benefit from anti-EGFR therapy 
(regardless of antibody mechanism of action) and it is currently only offered 
to patients with wild-type KRAS cancers.195 Immune cell populations within 
the tumour microenvironment can either support tumour growth or contribute 
to anti-tumour activity and as such can be used as diagnostic and prognostic 
biomarkers. High lymphocyte counts typically are reported to correlate with 
good prognosis and high tumour-associated macrophages (TAM)/neutrophils 
(TAN) are associated with poor prognosis.196 Interestingly, a controversial role 
for TAM has been described for CRC with both pro- and anti-tumour activities 
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being reported. Acting as ‘pro-tumour macrophages’ TAMS promote initiation 
and metastatic progression of tumour cells, stimulate tumour angiogenesis 
and via the modulation of T-cell activity inhibit anti-tumour immune 
responses.196 Furthermore, TAMS are reported to protect colorectal cancer 
cells from TNF-related apoptosis induced ligand (TRAIL)-mediated 
apoptosis.197  
Conversely, strong evidence also exists for the anti-tumour activity of TAMS 
with several authors reporting an association between increased macrophage 
infiltration and improved outcomes, the mechanisms behind which remain less 
clear.198–201 Some suggested mechanisms include macrophages along the 
tumour margin inducing apoptosis in a Fas ligand-dependent process, as 
reported by Sugita et al. (2002)199 or alternatively peritumoral macrophages 
differentiating into a tumoricidal phenotype as a result of reduced tumour 
derived cytokine exposure and being located in a less hypoxic area.202,203 
Clearly, harnessing the immune cell repertoire within the tumour is likely to be 
important for generating objective clinical responses and it is possible that 
immune cell activation could increase the efficacy of anti-EGFR 
immunotherapy for both wild-type and mutant-KRAS CRC. 
Oncolytic viruses (OV) preferentially replicate in cancer cells causing cell 
death. Oncolytic Reovirus, a clinically advanced OV, exerts its cytotoxic 
effects by direct oncolysis (reported to be caspase-dependent and therefore 
apoptotic in nature) and/or activation of anti-tumour immunity.204 Reovirus 
sensitivity has been reported to be dependent on KRAS-mutations, or 
downstream activating signalling mutations (such as PI3K) (Figure 1.3) hence 
KRAS-mutant patients that are resistant to cetuximab should be susceptible 
to Reovirus-induced oncolysis.  As such we hypothesise, that immune 
activation of monocytes, neutrophils and NK cells by Reovirus may potentiate 
cetuximab/panitumumab mediated-ADCC/ADCP.  In support of this, 
published research has demonstrated that Reovirus can; activate monocytes 
within white blood cells (WBCs)205; activate NK cells both in vitro and in vivo206; 
be isolated from CRC liver metastases after systemic delivery206; and enhance 
rituximab-mediated ADCC of autologous CLL cell targets.205  
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Recently, detailed analysis of CRC liver metastases demonstrated that B-Cell 
Lymphoma Extra Large (BCL-XL), an anti-apoptotic, pro-survival protein 
associated with advanced disease and resistance to chemotherapy, is 
upregulated in CRC and associated with KRAS-mutations.207  Interestingly, 
inhibition of BCL-XL, using the pro-apoptotic BH3 mimetic (ABT-737) which 
mechanistically antagonizes the BCL-2 family of anti-apoptotic proteins, was 
shown to sensitise HRASG12V-expressing colorectal cancer cells to cetuximab 
cytotoxicity.207  As such, it has been proposed that combination strategies 
incorporating ABT-263/Navitoclax (a clinical grade BH3-mimetic) could have 
the potential to increase OV direct cytotoxicity.208 
These hypotheses remain untested and could provide strong evidence to 
support the use of OV, in appropriate combinations with either 
cetuximab/Panitumumab and/or BCL-2 family antagonists for all CRC 
patients, including those with EGFR-signalling mutations or specifically to 
target those patients resistant to anti-EGFR monotherapy.  
 
3.2 Results 
3.2.1 Colorectal cell lines are variably susceptible to Reovirus 
killing 
Previous members of the group have demonstrated that a number of CRC 
cells are susceptible to Reovirus-induced oncolysis204 and replication-
competent Reovirus can be recovered from CRC liver metastases after 
intravenous injection prior to surgical resection.206 Previous work has however 
not been contextualised with regard to genetic mutations and has utilised a 
selective and limited panel of colorectal cell lines. This study therefore initially 
aimed to broaden the range of cell lines investigated, examining their 
susceptibility to OV killing using a Live/Dead™  flow cytometry cell viability 
assay. 
 
Nine colorectal cell lines in total were available for experimentation from either 
collaborative groups or from within the local cell bank library. A summary is 
shown in Table 3.1. 
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Table 3.1 CRC cell line library 
Summary of original patient demographics, cancer site and disease profile. (un = 
unknown)  
 
A broad range of mutational profiles exist within this panel of cell lines (Table 
3.2) and we therefore planned to utilise this library of CRC cell lines to test 
susceptibility of various KRAS/BRAF/PI3KCA mutations to Reovirus 
cytotoxicity using cell viability (Live/Dead™  and MTT (data not shown)) 
assays. This is important given that we know Reovirus can access CRC in 
particular, liver metastasis, following systemic delivery to cancer patients. 
Levels of cell death were  examined in the context of KRAS/BRAF/PI3KCA 
mutations to determine whether a specific genetic mutation, or combinations 
thereof, could be used to predict Reovirus sensitivity. 
Cell	Line Age Ethnicity	 Gender	 Organ	 Disease Stage Derivation Morphology
SW480 50 Caucasion Male Colon Colorectal	Adenocarcinoma Dukes	B	 Primary	Tumour EpithelialSW620 51 Caucasion Male Lymph	Node	Metastasis Colorectal	Adenocarcinoma Dukes	C	 Metastasis EpithelialHCT116 48 Caucasion Male Ascending	Colon Colorectal	Adenocarcinoma Dukes	D Primary	Tumour EpithelialColo320 55 Caucasion Female Sigmoid	Colon Colorectal	Adenocarcinoma Dukes	C Primary	Tumour Rounded	&	RefractileHT29 44 Caucasion Female Colon Colorectal	Adenocarcinma Dukes	C Primary	Tumour EpithelialLoVo 56 Caucasion Male Left	Supraclavicular	Lymph	Node
Colorectal	Adenocarcinma Dukes	C Metastasis Epithelial
LIM1215 34 Caucasion Male OmentalMetastasis Heridatory	nonpolyposis	colorectal	cancer
Duke	D Metastatis Epithelial
LIM1899 UN Unknown Unknown Colon Colorectal	Adenocarcinoma Dukes	C Primary	Tumour Epithelial,	Rounded	&	clusteredLIM2408 UN Unknown Unknown Splenic	Flexure Moderately	differentiated	adenocarcinoma
Dukes	C Primary	Tumour Epithelial
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Table 3.2 CRC cell line panel. 
Table highlighting reported EGFR expression and KRAS/BRAF/PI3KCA mutational 
status within the experimental CRC cell line panel. 
 
3.2.2 Reovirus demonstrates variable levels of cytotoxicity 
against CRC cells with different mutational characteristics.  
Initial experimentation therefore involved the direct cytotoxic potential of 
Reovirus on our panel of CRC cell lines. All nine available cell lines were 
initially studied, however, for the purposes of this report two of the lines were 
excluded. Both LOVO and LIM1215 cell lines showed wide variability in results 
and high levels of cell culture death in the absence of treatment. Further 
examination demonstrated mycoplasma infection and despite attempts to 
decontaminate the stored samples a decision was made to exclude these 
lines from further experimentation. 
SW480, SW620, HCT116, Colo320, HT29, LIM1899 and LIM2408 cell lines 
were directly infected with 0, 0.1, 1 and 10pfu/cell Reovirus for 24-96 hours 
before cell viability was determined using Live/Dead™  cell viability assay and 
flow cytometry. Figure 3.1 shows data for the 48 and 72 hour time points. 
SW480 SW620 HCT116 Colo320 HT29 LOVO LIM1215 LIM1899 LIM2408
EGFR
expression
Yes Low Yes No Yes Yes Yes Yes Yes
KRAS G12V G12V G13D WT WT G13D WT G12A WT
BRAF WT WT WT WT V600E WT WT WT V600E
P13K WT WT H1047R WT WT WT WT WT WT
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Figure 3.1 Reovirus-induced cell death in CRC Cell Lines. 
Cell lines A-G (A-SW480, B-SW620, C-HCT116, D-Colo320, E-HT29, F-LIM1899 
and G-LIM2408) were treated with 0 (control), 0.1, 1 and 10pfu/cell Reovirus for 48 
and 72 hours. At each time point cells were harvested and stained with Live/Dead™  
for assessment by flow cytometry. Graphs show mean percentage cell death of at 
least 3 independent experiments + SEM. Statistical significance is denoted by * 
p<0.05 (one-way ANOVA) 
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Our panel of cell lines responded with mixed sensitivity to infection with 
Reovirus. Consistent with previous data from our laboratory, SW480 cells 
showed a repeatable dose-dependent and time dependent response with 
maximal death seen at 72 hours with 10pfu/cell Reovirus. SW620 cells, the 
metastatic line relating to the SW480 primary are known to be more resistant 
to virotherapy and as such no death was seen at 48 hours but thereafter 
Reovirus killed in a dose and time dependent fashion. The suggestion of a 
continuing effect and further death was seen at 96 hours (data not shown) but 
for the purposes of this study we did not extend this time point further. Similar 
reduced sensitivity to Reovirus was observed in HT29 cell lines with only low 
level cell death seen following high dose, 10pfu Reovirus treatment. Increased 
cytotoxicity was seen in a time dependent fashion (16.3% to 29.9% for 10pfu 
at 48 and 72 hours respectively) but remained low when compared with other 
cell lines. 
As with SW480, Colo320 and LIM2408 cells were sensitive to Reovirus-
induced oncolysis even at lower doses of Reovirus. Maximal percentage cell 
death (58.3% and 47.9% respectively) was observed after 72 hours and 
treatment with 10pfu Reovirus. Moreover, HCT 116 cells demonstrated the 
most sensitivity to Reovirus cytotoxicity with cell death observed at early time 
points and low concentrations of virus (16.7% cell death at 48hrs and 
0.1pfu/cell Reovirus; 48.6% cell death at 72hrs and 0.1pfu/cell Reovirus) when 
compared to other cell lines.  
There was no cytotoxicity seen in LIM1899 across the time points implying 
that this cell line is completely resistant to Reovirus infection. Across our panel 
of cell lines there was no evidence that Reovirus induced death demonstrated 
any correlation to mutational status, however of note HCT116 were the most 
sensitive and contain mutational changes in the RAS pathway. Interestingly, 
Colo320 which are wild type and harbour no mutations in the 
KRAS/BRAF/PI3K pathway, and therefore maybe expected to be resistant are 
in fact sensitive to Reovirus-induced cell death. It remains unclear as to the 
mechanism behind this but hypothetically this could be due to mutations in 
alternative uncharacterised genes in the RAS pathway or alternatively that 
Reovirus sensitivity is not ubiquitously controlled by the RAS signalling 
pathway. 
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3.3 EGFR Binding studies 
Given that the mutational status of CRC cell lines did not correlate with 
Reovirus sensitivity, we wanted to confirm that the cell profiling reported in the 
literature was consistent with our in house cell populations. Particular focus 
was placed on EGFR binding, given its relevance to work discussed later in 
this chapter regarding anti-EGFR monoclonal antibody combination 
strategies. Cell surface expression of EGFR was determined using an anti-
human EGFR-PE monoclonal antibody by flow cytometry. All cell lines were 
tested and representative results are shown for 4 cell lines (Figure 3.2). 
SW480 cells demonstrated the most significant EGFR cell surface expression, 
whilst moderate expression was seen in HT29 and HCT116. As reported 
Colo320 CRC cells showed no evidence of EGFR expression. For the 
remaining cell lines tested, EGFR expression correlated with published 
reports (See Table 3.2).  
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Figure 3.2 Cell surface EGFR expression for four CRC cell lines. 
Freshly harvested cell lines were stained with an anti-human-EGFR-PE antibody or 
IgG isotype control. Cell surface expression was determined by flow cytometry (Red 
line: EGFR expression; shaded area: Isotype control). Data shown is representative 
of 3 independent experiments. 
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3.4 Combination strategies with BCL-2 antagonists. 
The PI3K-AKT and RAS-ERK pathways are two of the most important 
signaling pathways that regulate cell proliferation and survival. Functional 
mutations in genes for these two signaling pathways, such as RAF, RAS and 
PI3K are frequently observed in malignant tumours and result in abnormal 
activation causing primary drug resistance and reduced efficacy of 
chemotherapeutic agents.168,209,210 These pathways therefore present 
promising therapeutic targets however the targeting of individual molecules 
often results in only limited anti-tumour efficacy and as such combination 
strategies to target various aspects of the pathway could provide a more 
promising therapeutic effect. Interestingly, Leverson et al. (2015) 210 showed 
that inhibition of the PI3K-AKT or RAS-ERK pathway (by for example anti-
EGFR antibodies) upregulates the pro-apoptotic proteins BIM or BAD and 
downregulates the pro-survival proteins BCL-2 and MCL-1. These effects 
were significantly enhanced by co-treatment with the BH3 mimetic, ABT-263, 
and resulted in ‘on-target cancer cell killing activity’. 
 
ABT-263 (Navitoclax) is an orally administered active analogue of ABT-737, a 
BH3 mimetic designed to induce apoptosis by blocking the functions of the 
pro-survival BCL-2 family proteins. Combination strategies using ABT-263 
with various FDA approved drugs have reached clinical trials for the treatment 
of both solid tumours and haematological malignancies, however tumour cells 
expressing high levels of MCL-1 have shown resistance to both ABT-263 and 
ABT-737.178,211 Furthermore after long exposure to the BH3 mimetic inhibitors, 
resistance is acquired as a result of upregulation of MCL-1.212 
 
3.4.1 ABT-263 induced cell death in Colorectal Cell lines  
Given the mechanism of action of ABT-263 (i.e. modulation of the pro vs anti 
apoptotic pathway), we hypothesised that combination with OV (which can kill 
via apoptotic mechanisms) may increase the efficacy of oncolytic virotherapy 
producing a synergistic effect. ABT-263 activity and cell death is thought to 
rely on releasing BIM to promote apoptosis213. High levels of BIM are reported 
to predict an increased sensitivity to ABT-263 while resistance is correlated 
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with high MCL-1 levels. Various studies have documented that almost 50% of 
cancer cell lines are resistant to ABT-263 as a direct result of the variation in 
the levels of these pro vs anti-apoptotic molecules.183,214,215 Therefore, before 
exploring combination strategies we initially examined whether our library of 
CRC cell lines were sensitive to ABT-263 monotherapy.  
SW480, SW620, HCT116, Colo320, HT29, LIM1899 and LIM2408 cell lines 
were treated with 0, 0.1, 1 and 10μM ABT-263 for 24-96 hours before cell 
viability was determined using Live/Dead™ cell viability assay and flow 
cytometry. Results for 48 and 72 hours are shown in Figure 3.3. 
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Figure 3.3 ABT-263 induced cell death in CRC Cancer Cell Lines. 
Cell lines A-G (A-SW480, B-SW620, C-HCT116, D-Colo320, E-HT29, F-LIM1899 
and G-LIM2408) were treated with 0, 0.1, 1 and 10μM ABT-263 for 48 and 72 hours. 
At each time point cells were harvested and stained with Live/Dead™  for 
assessment of cell viability using flow cytometry. Graphs show mean percentage cell 
death of at least 3 independent experiments + SEM. Statistical significance is 
denoted by * p<0.05 (one-way ANOVA). 
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Treatment of our cell lines with ABT-263 resulted in a mixed response. 
Following treatment, two cell lines LIM1899 and Colo320 showed no 
significant change in cell viability, either in a concentration or time dependent 
manner. SW480 and LIM2408 cells were killed in the presence of ABT-263 in 
a concentration dependent manner, with no significant change in effect seen 
at different time points. For example, 10μM ABT-263 treatment of LIM2408 
resulted in 50.1% and 53.7% cell death at 48 and 72 hours, respectively, and 
similarly in SW480 cells treatment resulted in 55.7% and 60.6% cell death at 
the same time points. The remaining cell lines tested, SW620, HT29 and 
HCT116 were less sensitive to ABT-263 treatment at the 48 hour time point 
(29.4%, 12.8% and 34.1% cell death for 10μM ABT-263 at 48hrs, respectively) 
but responded to treatment in both a dose and time dependent fashion with 
increased death at 72 hours for SW620 (49.26%). HT29 (31.8%) and HCT116 
(43.9%).  
As with Reovirus, across our panel of cell lines there was no evidence that 
ABT-263 induced cell death demonstrated any correlation to cell line 
mutational status. Of note, however is that Colo320, which is wild-type in 
KRAS/BRAF/PI3K genotype was the least sensitive to ABT-263 killing. Whilst 
this may indicate a requirement for a positive mutational status to be present 
to allow independent ABT-263 killing a similar lack of response was also seen 
in the LIM1899 cell line which is KRAS mutant. The relevance of this remains 
unclear, but could result from differential downstream signalling pathways 
being modulated in response to the different codon mutations. To support this 
hypothesis, and whilst it remains controversial, some authors have suggested 
that sensitivity to certain therapeutic agents may be effected by the exact 
codon effected by the mutation.216,217 For example, Kumar et al (2014)217 
suggested that whilst mutational constitutive activation of the RAS/RAF/MAPK 
signalling pathway is generally accepted to result in drug resistance a 
proportion of patients with the KRAS G13D mutation did in fact respond to 
anti-EGFR antibody therapy. The complex interaction of cell signalling 
processes is beyond the scope of this study but it is clear that the interplay 
between EGFR signalling and expression of pro vs anti-apoptotic BCL-2 
protein family members is important to understanding how we might utilise, 
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and optimise, potential combination strategies both in the lab and 
translationally into the clinic.    
  
3.4.2 Efficacy of combining ABT-263 and Reovirus in vitro 
Given the variable response of our cell lines to both Reovirus, which kills by 
inducing apoptosis and ABT-263, a pro-apoptotic molecule, we then went on 
to investigate whether using both agents in combination may induce 
synergistic killing, enhancing the oncolytic potential of Reovirus. 
 
The panel of CRC cell lines were treated with various combinations of high-
dose and low-dose ABT-263 and high dose and low dose Reovirus alone, or 
in combination, and cell viability at various time points was assessed. 
Graphical representation of the data is presented in Figure 3.4. 
 
- 98 - 
 
0 0.1 1 10
0
20
40
60
80
Reovirus (pfu)
%
 C
el
l D
ea
th
0 0.1 1 10
0
20
40
60
80
Reovirus (pfu)
%
 C
el
l D
ea
th
0 0.1 1 10
0
20
40
60
80
Reovirus (pfu)
%
 C
el
l D
ea
th
0 0.1 1 10
0
20
40
60
80
Reovirus (pfu)
%
 C
el
l D
ea
th
0 0.1 1 10
0
20
40
60
80
Reovirus (pfu)
%
 C
el
l D
ea
th
0 0.1 1 10
0
20
40
60
80
Reovirus (pfu)
%
 C
el
l D
ea
th
0 0.1 1 10
0
20
40
60
80
Reovirus (pfu)
%
 C
el
l D
ea
th
0 0.1 1 10
0
20
40
60
80
Reovirus (pfu)
%
 C
el
l D
ea
th
48 hours 72 hoursA. SW480
B. SW620
C. HCT116
D. Colo320
- 99 - 
 
 
Figure 3.4 Reovirus and ABT-263 combination induced cell death in CRC 
cell lines. 
Cell lines A-G (A-SW480, B-SW620, C-HCT116, D-Colo320, E-HT29, F-LIM1899 
and G-LIM2408) were treated with 0, 0.1, 1 and 10μM ABT-263 and/or 0, 0.1, 1 and 
10pfu/cell Reovirus for 48-72 hours. At each time point cells were harvested and 
stained with Live/Dead™  for assessment of cell viability using flow cytometry. 
Graphs show mean percentage cell death of at least 3 independent experiments + 
SEM. Statistical significance is denoted by * p<0.05 (one-way ANOVA). 
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Combinations of Reovirus and ABT-263 demonstrated a mixed but largely 
limited effect of the combination therapy. SW620 CRC cells were the only cell 
line which showed a significant increase in cell death when compared with 
single agent therapy in a dose dependent and time dependent manner. 
Notably, however in LIM2408, SW480 and HT29 cell lines, maximal death was 
achieved with high dose ABT-263 alone and Reovirus demonstrated no 
additional effect over and above this treatment. To further analyse these data, 
and ascertain if there was either a synergistic or additive effect present, further 
analysis of the data was undertaken using a single chosen dose of both ABT-
263 (1μM) and Reovirus (10pfu/cell), at a single time point (72hrs) as a 
representative sample of response across the cell lines. Data is shown in 
Figure 3.5. 
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Figure 3.5 The effect of combining 10pfu Reovirus and 1μM ABT-263 on 
CRC cell death. 
Cell lines A-F (A-SW480, B-SW620, C-HCT116, D-Colo320, E-HT29 and F-
LIM2408) were treated with 1μM ABT-263 and 10pfu/cell Reovirus for 72 hours. Cells 
were harvested and stained with Live/Dead™  for assessment of cell viability using 
flow cytometry. Graphs show mean percentage cell death of at least 3 independent 
experiments + SEM. Statistical significance is denoted by * p<0.05 (paired student t-
test).  
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Disappointingly, increased death was only seen as a direct result of 
combination therapy in the SW620 cell line. Coefficient regression analysis, 
however, demonstrated no synergistic effect suggesting that the increased 
death seen was additive and the result of both agents working in 
mechanistically different ways rather than acting to enhance the effect of each 
other. 
3.5 Combination strategies to optimise Anti-EGF Receptor 
monoclonal antibody (Cetuximab/GA201) therapy. 
As discussed previously, alternative therapies that may act in combination or 
hypothetically be modulated by oncolytic Reovirus, are the anti-EGFR 
receptor monoclonal antibodies.  Clinically, Cetuximab and GA201 are directly 
cytotoxic against KRAS wild-type cells but exert limited toxicity against KRAS-
mutant cells. Hypothetically, Reovirus could enhance killing by promoting the 
ADCC/ADCP mechanisms of the anti-EGFR monoclonal antibodies. 
However, of note, it is possible that this effect may be countered, certainly in 
wild type cell lines, by antibodies blocking EGFR signalling and directly 
impeding the RAS signalling mechanisms used by Reovirus for direct killing, 
given that Reovirus oncolyis can be facilitated by constitutively activated 
EGFR-signalling pathways.218 
 
Utilising our panel of CRC cell lines with varying EGFR expression/genetic 
susceptibility mutations (Table 3.2) we first aimed to test the direct cytopathic 
effects of cetuximab and GA201 (data no shown) before investigating the 
ability of potential reciprocal interaction with Reovirus treatment. Having 
confirmed EGFR cell-surface expression in our CRC cell line was in 
accordance with reported literature (Figure 3.2), we then sought to confirm 
EGFR-antibody binding to CRC cell lines using FACS (Figure 3.6).  
- 103 - 
 
 
Figure 3.6 Cetuximab binding studies in CRC cell lines with varying 
EGFR expression.  
Four cell lines (HCT116, SW620, SW480 and Colo320) were selected for their variable 
EGFR expression status. EGFR expression and Cetuximab binding were compared. A.(i) 
shows a FACS plot of EGFR expression on SW480 CRC cell lines by flow cytometry 
compared with A(ii) showing SW480 cells labelled with 5µg/mL cetuximab for 30mins at 
37°C; Binding of Cetuximab was determined using a FITC-conjugated anti-human IgG1 
antibody and flow cytometry.  B. Cell lines were labelled with increasing doses of 
cetuximab (0, 1.25, 2.5, 5 and 10μg/mL) for 30mins at 37°C and binding was determined 
using FITC-conjugated anti-human IgG1 antibody and flow cytometry; Representative 
FACS plots are shown. C. FACS data was quantified as mean fluorescent intensity. Bar 
charts represent EGFR (left) and cetuximab binding (5μg/mL) (right) for each cell line 
investigated. Graphs show mean + SEM of 2 independent experiments.  
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Four cell lines were selected for their variability in EGFR expression and 
KRAS mutant status. SW480 and HCT116 both express EGFR on their cell 
surface, SW620 has low EGFR cell surface expression and Colo320 has no 
EGFR cell surface expression as confirmed in earlier experimentation (Figure 
3.2) and consistent with reported literature. As expected the data 
demonstrates binding of cetuximab in the cell lines with high EGFR 
expression, limited cetuximab binding in SW620 cell lines, consistent with the 
low EGFR expression and no evidence of cetuximab binding on Colo320 cells. 
Importantly, of note, both SW480 and HCT116 cell lines are KRAS genotype 
mutants and additionally HCT116 also has a PI3K mutation. As such 
cetuximab is likely to demonstrate less efficacy as a direct agent but may act 
via ADCC triggered by FC𝛾R engagement with NK cells. In support of this 
there is good evidence that cetuximab-mediated ADCC activity is correlated, 
with the cell surface expression level of EGFR, regardless of the mutational 
status of the CRC cell line.219 
 
3.5.1 Cetuximab induced cell death in Colorectal Cell lines 
Clinically cetuximab only achieves a less than ten percent objective response 
rate when utilised as a monotherapy in an unselected patient population and 
only 25% clinical response in those patients genotyped for wild-type KRAS 
and BRAF genes.220,221 Before investigating combination strategies we aimed 
to assess whether our panel of colorectal cell lines would respond in a similar 
fashion to cetuximab monotherapy in vitro.  SW480, HCT116, HT29, SW620, 
Colo320 and LIM1899 cell lines were directly treated with 0, 0.1, 1 and 
10μg/mL Cetuximab for 48 (data not shown) and 72 hours before cell viability 
was determined using Live/Dead™  cell viability assay and flow cytometry. 
Similarly, to confirm methodological accuracy treated cell lines were assessed 
by MTT assay to determine any anti-proliferative and cytotoxic effects. Figure 
3.7 shows data at 72 hour time point for both MTT and Live/Dead™ viability 
assays with increasing doses of cetuximab. 
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Figure 3.7 Cetuximab monotherapy was not cytotoxic against CRC cell 
lines despite KRAS/BRAF status. 
A) CRC cell lines SW480, HCT116 and HT29 were seeded at 8 x 103 cells per well 
in a 96-well plate  and treated with cetuximab at concentrations of 0, 0.1, 1 and 10 
μg/mL. 72 hours post treatment, MTT was added for 4 hours and DMSO used to 
solubilise cells. Percentage viability was calculated as absorbance measured relative 
to untreated cells. Graphs show mean ± SEM for 3 independent experiments. B) 
Colorectal cell lines were treated with 0, 0.1, 1 and 10μg/mL Cetuximab for 72 hours 
before being harvested and stained with Live/Dead™  to assess cell viability by flow 
cytometry. Graphs show mean percentage cell death of 3 independent experiments 
± SEM. 
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In our cohort of cell lines tested, we were unable to illicit or demonstrate any 
cetuximab cytoxicity using either MTT or Live/Dead™  cell viability assays. No 
cell death was seen even at high cetuximab doses and previously reported 
significant time points. These findings are consistent with recently published 
data which suggests that single agent cetuximab-induced cytotoxicity is only 
seen in colorectal cell lines which are EGFR positive and RAS wild type in 
their genotype. The only such cell line in our panel which would meet this 
criteria is LIM1215 which was excluded from our study based on mycoplasma 
contamination issues mentioned previously.  The other RAS wild type cell line 
included Colo320, does not express EGFR and would therefore preclude the 
action of an anti-EGFR binding antibody; Similarly HT29 which whilst RAS 
wild type, has a BRAF mutation and as such acts to constitutively activate the 
RAS-BRAF-PI3K cascade, downstream of EGFR. It is therefore perhaps not 
surprising that in the tested cell line panel we were unable to illicit any 
demonstrable single agent cetuximab-induced cytotoxicity. However, the 
absence of direct cetuximab killing enabled us to assess the efficacy of 
cetuximab-mediated immune based killing mechanisms such as NK-mediated 
ADCC. 
 
3.5.2 The combination of cetuximab and Reovirus increases 
ADCC–mediated killing. 
Strategies to overcome the inhibitory effect of RAS-RAF-MAPK mutations 
have been widely explored and tested in order to enhance the efficacy of anti-
EGFR antibody therapy, these include consideration of cell-mediated 
ADCC/ADCP.  
After a monoclonal antibody binds to the tumour antigen, the Fc portion of the 
monoclonal antibody will interact via the Fc𝛾R on the surface of an immune 
effector cell (e.g. NK cells). Responses to this can be stimulatory or inhibitory 
depending on both the Fc𝛾R triggered and the effector cell involved. Several 
immune effector cells (NK cells, T cells and macrophages) have the ability to 
recognise target cell populations through FcR-mediated antibody binding 
mechanisms, for example EGFR on the surface of colorectal cells will bind 
Cetuximab and can lead to potent anti-tumour immunity. NK cells can be 
- 107 - 
activated by binding monoclonal antibodies (such as cetuximab) through 
engagement of Fc𝛾R on their surface and death of the antibody opsonised 
cancer cell target. Various ADCC mechanisms have been reported  including 
pro-inflammatory cytokine release (IFN𝛾), cytotoxic granule exocytosis and 
TNF family death receptor signalling which ultimately result in target cell 
apoptosis.222 
As previously discussed, it is well understood that monocytes and NK cells 
play a crucial role in cetuximab-mediated ADCC and our laboratory has 
previously demonstrated that NK cells isolated from both healthy donor and 
colorectal cancer patient PBMCs can be activated by Reovirus, both in vitro 
and in vivo.204 We therefore planned to investigate if Reovirus activation of 
PBMCs and resultant NK cell activation could increase cetuximab mediated-
ADCC in a mutant KRAS colorectal cell line population (SW480 cells) using a 
51Chromium release assay. Results are shown in Figure 3.8. 
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Figure 3.8 Combination of cetuximab and Reovirus increases ADCC-
mediated killing. 
Healthy donor PBMCs were harvested from whole blood and treated with 0pfu/cell or 
0.1pfu/cell Reovirus overnight. Treated PBMCs were then co-cultured with 51Cr-
labelled SW480 cells ± cetuximab-binding at different effector:target ratios for 4hrs; 
% lysis was determined by 51Cr-release using a Microbetajet scintillation counter. 
Data is presented from a single experiment.  
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At all effector:target ratios examined Reovirus activated PBMC’s 
demonstrated a clear increase in cetuximab-induced ADCC. Of note, dose 
dependent cell lysis was seen in both independently treated cell populations. 
Reovirus activated PBMCs in the absence of cetuximab resulted in 40% lysis 
at the 50:1 E:T ratio, consistent with activated NK cells acting as the main 
cytolytic agent. Interestingly, despite SW480 demonstrating a mutant KRAS 
genotype, cetuximab treatment alone also resulted in 45% lysis at the 50:1 
E:T ratio.  This is consistent with reported literature demonstrating that 
cetuximab has the potential to act via two independent pathways; as used in 
the clinical setting, in WT cell lines through direct ligand binding and disruption 
of the RAS-RAF-PI3K pathway and in this case, in a constitutively activated 
mutant cell line, SW480, by recruitment and activation of NK cells via FcR 
binding and induction of ADCC. Despite the fact that low level cell lysis was 
seen within those cell populations treated with Reovirus and cetuximab 
independently, a combination strategy produced improved killing in the 
experimental setting with Cetuximab induced-ADCC being enhanced by 
Reovirus activation with a resultant 67% lysis at the 50:1 E:T ratio, 17% and 
12% greater than Reovirus and cetuximab treatment alone, respectively. 
 
3.6 Discussion 
This chapter aimed to examine the use of oncolytic Reovirus as a potential 
combination partner with existing and developing colorectal cancer therapies.  
Anti-EGFR antibody treatment has proved highly effective for those patients 
who are susceptible, however they remain ineffective as a monotherapy for 
the large majority of colorectal cancer patients seen in the clinical setting.  
Hypothetically the use of these agents in combination with oncolytic virus 
should complement, enhance and improve their anti-tumour efficacy. Likewise 
ABT-263 has been lauded as an agent with great promise for the treatment of 
various solid tumour types. Clinically Navitoclax has reached phase II trials for 
the treatment of both SCLC and haematological malignancies,190,223,224 
however, disappointingly despite positive early data has demonstrated limited 
single agent activity in the clinical setting. Despite limited tumour responses,  
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correlation with several putative biomarkers measured at the time suggest that 
Navitoclax is acting with a positive benefit in patients and may enhance the 
sensitivity of solid tumours to traditional cytotoxic agents.190  The focus, 
therefore shifted to treatment strategies involving its potential use in 
combination with other agents. Previous data reported from our lab has 
demonstrated that Reovirus when combined with ABT-263 shows increased 
efficacy against CLL targets and therefore the combined activity against a 
panel of colorectal targets was of interest.225 
 
With regard to ABT-263 and despite previous promising early data generated 
in ex-vivo CLL samples which showed enhanced cytotoxicity at low doses of 
virus and ABT-263, initial experimentation using our cell line panel was 
disappointing. The results of combining ABT-263 with Reovirus only showed 
evidence of increased killing in one cell line, SW620. Maximal percentage cell 
death across the other cell lines tested was seen with single Reovirus 
treatment, and the addition of ABT-263 offered no propensity to demonstrate 
an increase in recorded cell death levels. In SW620 CRC cells, where an 
objective response to combination treatment was seen, statistical analysis 
showed no evidence of synergistic activity between the two agents.  It is 
presumed therefore that the increased oncolysis witnessed was therefore a 
result of an additive effect rather than as hypothesised, ABT-263 acting to 
alter the sensitivity of the CRC cells.   
 
Given the lack of synergistic efficacy witnessed in these preliminary screening 
experiments further mechanistic exploration was not pursued, however it 
would be interesting to further examine the expression of anti-apoptotic 
proteins such as BCL-2/BCL-XL/BCL-w by intracellular-FACS or western blot. 
Hypothetically it might be that Reovirus is acting to modulate the pro vs anti-
apoptotic profile of the cancer cell and by doing so in CRC cells is rendering 
ABT-263 activity ineffectual. Moreover, it is possible that the CRC cells tested 
in this study do not have dysregulated or overexpressed anti-apoptotic 
proteins (ie. BCL-2/BCL-XL/BCL-w) 
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Further consideration might also go to whether the ‘scheduling’ of agents may 
effect potential synergistic efficacy. Reovirus infection is known to alter the 
expression of genes associated with apoptosis and pathogenesis and as such 
can act to modulate the pro vs anti-apoptotic profile of cancer cells. 
Specifically relevant to ABT-263 combination strategies, Clarke et al. (2005)226 
report a detailed analysis of the apoptotic mechanisms involved in Reovirus 
infection. The authors demonstrated induction of  MCL-1, BNIP-1 (a BCL-2 
interacting protein) and additionally the upregulation of a survival motor 
neuron (SMN) gene which encodes for SMN proteins. The SMN protein 
interacts with BCL-2 conferring protective effects against both BAX-induced 
and FAS-mediated apoptosis. It is feasible, therefore, that to see maximal 
efficacy in this combination strategy we need to initially ‘prime’ CRC cell lines 
with Reovirus to upregulate anti-apoptotic proteins and induce a resistant 
phenotype before treatment with ABT-263 to modulate this Reovirus-induced 
phenotype and thereby enhance killing. However, interestingly previous 
studies reporting positive synergistic outcomes with BH3-mimetics, in 
combination with other small molecule inhibitors in a variety of haematological 
and solid tumours have not reported the need for treatment 
scheduling.183,208,210 
 
To date, there is no published literature reporting the use of Reovirus with 
BH3-mimetics, however Samuel et al. 2010227 examined the use of the BCL-
2 inhibitor Obatoclax (GX15-070), which acts via a similar mechanism to ABT-
263, and vesicular stomatitis virus (VSV) in chronic lymphocytic leukaemia 
(CLL). In CLL patients, high levels of BCL-2 correlates with chemoresistance 
and a reduced overall survival rate as a result of enhancing leukemogenesis 
by interfering with apoptosis. Additionally, BCL-2 expression has also been 
shown to interfere with VSV-oncolysis in vitro in primary CLL cell lines. The 
authors therefore rationalised that combining VSV with Obatoclax could 
potentially act synergistically to enhance anti-tumour activity. In both in vitro 
and in vivo models, an enhanced effect was seen in response to combination 
treatment. Further examination of the mechanistic process driving this 
enhanced killing revealed stimulation of the apoptotic pathway, with increased 
caspase-3 and -9 cleavage, NOXA up-regulation and the release of BAX and 
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MCL-1. Thereafter the same group used a similar strategy combining VSV 
with ABT-737 in primary ex vivo CLL patient samples. As before, they reported 
that the combination resulted in an enhanced therapeutic effect by inducing 
apoptosis to mediate the cytolytic effect of VSV.228 Alternative tumour types 
and/or oncolytic viruses have not been explored further in the literature and 
as such would certainly provide an interesting direction of investigation for 
future studies. 
 
With this in mind, ABT-263 monotherapy also had a variable cytotoxic effect 
on our cell line panel. There is no published data available with respect to the 
‘LIM’ cell lines however our findings with respect to ABT-263 sensitivity in 
colorectal cell lines are generally consistent with other groups.211,229 As 
discussed, cell death occurs via an apoptotic mechanism and variation in the  
BCL-XL to BAX ratio plays a key role in cell sensitivity and level of ABT-263-
death seen. Cell lines with high expression of BCL-XL tested include HT29 and 
SW480 which both showed increased sensitivity to direct ABT-263 
cytotoxicity.230 No significant cell-death was observed in response to ABT-263 
treatment in Colo320 cells however, these cells are reported to have no BCL-
XL expression but similar levels of BAX to the other cell lines tested. The result 
of this is a much lower BCL-XL to BAX ratio and reduced sensitivity to ABT-
263.231 Indeed this may only be the case for ABT-263 as you might generally 
expect that cells with lower levels of anti-apoptotic proteins (such as BCL-XL) 
may have an increased sensitivity to drugs that kill by apoptotic mechanisms. 
 
There is very limited use of LIM cell lines within the literature which may reflect 
some of the difficulties we encountered in this study. However consideration 
should be given to the ABT-263 and Reovirus induced cytotoxic resistance, 
demonstrated by LIM1899 cells, which may be caused hypothetically by high 
expression of an alternative anti-apoptotic protein, MCL-1. In a range of 
colorectal cell lines tested, Shao et al. (2013)211 highlighted high levels of 
MCL-1 expression on tumour cells to be directly associated with resistance to 
ABT-263. Similarly, Kelly et al. (2012)232 and Knowlton et al. (2012)233 showed 
that Reovirus mediated apoptosis induces the pro-apoptotic BCL-2 homology 
3 (BH3)-only protein, NOXA and knockdown models confirm a significant 
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reduction in Reovirus-induced apoptosis in those cells lacking this pro-death 
protein. The NOXA/MCL-1 ratio is widely reported to be critical to apoptosis 
with those cells expressing NOXA and MCL-1 at different ratios correlating 
well with the extent of apoptosis seen.234,235 Given this, it is likely that over 
expression of MCL-1, may also impede Reovirus-toxicity. No reported 
literature exists for LIM1899 cell lines with respect to the levels of NOXA and 
MCL-1 protein expression however, detailed characterisation would be 
valuable to examine the potential role of MCL-1 in Reovirus and ABT-263 
resistance observed in this cell line.  
Apoptotic mechanisms with respect to anti-EGFR antibody therapy 
demonstrate, more predictably perhaps, that high levels and not low levels of 
BCL-XL are associated with drug resistance and interestingly inhibition of these 
apoptotic proteins can enhance cetuximab cytotoxicity in KRAS-mutant cell 
populations.207 Kasper et al. (2012)207 defined the mechanism by suggesting 
that mutant RAS confers anti-EGFR antibody resistance not purely by 
constitutively activating the RAS/RAF/PI3K cascade but also by blocking 
apoptotic caspase activation through a pathway regulated by upregulation of 
BCL-XL. As a result, the authors were successfully able to reverse RAS-
mediated resistance to cetuximab using ABT-737, a closely related pre-cursor 
to ABT-263. By antagonising the anti-apoptotic activities of BCL-2, BCL-XL and 
BCL-w but not MCL-1 in RAS mutant HRASG12V-Difi cells, cetuximab-induced 
apoptosis was also restored. Unfortunately our study did not investigate the 
ability of ABT-263 to enhance Cetuximab killing of mutated CRC cells but this 
would be of interest for future studies.  
 
Cetuximab resistance remains complex and clinically its use remains limited 
to the treatment of wild-type KRAS colorectal cancer (CRC). Combination 
strategies continue to be explored to overcome these therapeutic challenges 
and include combinations with various chemotherapeutic agents and 
immunomodulators. To date there has been limited success at translating 
promising pre-clinical data into the clinical setting. 
 
Reovirus also exerts its cytotoxic effects by two mechanisms;  direct oncolysis 
via an apoptotic pathway or alternatively, activation of anti-tumour immunity. 
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Interestingly, Maitra et al.236 demonstrated that Reovirus preferentially exerts 
its apoptotic effect in KRAS mutant CRC cell lines and not wild-type cells, the 
opposite to cetuximab direct killing.  They showed, for example that induction 
of apoptosis in the KRAS mutant cell line, HCT116, was more significant when 
compared to its isogenic KRAS WT derivative. In our cell line cohort, Colo320 
represents the only wild type cell line for the KRAS/BRAF/PI3K pathway 
tested, and we would therefore expect this to be more resistant to Reovirus 
killing, however contrary to this, our data showed that this cell line was in fact 
one of the more sensitive CRC cell lines to direct Reovirus killing. Predicting 
biomarkers for Reovirus response is complex and multi-factorial in nature but 
our data supports that of Twigger et al. (2012)237 who also failed to identify 
any correlation between Reovirus sensitivity and the  EGFR/RAS/MAPK 
pathway in a panel of 15 Head and Neck cancer cell lines.  
 
Similarly HT29 cells showed the least sensitivity to Reovirus treatment with 
the exception of LIM1899 which showed no evidence of cell death at all. HT29 
cells have a V600EBRAF mutation and would therefore, based on previous 
reported literature be expected to respond well to Reovirus therapy. Roulstone  
et al. (2015) 238, investigated the use of BRAF inhibitors (PLX4720) to enhance 
Reovirus cytotoxicity and found that against expectation, BRAF inhibition 
paradoxically led to enhanced cell killing in BRAF mutated melanoma cell lines 
again suggesting that the mechanism of Reovirus sensitivity remains 
incompletely understood. As a result attempts to study a single element 
independently within the complex interplay of mechanisms involved is likely to 
have significant limitations in translational endpoints making the study of 
combination therapies for the treatment of solid tumours a challenging area.  
 
Interestingly whilst not continued in the context of this research, preliminary 
results did demonstrate the ability of Reovirus to increase EGFR-mediated 
ADCC in a KRAS mutant cell line, SW480, as demonstrated by 51Cr release-
assay. The initial data is certainly promising and should form the basis of 
further work looking at a spectrum of CRC cell lines and experimental 
duplication to validate these results. Additionally, whilst beyond the scope of 
this thesis, this preliminary work does provoke many questions that would 
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certainly be of interest. Examples include exploring whether OV-induced 
changes in NK cells, macrophages, or levels of cell surface EGFR expression 
on target cells may influence the efficacy of anti-EGFR antibodies such as 
cetuximab; potentially reversing the suppressive cytokine milieu and 
increasing the anti-tumour properties seen.  
 
Indeed, various work has previously been done confirming the role of both NK 
cells and monocytes in mediating antibody-dependent lysis in CRC cells but 
NK depletion studies could be used to further clarify if cetuximab-induced 
ADCC is NK cell dependent across our panel of cell lines, regardless of 
mutational status. Abdullah et al. (1999)239 isolated NK cell populations from 
normal and colorectal cancer patients and compared their ability to mediate 
ADCC against HT29 CRC cells, before using depletion experiments to confirm 
their findings. They found NK cells to be the most important effectors 
mediating ADCC in vitro and furthermore confirmed an impairment in NK cell 
function in CRC patients. Similarly Kurai et al. (2007)240 studied cetuximab-
mediated ADCC in lung cancer and compared the effector cells; PBMCs, 
purified T cells, monocytes and NK cells from healthy and patient donors. 
They concluded that CD3-CD56+ NK cells were primarily responsible for 
cetuximab-induced ADCC and interestingly this could be augmented by IL-2, 
raising the question of using cytokines as additional combination 
immunotherapy.  
 
With respect to Reovirus, Adair et al (2013)204, demonstrated that patient 
PBMC-NK cells from CRC patients were activated by Reovirus to a similar 
level, and by the same mechanism, as healthy donor PBMC-NK cells. 
Furthermore, liver mononuclear cells (LMC)- NK cells isolated from patients 
with metastatic colorectal cancer were also activated by Reovirus to target 
CRC tumour cells. An inflammatory milieu was generated in response to 
Reovirus activation which would likely negate the potential need for additional 
cytokines as suggested above.  
 
Blockade of Fcγ receptors (CD16/CD32/CD64) could identify which FcR are 
important in the mechanism involved. A number of studies have shown that 
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anti-tumour activity for various tumour specific monoclonal antibodies is 
associated with high affinity FcRs, based on their genotype.  Broadly speaking 
FCγR IIa and IIIa polymorphisms have been shown to play an important role 
in clinical outcomes.82,84 For example, further specific analysis by Zhang et al. 
(2007) suggested that the FCγR IIIa FF genotype invoked an increased 
survival and treatment benefit with Cetuximab over the FCγR IIIa VV 
genotype,85 this has however since been disputed by Meller et al. (2013) who 
concluded that differences in FCγR IIIa genotype inferred no ability to predict 
cetuximab sensitivity.241 
 
EGFR is overexpressed in various solid tumours and as such targeting it using 
monoclonal antibodies is attractive. Similarly, identifying reliable biomarkers 
of clinical efficacy, such as EGFR expression remain a priority in order to 
personalise targeted therapies towards individual patients in the clinical 
setting. However, controversy remains with regard to how EGFR surface 
expression may relate to cetuximab efficacy with conflicting evidence 
presented in various tumour types. Pirker et al. (2012)242 demonstrated that 
high EGFR expression can be used as a positive predictive biomarker of 
efficacy in patients with advanced non-small cell  lung cancer (NSCLC) after 
analysing data generated from a phase III First-Line ErbituX in lung cancer 
(FLEX)243 study. Conversely, Licitra et al. (2013)244 prospectively collected 
tumour immunohistochemistry data from patients in two further phase III trials 
examining the effect of cetuximab in both recurrent/metastatic squamous cell 
carcinoma of the head and neck (SCCHN) and KRAS wild-type metastatic 
colorectal cancer (EXTREME245 and CRYSTAL,79 respectively). The authors 
showed that the addition of cetuximab to chemotherapy in these tumours 
improved survival regardless of tumour EGFR expression.  
 
Whilst clinical trial data is useful translationally in the clinic,  the mechanism 
of action behind this variation remains unclear from these studies. A 
systematic review by Derer et al. (2013)246 therefore set out to examine the 
mode of action of EGFR antibodies against EGFR cell surface expression. 
The authors concluded from their findings that the different mechanisms of 
cetuximab action discussed earlier may be more effective in different settings 
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depending on EGFR tumour expression. The study suggests that cetuximab-
ADCC may predominate in tumours expressing high levels of EGFR, whereas 
effects resulting from direct ligand binding inhibition may be more important in 
those patients with tumours expressing low EGFR levels. Given these findings 
exploring further the effects seen in our in vitro studies (Figure 3.7; Figure 3.8) 
with respect to both direct and immune-mediated cetuximab mechanism of 
action against the variable cell surface EGFR expression of our cell line panel 
(Figure 3.2) may have yielded interesting correlating data. 
 
Finally, of note, problems encountered with the LIM cell lines, and particularly 
LIM1215 certainly resulted in a less complete data interpretation given the 
loss of our EGFR positive, KRAS/BRAF/PIK3 wild-type cell line. Useful 
analysis would have been generated from comparable results against this 
control cell line, however disappointingly this proved not to be possible. There 
are indeed limited reported cell line options available that are EGFR positive 
and KRAS/BRAF/PIK3 wild-type in their genotypic/phenotypic makeup but a 
suitable alternative for future work could be Caco-2 cells used in similar 
studies by Shigeta et al. (2013).247 In this study, the authors used Caco-2 as 
a wild-type control to evaluate the correlation between EGFR levels detected 
by Cetuximab and drug sensitivities of SW480 and HCT116 CRC cell lines. 
They conclude that in their study, high EGFR expression correlates with 
strong Cetuximab response. Acquisition of this cell line may allow direct 
comparison with our panel of mutant cell lines and may lead to further 
conclusions being drawn. 
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Chapter 4  
JX-594 Mediated Direct Oncolysis and Cell Death 
Mechanisms 
4.1 Introduction 
Infection of tumour cells by JX-594 triggers a cascade of events which 
ultimately leads to tumour cell death. JX-594 is known to kill target cells by 
direct oncolysis but also induces a pro-inflammatory tumour 
microenvironment which promotes immune cell recruitment stimulating innate 
and adaptive anti-tumour immunity.248 
Various modes of administration have been tested and shown to be safe in 
early clinical studies for a wide variety of oncolytic agents. Delivery methods 
tested have included intratumoural (IT), intraperitoneal (IP), intrapleural (IPl) 
and intravenous (IV), however it is clear for the widespread translational 
application of oncolytic viruses, and to harness their full potential to target 
disseminated malignant disease, systemic delivery remains the most practical 
approach.249 
In order to allow both direct oncolysis, activate the innate immune response 
and prime adaptive anti-tumour immunity, it is considered vital that the virus 
can primarily access tumour. Previous members of the Melcher group, using 
oncolytic Reovirus as an OV, have demonstrated that not only can Reovirus 
be recovered from tumour (colorectal liver metastases) after systemic delivery 
in humans, moreover, there was no evidence of toxicity as a result of 
widespread infection, dissemination and replication.206 Likewise, JX-594 
(Pexa-Vec) has been evaluated in 12 completed and ongoing clinical trials 
including greater than 1000 individual Pexa-vec treatments in total (IV or 
IT).250 Systemic delivery was safe and well tolerated, associated with dose-
dependent delivery to multiple solid tumour types (including colorectal cancer, 
lung cancer, pancreatic cancer and mesothelioma) and demonstrates 
antitumour activity at high doses.138,251  
There remains limited published data, however with regard to the effects of 
JX-594 once it has reached its primary tumour target and similarly, little is 
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known about the potential viral effects in other tissues not directly related to 
the primary tumour. Clearly this may be of significant therapeutic importance. 
With most adjuvant therapy focussing on the clearance of micro-metastatic 
disease to prevent recurrence or non-resectable disseminated malignancy, 
organs and tissues that may harbour micrometastases, for example lymph 
nodes or blood where circulating tumour cells reside (CTC’s) are of particular 
interest. Conceptually, OV could eradicate this low volume disease by direct 
oncolysis (Chapter 4) or activation of an appropriate immune response 
(Chapter 5). 
Vaccinia virus has been described as being able to utilise various cytolytic 
mechanisms to implement tumour cell death, however these mechanisms 
remain poorly understood. Evidence of  apoptosis, necrosis, programmed 
necrosis (also known as necroptosis) and autophagy have all been reported 
at least in part in response to vaccinia virus in a variety of cell types and in 
some reports various components of each pathway interacting with one 
another have been described.159 However there remains limited work 
characterising these mechanisms of cell death in malignant tumour cells 
Understanding the mechanism surrounding direct tumour oncolysis is a 
rapidly evolving field and it is increasingly becoming clear that signalling 
pathways regulating the mechanisms of cell death and cell survival are tightly 
regulated via complex molecular interplay. Indeed it is likely that all the cell 
death modalities (apoptosis, necrosis, programmed necrosis and autophagy) 
triggered by death receptor activation in cells are unlikely to be mutually 
exclusive and as such interact with each other via a complex cascade of 
intracellular signalling and crosstalk.252 
There are no previous reports in the literature studying death mechanisms of 
JX-594 in colorectal cancers cells specifically and as such this chapter aims 
to explore some of the direct oncolytic mechanisms used by the virus as part 
of its therapeutic armamentarium against cancer targets. Identifying these 
mechanisms may allow complimentary combination approaches to be 
identified. 
Of note, some of the preliminary work referred to in this thesis was completed 
in part by my predecessors, Rajiv Dave. This work is as yet unpublished but 
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has been submitted and accepted as his MD thesis to the University of Leeds 
(2014).253  
 
4.2 Colorectal cell lines are susceptible to JX594 killing, viral 
replication and infection. 
Initial work completed by the Melcher group had demonstrated that the 
colorectal cell lines, SW480, SW620, LoVo and HCT116 were susceptible to 
killing by JX-594, as assessed by Live/Dead™ and MTT assays.253 
Furthermore, cell lines were infected by JX-594 as demonstrated using a 
green fluorescent protein (GFP) expressing virus (JX594-GFP) and 
visualisation of GFP using a confocal laser scanning microscopy. Plaque 
assays, thereafter, demonstrated that JX-594 replicated in all cell lines tested 
(data not shown). 
For the purposes of this work, we focussed on the cell lines SW480 and 
SW620. These cells lines were derived from the same 50 year old patient prior 
to any adjuvant therapy and represent a primary (SW480) and metastatic 
(SW620) colorectal tumour, respectively. SW480 cells were established from 
a resected Dukes B primary large bowel cancer specimen and the SW620 
cells from an intraabdominal lymph node metastasis resected six-months after 
primary surgery. 
Figure 4.1 shows images of both cells lines taken during in vitro cell culture. 
SW480 cells (Figure 4.1A) were larger in size and displayed an epithelial-like 
morphology. SW620 cells (Figure 4.1B) demonstrate rounder, more 
aggregated characteristics and notably grow much faster than the primary cell 
line, SW480.  
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Figure 4.1 In vitro images of SW480 and SW620 human colorectal 
adenocarcinoma cell lines. 
SW480 (A) and SW620 (B) were cultured as described in section 2.2. DMEM 
supplemented with 10% FCS and passaged regularly at sub confluent levels. Original 
magnification 10x.  
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To corroborate the groups previous findings and standardise data, 
Live/Dead™  assays were repeated with new JX-594 virus stock on SW480 
and SW620 cell lines. With increasing doses of virus, and increasing time (48-
96hours), JX-594 demonstrates a statistically significant dose-dependent and 
time-dependent cytotoxic effect, with maximal death observed at 10pfu/cell 
and 96 hours post-infection for both cell lines (Figure 4.2). Given the related 
nature of the cell lines, direct comparison is interesting and whilst not 
statistically significant the SW620 metastatic cell line appeared, particularly at 
earlier time points to be more resistant to the JX-594 oncolysis and required 
higher viral titres to produce comparable levels of killing. (Figure 4.3) 
 
 
 
 
 
 
 
 
- 123 - 
 
Figure 4.2 Colorectal cell lines are susceptible to JX-594-induced 
oncolysis.  
Colorectal cell lines (a) SW480 (b) SW620 were seeded at 2 x 105 cells/well in a 6-
well plate and infected with JX-594 at concentrations of 0, 0.1, 1 and 10 pfu/cell for 
48-96 hours. At each time point cells were harvested and stained with Live/Dead™  
for assessment by flow cytometry. Graphs show mean + SEM of three (N=3) 
independent experiments. Statistical significance is denoted by *p<0.05, ** p<0.005, 
***p<0.001 (one-way ANOVA). 
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Figure 4.3 SW620 metastatic CRC lines are more resistant to JX-594 
oncolysis than SW480 lines. 
SW480 and SW620 were seeded at 2 x 105 cells/well in a 6-well plate and infected 
with JX-594 at concentrations of 0 and 10 pfu/cell for 48-96 hours. At each time point 
cells were harvested and stained with Live/Dead™  for assessment by flow 
cytometry. Graphs show mean + SEM of 3 (N=3) independent experiments.  
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4.3 Evaluating mechanisms by which JX-594 kills CRC 
tumour cells 
4.3.1 Caspase-dependent apoptosis 
Having demonstrated that colorectal cell lines were susceptible to JX-594 
killing, the mode of tumour cell death was then explored given that 
understanding the molecular mechanism involved in cell death could allow us 
to develop combination strategies with oncolytic viruses  
Previous work has demonstrated increased expression of active Caspase-3, 
a member of the Cysteine-aspartic acid protease (Caspase) family, important 
for the execution phase of apoptosis, following infection with JX-594. Using 
an active caspase-3 apoptosis kit, Dave (2015) 
(etheses.whoterose.ac.uk/6887) showed approximately 60-65% of SW480 
cells and 35-40% of SW620 cells expressed active caspase-3, 96 hours 
following JX-594 infection (data not shown). Hence, it was therefore 
hypothesized that JX-594 may induce death in a caspase-dependent manner, 
classically associated with programmed apoptosis.  
Building on these initial observations, this study aimed to further elucidate the 
role of caspase-mediated apoptosis in SW480 and SW620 cell lines using Z-
VAD-FMK, a pan-caspase inhibitor which inhibits caspase-dependent 
apoptosis by binding irreversibly to the catalytic site of caspase proteases. 
Mel888 cells, a human melanoma cell line, have previously been shown to 
undergo oncolysis in response to Reovirus in an apoptotic fashion and 
therefore acted as a positive control.  Z-VAD-FMK was added to the cell 
culture medium 1 hour prior to infection with JX-594 and cell death was 
measured 72 and 96 hours following infection using a Live/Dead™ flow 
cytometry assay. Results are shown in Figure 4.4.  
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Figure 4.4 Effect of Z-VAD-FMK on JX-594 induced cell death. 
SW480 (a), SW620 (b) and Mel888 (c) cell lines were treated with ± 50μM Z-VAD-
FMK for 1 hour prior to infection with 0, 0.1, 1 and 10 pfu/cell JX-594 (A & B) or 
Reovirus (C). Cells were harvested  72 and 96 hours post JX-594-infection or 48 
hours after Reovirus treatment. Cell death was assessed using Live/Dead™ cell 
viability assay. Graphs show mean percentage cell death (n=3) + S.E.M. Statistical 
significance is denoted by *p<0.05 (One-way ANOVA). 
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The addition of Z-VAD-FMK prior to infection significantly decreased 
Reovirus-induced cell death in the Mel888 control cell line (44% to 16% at 
10pfu/cell) demonstrating that the inhibitor used was functional. In contrast, Z-
VAD-FMK did not inhibit JX-594-induced cell death at 72 or 96 hours in either 
the SW480 or SW620 cell lines. These results were consistent between the 
two cell lines. 
Taken together the results suggest that Reovirus induces death in a caspase 
dependent apoptotic manner, however JX-594, despite induction of caspase-
3 does not induce caspase-dependent apoptosis. These findings are 
consistent with previous literature studying VV mechanism of death in ovarian 
cancer cells. Whilding et al. (2013) 159 reported upregulation of various 
markers of apoptosis following VV infection, including caspase-3, however 
inhibition of apoptosis by Z-VAD-FMK failed to attenuate the cytotoxicity of 
VV. This study also highlighted that VV utilises multiple mechanisms to induce 
cell death and there is therefore a need for the use of a broad spectrum of 
assays to evaluate OV-induced cell death.  
 
4.3.2 Necrosis/Necroptosis 
Given the lack of evidence for caspase-dependent apoptotic cell death 
pathway by JX-594, alternative death pathways were investigated. As 
discussed previously, necrosis and its regulated form necroptosis are  cellular 
mechanisms of necrotic cell death induced by apoptotic stimuli under 
conditions where apoptotic execution is prevented.254 Using Necrostatin-1 
which inhibits the kinase activity of RIP-1, and Necrosulfonamide which 
targets mixed lineage kinase domain like protein (MLKL), we investigated 
whether JX-594 kills colorectal cell lines by necroptosis, as previously 
described by Whilding et al. (2013)159 in ovarian cancer cell lines. Interestingly 
the authors reported a dose dependent inhibition of  VV activity by both RIP-
1 and MLKL antagonism, both alone and in combination with Z-VAD-FMK. 
As such Necrostatin-1 ± Z-VAD-FMK and Necrosulphonamide, respectively 
were added to the cell culture medium 1 hour prior treatment with JX-594 for 
96 hours and subsequent levels of cell death measured using Live/Dead™ 
and flow cytometry. Results are shown in Figure 4.5. 
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Figure 4.5 Role of Necrosis/Necroptosis in JX-594-induced cell death. 
SW480 (Left) and SW620 (Right) cell lines were treated with JX-594±10μM 
Necrosulphonamide (A), or 50 μM Necrostatin-1 in the presence or absence of 50µM 
Z-VAD-FMK (B), 1 hour prior to infection with 0, 0.1, 1 and 10 pfu/cell JX-594. Cell 
were harvested at 96 hours and  level of cell death assessed using Live/Dead™ cell 
viability assay. Graphs show mean percentage cell death (n=2) + S.E.M. Statistical 
significance is denoted by *p<0.05 (Student t-test). 
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In a similar fashion to the apoptotic inhibitor Z-VAD-FMK, both necrostatin-1 
and necrosulphonamide had no effect on the levels of cell death induced by 
JX-594 at 96 hours suggesting the virus is not acting via a necroptotic 
pathway. Similarly, the combination of Z-VAD-FMK and necrostatin-1 had no 
discernible effect on percentage cell death. Interestingly, necrostatin-1 
appeared to enhance the virus induced cytotoxicity in SW480 cell lines at 
lower doses of virus; Percentage cell death increased from 21.6% to 45.6%  
after treatment with 0.1pfu JX-594 for 96 hours in the presence of 50μM 
necrostatin-1. This effect was not seen in the metastatic SW620 cells. The 
mechanism behind this remains unclear with limited data in the literature 
investigating the mechanistic process behind VV-induced cell death. 
Interestingly though both Whilding et al. (2013) and Baird et al. (2008) also 
observed an increase in cell death in response to cell death inhibitors. In 
IGROV1 cells, an ovarian cancer cell line, treatment with combinations of  Z-
VAD-FMK and VV and 3-MA and Adenovirus resulted in increased cell 
cytoxiticity.159,255 Clearly VV-induced cell death remains a complex process 
with multiple positive and negative feedback pathways, with the potential for 
some pathways to be acting to promote cell survival.  
 
4.3.3 High Mobility Group Box Protein B1 (HMGB1) is absent from 
JX-594-mediated cell death 
HMGB1 is a non-histone nuclear protein involved in the structural organization 
of DNA and is released following cell activation or alternatively as a result of 
cell necrosis. After its release from the cell, HMGB1 acts as a potent danger 
signal and mediates inflammation and immune activation.256 Free HMGB1 
release is not usually a feature of apoptotic cell death and instead is 
translocated into membranous vesicles generated by apoptosing cells.256 In 
contrast, cells undergoing necrosis are reported to release HMGB1 into the 
extracellular space and vaccinia virus specifically has been shown to induce 
a necrosis-like morphology with resulting, and demonstrable, HMGB1 release 
in ovarian cancer cell lines.159  
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To further delineate the cellular death mechanisms at play we examined 
HMGB1 release in cell free supernatants harvested from JX-594 infected 
SW480 and SW620 cell lines. 
Treatment with 1pfu/cell JX-594 for 72 and 96 hours results in significant cell 
death in both SW480 and SW620 cell lines, as shown in Figure 4.2. Western 
blots of cell-free supernatants taken at these time points however, showed no 
evidence of detectable levels of HMGB1, despite strong and proportionate 
bands with the positive controls (DLD-1 cell lysates; Figure 4.6). These data 
would fit with a more apoptotic cell death morphology given the previously 
observed induction of caspase-3, lack of effect observed in combination with 
necrostatin-1 and necrosulphonamide and the expectation of necrotic cell 
death to produce high levels of extracellular HMGB1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 131 - 
 
 
 
Figure 4.6 Detection of HMGB1 by Western Blot. 
Cell-free supernatants were collected from SW480 and SW620 cells, 72 (data not 
shown) and 96 hours after treatment with JX-594 at 1pfu/cell. Supernatants were 
prepared for western blot by mixing 1:1 in Laemmli buffer prior to loading onto a 12% 
SDS-PAGE gel in duplicate (channel 5-8). Molecular weight markers and control 
DLD-1 cell lysates were also mixed 1:1 in Laemmli buffer and loaded in duplicate at 
20μl (channel 1 and 2) and 10μl (channel 3 and 4) respectively. Following protein 
transfer to nitrocellulose membranes, membranes were blocked and stained with an 
anti-human HMGB1 antibody followed by a goat anti-mouse secondary antibody. The 
result shown is a representative example of n=3 independent experiments.  
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4.3.4 Autophagy 
Autophagy is a conserved homeostatic mechanism of lysosomal degradation. 
Accumulating evidence suggests that OVs interact with the autophagy 
machinery in infected tumor cells, and may play a role in virus-mediated 
cancer cell death. A number of studies have reported that modulating 
autophagy with autophagy inducers, such as rapamycin or RAD001, can 
augment the anti-tumour effect of adenovirus in glioma cells and Newcastle 
disease virus in lung cancer cells.257–259 With respect to vaccinia virus, 
Whilding et al.159 suggested that VV may interfere with the autophagic process 
but does not rely on autophagy to induce cell death. Given these previous 
findings it was therefore of interest to examine the effect of autophagic 
inhibition on JX-594-induced oncolysis in the colorectal cell lines, SW480 and 
SW620.  
3-Methyladenine (3-MA) inhibits PI3K which is known to control the activation 
of mTOR, a key regulator of autophagy. By inhibiting PI3K, 3-MA serves to 
block autophagosome formation and thus inhibits autophagy.260 3-MA  was 
added to the cell culture medium 1 hour prior to infection with JX-594 and cell 
death was measured using Live/Dead™ flow cytometry. Results are shown in 
Figure 4.7. 
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Figure 4.7 Effect of 3-MA, an autophagy inhibitor on JX-594-induced 
SW480 and SW620 cell death. 
SW480 (A) and SW620 (B) cell lines were treated with ± 50μM 3-MA, 1 hour prior to 
infection with 0, 0.1, 1 and 10 pfu/cell JX-594. Cell were harvested at 96 hours and  
level of cell death assessed using a Live/Dead™ cell viability assay. Graphs show 
mean percentage cell death (n=2) + S.E.M. Graph (C) represents the same data 
directly comparing the effect of 3-MA on SW480 and SW620 cell lines after infection 
with 10pfu/cell JX-594.  Statistical significance is denoted by *p<0.05 (Student t test). 
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As with apoptosis and necrosis/necroptosis inhibition, 3-MA did not inhibit JX-
594-mediated oncolysis in either the SW480 or SW620 cell lines suggesting 
the mechanism of cell death is not autophagy related, as previously reported 
in ovarian cancer models. Interestingly, as seen in Figure 4.5 as a direct result 
of necrostatin-1, JX-594-induced cell death of SW480 cells was in fact 
significantly augmented by 3-MA with the percentage cell death increasing 
from 25.95% to 53.75% and 33.85% to 63.55% for 1pfu and 10pfu/cell JX-594 
(Figure 4.7C), respectively. The mechanism behind this effect remains unclear 
but may simply be the result of autophagy eradicating virus from the cell.  
 
4.4 Discussion 
Taken together these data show that JX-594 triggers significant cell oncolysis 
associated with up-regulation of caspase-3 and the absence of HMGB1 
release which is consistent with apoptosis being the primary cell death 
pathway. Activation of the full apoptotic effector pathway however is not 
induced given the inability of Z-VAD-FMK to block cell death. This suggests 
death may not be caspase mediated or apoptosis alternatively apoptosis can 
be bypassed. Similarly virus oncolysis does not occur via necroptosis or 
autophagy given the inability of necrostatin-1, necrosulphonamide or 3-MA to 
block JX-594 induced cell death.  
Studies available in the literature examining the mechanisms by which 
oncolytic JX-594 induces tumour death are limited, however, those available 
both support and refute our findings. Probably the most comparable study in 
the literature was conducted by Whilding et al. (2013)159 who evaluated 
apoptosis, necroptosis and autophagy in ovarian cancer cell lines following 
infection with a lister-strain VV. They demonstrated as with our study that 
despite some features of apoptosis being present, (the appearance of sub-G1 
DNA populations, phosphatidylserine externalisation and PARP cleavage), 
VV did not induce death via an apoptotic mechanism.  
Conversely, however, VV-induced apoptotic death has been reported in 
various malignant cell lines including both melanoma and cervical 
cancer.162,261 In these studies, both authors utilised a wild type VV strain 
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Western Reserve (WR), and these data may therefore represent strain 
specific variation. Furthermore, further analysis reveals the conclusions drawn 
by Liskova et al. (2011)261 in HeLa and BSC-40 cell lines were solely based 
on the upregulation and activation of caspase 2, 3 and 4 using the WR strain. 
As with both our study, and Whilding and colleagues, the authors failed to 
demonstrate any significant effect using both pan-caspase inhibitors (Z-VAD-
FMK) and inhibitors of calpain and cathepsin D and E. 
Examining apoptosis in isolation is clearly complex with no single assay able 
to adequately demonstrate the significance of the role it plays. As such, there 
is a need for multiple assays to explore the various aspects of these pathways 
in combination, however, this remains challenging. To illustrate the 
challenges, examples in the literature include identifying features classically 
reported as consistent with apoptosis, including Bax-mediated release of 
apoptosis-inducing factor, which have subsequently been described as a 
critical step in programmed necrosis.262 It is now generally accepted that the 
pathways involved in apoptosis, necrosis and autophagy share a large 
numbers of similarities and it is therefore unsurprising that delineating a single 
pathway in this study was unsuccessful.  
Further challenges are highlighted by the role of alternative pathways that can 
be bypassed by traditional inhibitor molecules. Lafont et al. (2010)263 studied 
the function of caspase-10 in response to FasL (a member of the TNF receptor 
super family) to mediate cell death. They reported that in the presence of Z-
VAD-FMK, FasL activation initiated by RIP-1 could trigger an alternative, non-
apoptotic caspase-dependent form of cell death dependent on caspase-10. 
The study highlights that whilst Z-VAD is often utilised as a pan-caspase 
inhibitor, it may be that cell death pathways exist utilising alternative caspases 
not effectively targeted by Z-VAD. Similarly, a study by Lieberman et al. 
(2010)264 demonstrated that granzyme A, a serine protease found in killer cell 
cytotoxic granules, could activate caspase-independent programmed cell 
death that morphologically resembled apoptosis but had unique substrates 
and mediators. Indeed whilst Z-VAD-FMK has been used in many studies to 
block apoptotic cell death, the literature also reports that it may sensitise cells 
to necrosis and actively induce autophagy.265 
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Given the mixed evidence for an independent apoptotic pathway being utilised 
by JX-594, we went on to explore alternative mechanisms, such as 
necroptosis and autophagy. Whilding et al. (2013) demonstrated that vaccinia 
virus was capable of ‘inducing a regulated and programmed necrotic cell 
death’ in ovarian cancer cell lines. Their data demonstrated that VV induced 
a reduction in intracellular ATP, modified mitochondrial metabolism and 
released HMGB1, consistent with necroptosis. Furthermore using the 
necroptosis inhibitors, necrostatin-1 and necrosulphonamide, they 
demonstrated a dose-dependent abrogation of virus induced cell death. 
Similarly, Heinrich et al. (2017)266 explored the type of cell death induced by 
VV in melanoma cell lines using FACS staining for phosphatidylserine 
(expressed by early apoptotic cells) and DNA of necrotic cells stained with PI. 
Treated cells demonstrated a more necrotic type cell death. 
In our study in colorectal cell lines, despite good levels of JX-594-induced cell 
death we were unable to demonstrate any effect of either necrosulphonamide 
or necrostatin-1 and no evidence of HMGB1 release in the cell free 
supernatants. These data are at odds with Whilding’s study and would support 
the suggestion of a classical apoptotic mechanism. Whilst it is possible that 
results are variable between different cancer models tested, interestingly, this 
is also the opposite to findings by Guo et al. (2005)267, using the CRC cell line 
HT-29. The authors reported a time-dependent increase in HMGB1 detection 
by Western Blots following infection with a WR VV. The same paper also 
reported features consistent with apoptotic death reconfirming the complex 
nature of cell death pathways. In addition, differences between virus strains 
as well as cancer cell population variability may also account for the conflicting 
results observed. Indeed, the various VV strains commonly used have been 
reported to encode for different apoptotic and necroptosis inhibitors, and 
inducers of immunogenic cell death which makes like for like comparison 
across a spectrum of viruses studied difficult. Examples of molecules encoded 
by VV include the direct caspase/serine protease inhibitor, cytokine response 
modifier A (CrmA) and F1L which is a direct inhibitor of Bax and Bak.268 
Interestingly, in a recent study by Schock et al. (2017)269 examining the 
prevalence of virus-induced necroptosis across a broad range of virus strains, 
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only two of the seven viruses investigated resulted in significant necroptotic 
cell death demonstrating the diversity of these agents. 
Very limited data exist with regard to the role of autophagy in VV-induced cell 
death, however interestingly there is an increasing body of evidence to 
suggest that various OV may interact with intrinsic autophagic mechanism to 
exert anti-tumour effects. Our study did not identify any evidence of autophagy 
as the underlying pathway responsible for cell death but did suggest that 
modulating autophagy could be used to enhance direct lytic killing by VV. 
Autophagy was first recognised as a virus-induced cell death mechanism by 
Ito et al. (2006)257 using a glioma cell model infected with adenovirus. 
Autophagy was assessed by examining cell morphology, the formation of 
acidic vesicular organelles, signalling via mammalian target of rapamycin 
(mTOR) and Western Blot analysis to monitor ‘an autophagy associated 
molecule’. However, in a recent review of the current literature by Hu et al. 
(2017)270 the authors concluded that the underlying mechanisms by which 
autophagy exerts both direct and anti-tumour effects remains largely 
unknown. However, interestingly they identified four distinct OV’s that had 
been reported in the literature to modulate autophagic pathways to induce 
both an innate and adaptive immune response (Herpes simplex, Adenovirus, 
Newcastle disease virus and Measles) indicating autophagy may also 
contribute to OV-mediated immunotherapy. 
As described, the pathways involved in JX-594 are complex, multifaceted and 
remain to be completely elucidated. Our data is consistent with JX-594 
inducing significant cell oncolysis which has previously been reported by 
colleagues to be associated with the upregulation of caspase-3.  The 
additional absence of HMGB1 release further supports apoptosis being the 
primary cell death pathway. However, it is possible that the full apoptotic 
effector pathway is not induced given the inability of Z-VAD-FMK to inhibit JX-
594-induced oncolysis. Whilst definitive conclusions are difficult it is possible 
that death is not solely caspase mediated, or that tumour cells utilise 
alternative caspase pathways, not inhibited by Z-VAD-FMK, for example 
caspase 10 not thought to be inhibited. It remains unclear how JX-594 induces 
tumour cell death however, it is likely that a mixed non-linear morphology 
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probably exists, incorporating complex feedback systems and a programmed 
series of events.  
Understanding the complex interplay of OV’s with cell death mechanisms 
remains an area of significant research and as such continues to provide 
potential therapeutic targets and areas of interest for future studies. For 
example, recent advances in our understanding of the potential for autophagy 
modulators to regulate OV-induced antitumour immune responses (as 
reviewed by Hu and colleagues (2017)270) could provide potential therapeutic 
combination strategies and would certainly provide interesting continuation 
work for this thesis. Furthermore, delineating further the mechanisms behind 
our observation of necrostatin-1 potentiating VV-induced cytotoxicity in 
primary cancer SW480 cell lines would significantly enhance our 
understanding and may provide options to explore novel targeted strategies. 
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Chapter 5  
JX-594-induced innate immune response 
5.1 Innate immune activation in the blood 
It is increasingly evident that for oncolytic viruses to be effective as anti-cancer 
therapies, irrespective of their direct oncolytic effect or cytotoxic pathways, 
they must be highly immunogenic and stimulate an innate and/or adaptive 
immune response. Likewise, as more work has been undertaken to evaluate 
the mechanisms underpinning cancer immunotherapy, the importance of 
immune activation has been recognised as increasingly important. The 
interaction between innate and adaptive immune effectors such as cross-
activation between DC and NK cells and evidence of improved clinical 
outcomes in colorectal tumour infiltrated with both innate NK cell and adaptive 
T cells, highlights the importance of harnessing both arms of the immune 
response.38,271–273 
As previously discussed, the immune response triggered by oncolytic viruses, 
such as JX-594 or Reovirus is of critical benefit to the clinical efficacy of these 
treatments. Importantly, these anti-tumour immune effects have been 
enhanced in virus platforms by the use of genetic modification and the 
insertion of various immune genes. Examples include, Kottke et al. (2009)274 
who showed that the addition of IL-2 enhances the anti-tumour immune effects 
of Reovirus and is associated with an adaptive response against tumour-
associated antigens (TAA) in tumour draining lymph nodes. Similarly, the 
insertion of GMCSF into VV generates a systemic anti-tumour response in 
vivo associated with the recruitment and activation of DC into the tumour 
microenvironment.275 
Furthermore, the trafficking of immune cells to lymph nodes is well established 
to play a pivotal role in immunity and as such, clearance and detection of 
lymph node micrometastasis is the focus of multiple pre-clinical and clinical 
trials particularly in the field of colorectal and breast cancer.276–278 The 
combination of OV-immunogenicity and the prevalence of both 
micrometastasis and circulating tumour cells therefore makes the study of 
both lymph nodes and blood an obvious target for OV research. Indeed, 
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unpublished data from Breitbach et al., a collaborative group in Canada 
demonstrated that, as seen with Reovirus, JX-594 can be recovered from 
blood, lymph nodes, normal liver, primary colon and metastatic colorectal liver 
metastasis after i.v. delivery in patients with metastatic colorectal cancer. 
Therefore, to address the potential wider immune response to systemic 
delivery of JX-594, and assess the viruses ability to generate anti-tumour 
effects both in blood and at distant sites harbouring non-resected microscopic 
disease, we investigated the innate effects of JX-594.  Initial studies focussed 
on the blood of healthy volunteers and colorectal cancer patients and 
thereafter we examined the same immune responses in freshly resected 
lymph node tissue from colorectal cancer patients. 
 
5.2 Natural Killer Cells in JX-594 infection 
Following intravenous administration of JX-594, high-doses of virus will be 
present in the circulating blood. Not only is this relevant to virus carriage but 
the presence of circulating tumour cells (CTC) within the blood has been 
reported to be associated with significantly increased recurrence, mortality 
rates and poor prognostic outcomes.279 In colorectal cancer the stimulation of 
an anti-tumour innate immune response in this setting, and indeed in other 
micrometastatic sites, may be sufficient to provide a therapeutic effect and 
clear tumour even if there is minimal virus access and yield. 
Within the group, NK cells have been the focus of attention as a marker of 
innate immune activation. Colleagues have previously demonstrated NK cell 
activation and immune-mediated killing in PBMCs following treatment with 
Reovirus.206 
Defined as CD3-veCD56+ve lymphocytes, NK cells constitute between 10-20% 
of the PBMC population. They can be sub-classified into two distinct forms 
based on their discrete functions, properties and phenotypes. CD56Dim cells 
are highly cytotoxic and are predominantly found in the blood and at sites of 
inflammation whereas, CD56Bright cells are reported to have little cytotoxic 
activity, and play an important role in immunoregulation, rapidly inducing 
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cytokine production. This phenotype makes up the majority of NK cells found 
in lymph nodes.280   
Figure 5.1 denotes the typical phenotypic appearances of NK cell populations 
in healthy donor PBMC as seen following flow cytometry. 
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Figure 5.1 Phenotypic appearances of CD3-CD56+ lymphocytes (NK 
cells) and their discrete subpopulations CD56Dim and CD56Bright in 
PBMCs as demonstrated by Flow Cytometry.  
PBMCs were prepared from whole blood of healthy volunteers and stained using 
CD3-PerCP and CD56-PE anti-human antibody. Cell were analysed using flow 
cytometry. (A) denotes a forward scatter (FSC) vs side scatter (SSC) dot plot with the 
R1 gate incorporating the lymphocyte cell population. (B) shows a BL3 fluorescence 
channel (CD3- PerCP) vs BL2 (CD56-PE) of the R1 selected cell population. The R2 
gates surrounds the total NK cell population (CD3-CD56+), 10-15% NK cells within 
total PBMCs. Bright and dim arrows delineate the sub-populations within this gate. 
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5.3 NK Cell Activation and CD107 Degranulation 
CD69 is a membrane receptor glycoprotein which is transiently expressed 
after activation of haematopoietic derived cells with the exception of 
erythrocytes281. In resting lymphocytes it is not normally detectable, however 
selective expression occurs as a result of active immune responses and in 
chronic inflammatory infiltrates. Activation of NK cells leads to rapid CD69 
expression associated with NK-cell derived cytotoxicity, regulation of NK cell 
proliferation and down regulation of cell auto-immunity.281 Furthermore, CD69 
acts to regulate the expression of other functional activation molecules such 
as TNF-α, CD25 and intracellular adhesion molecule-1 (ICAM-1) and 
mobilizes calcium in pre-activated NK cells.282,283 CD69 can therefore be 
utilised as an important early marker of NK cell activation. A typical histogram 
plot showing CD69 expression (FITC) of a resting NK cell population is shown 
in Figure 5.2. 
A second marker that can be utilised for the investigation of NK cell functional 
activity is a highly glycosylated lysosomal membrane protein, CD107 (also 
known as lysosomal-associated membrane protein (LAMP-1). NK cells 
contain high concentrations of preformed cytolytic granules within their 
cytoplasm containing cytolytic proteins, such as perforin and granzyme. These 
granules are specifically designed to induce death in target cells following their 
release. Perforin and granzyme work synergistically to induce target cell 
death, with perforin being responsible for pore formation in cell membranes 
allowing delivery of granzymes (serine proteases), where they activate distinct 
cell death pathways.264,284 Activation of NK cells results in rapid release of 
these granules triggering cell lysis and death. CD107 is found lining the 
surface of these granules and has been described as a good marker of NK 
cell functional activity.285 As such, the transient expression of CD107 on the 
cell surface in concordance with loss of perforin correlates well with NK cell 
mediated lysis of target cells. Brefeldin A is utilised in the assay to prevent 
CD107 recycling into the Golgi complex, resulting in accumulation of proteins 
in the endoplasmic reticulum and enhanced detection of molecules of interest 
at the cell surface.  Expression of CD107 is observed within 2 hours of cell 
stimulation making CD107a and CD107b ideal markers of NK cell activity.285–
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288 A representative flow cytometry picture of NK cell degranulation is shown 
in Figure 5.2.. Increased CD107a/b expression is consistent with enhanced 
NK cell degranulation.  
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Figure 5.2 Flow Cytometry analysis of NK cells (CD3-CD56+ lymphocytes), 
CD69 (FITC) expression and degranulation within PBMCs. 
PBMCs were prepared from whole blood of healthy volunteers and stained using 
CD3-PerCP and CD56-PE anti-human antibodies. FSC vs SSC dot plot with the R1 
gate incorporating the lymphocyte cell population and a BL3 fluorescence channel 
(CD3-PerCP) vs BL2 (CD56-PE) of the R1 selected cell population, as shown in 
figure 5.1 to identify NK cells. (A) delineates a typical histogram plot showing CD69 
expression (FITC) on NK cells. (B) shows a representative flow cytometry picture of 
NK cell degranulation following co-culture with a target cell population (SW480) ± VV; 
PBMCs were stained with antiCD107a-FITC and anti-CD107b-FITC in the presence 
Brefeldin A.  
 
 
 
 
Degranulation
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5.3.1 JX-594 activates NK cells in healthy donor PBMCs 
Utilising CD69 and CD107 as markers of NK cell activation we investigated 
whether JX-594 could activate NK cells within healthy donor PBMCs. PBMCs 
were isolated from whole blood venesection of healthy donor volunteers by 
density gradient centrifugation. Isolated PBMCs were treated with 0, 0.1 and 
1pfu/cell of JX-594 for 24 hours before being harvested for flow cytometry; 
CD69 expression was quantified using mean fluorescence intensity after 
staining with a CD69-FITC anti-human antibody. Treatment of PBMCs with 
JX-594 activated NK cells, increasing CD69 expression in a dose-dependent 
manner (Figure 5.3A). 
Similarly PBMCs from the same donor blood were treated with 0, 0.1 and 1 
pfu/cell JX-594 overnight before being co-cultured with SW480 and SW620 
target cells at a ratio of 10:1 (PBMCs:Target cells) for 4 hours. Cells were 
stained with CD107a and CD107b and expression was examined using flow 
cytometry. The presentation of target cells to JX-594-treated PBMCs resulted 
in a dose dependent increase in NK cell degranulation with similar 
enhancement of expression observed in response to both SW480 (18% 
control, 28% 0.1pfu/cell and 36% 1pfu/cell JX-594) and the metastatic cell line 
SW620 (17% control, 27% 0.1pfu/cell and 32% 1pfu/cell JX-594). Results are 
shown in Figure 5.3B. 
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Figure 5.3 JX-594 activates NK cells in healthy donor PBMCs.  
PBMCs were isolated from whole blood of healthy donor volunteers by density 
gradient centrifugation. Isolated PBMCs were treated with 0, 0.1 and 1pfu/cell JX-
594 for 24 hours before being harvested and stained with CD3/CD56/CD69-FITC 
antibody or co-cultured with SW480 and SW620 colorectal cell lines prior to staining 
with CD3/CD56/CD107a/b-FITC antibodies. Mean CD69 expression (A) and the 
percentage of NK cells expressing CD107a/b (B) measured using flow cytometry; 
graphs show mean + SEM for 4 individual healthy donors. 
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5.4 JX-594 induces type I IFN and GMCSF release in healthy 
donor PBMCs 
To further delineate the mechanism by which NK cells were activated in 
response to JX-594, we analysed the cell free supernatants from PBMC cell 
cultures after infection with JX-594. The innate immune response relies on 
cell-cell cross talk, with NK cells responding to interaction with other immune 
cells, such as dendritic cells and macrophages, or the secretion of soluble 
factors (cytokines). Cytokines known to activate NK cells include IFN-α, IFN-
β (Type I IFNs), IL-2, IL-10, IL-12, IL-15 and IL-18, whilst cytokines released 
by activated NK cells include IFNγ, TNF-α, IL-13 and GMCSF.289 
To examine the secretion of selected cytokines, cell-free supernatants were 
collected from PBMCs which had been treated with 0, 0.1, 1pfu/cell JX-594, 
or 0.1 and 1pfu/cell Reovirus for comparison and analysed by ELISA. There 
was no evidence of IL-2, IL-6, IL-8, IL-10, TNF-α or IFNγ (data not shown). 
However, JX-594 did lead to the production of IFN-α and GMCSF, but no IFN- 
β (Figure 5.4). Our group has previously demonstrated the secretion of IFN-α 
and IFN-β in response to Reovirus treatment and a direct virus comparison 
was of therefore of interest. As demonstrated in Figure 5.4, JX-594 infected 
PBMCs produce a relatively low level of IFN-α (A) compared to Reovirus and 
no IFN-β (B), however there is a significant dose related increase in GMCSF 
(C) which was not seen after Reovirus treatment. It remains unclear if this 
increase in GMCSF is as a result of immune activation and cytokine release 
from activated NK/PBMC cells, or secondary to the early replication of JX-594, 
which has been genetically engineered to encode GMCSF. To examine this 
further, GMCSF release was examined following treatment of PBMC with a 
non-GMCSF encoded virus (VV-LUC) using independent healthy donors. 
Despite the absence of the virus encoded GMCSF virus modification, 
significant levels of GMCSF secretion were still seen following infection with 
VV-LUC (1549pg/ml, 1pfu/cell VV-LUC). Graphical representation is shown in 
Figure 5.5. Whilst this was less than that seen with JX-594-GMCSF 
(3874.8pg/ml, 1pfu/cell JX-594-GMCSF-GFP) it is strongly suggestive that 
GMCSF release is in fact, at least in part, as a result of immune cell activation 
rather than simply the result of viral replication. 
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Figure 5.4 IFN and GMCSF production from JX-594 treated PBMCs. 
PBMCs were isolated from peripheral blood of healthy donors. Cells were treated 
overnight with 0, 0.1 and 1pfu/cell JX-594 and/or 0.1 and 1pfu/cell reovirus. Cell-free 
supernatants were collected and analysed by ELISA for the presence of IFN- α (A), 
IFN- β (B) and GMCSF (C). Graphs show mean + S.E.M for 3 individual donors. 
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Figure 5.5 GMCSF production from VV-Luciferase treated PBMC. 
PBMCs were isolated from peripheral blood of healthy donors. Cells were treated 
overnight with 0, 0.1 and 1pfu/cell VV-luciferase. Cell-free supernatants were 
collected and analysed by ELISA for the presence of GMCSF. Graphs show mean + 
SEM for 4 individual donors. Statistical significance is denoted by *p<0.05 (One-way 
ANOVA). 
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5.5 JX-594 mediated NK cell activation is dependent on type 
I IFN in healthy donor PBMCs 
The role of the type I IFNs is of particular interest with several studies reporting 
them to have a decisive role in the activation of NK cells. Despite relatively 
low levels of Type I IFNs identified in PBMC supernatants as a result of JX-
594 treatment we wanted to confirm whether the NK cell activation 
demonstrated in Figure 5.3 was dependent on type I IFN production. CD69 
activation and CD107 degranulation assays were therefore repeated in the 
presence or absence of IFN blocking antibodies in three independent healthy 
donor volunteers.  Assays were carried out in a directly comparable fashion 
to previous experiments with the modification that 30 minutes prior to the 
addition of JX-594 to PBMCs, combinations of soluble IFN blocking serum and 
IFN receptor blocking antibodies were added alongside appropriate 
serum/isotype antibody controls. 
Figure 5.6A demonstrates increased CD69 expression following infection with 
JX-594 in a dose dependent fashion. Significantly this response is completely 
removed in the presence of IFN blocking serum antibodies and restored to 
normal levels in the presence of serum/isotype controls. Similarly, Figure 5.6B 
shows that JX-594 activated NK cells degranulate to a significant level against 
both SW480 and SW620 target cells. In addition, degranulation was also IFN-
dependent and was inhibited to baseline levels when IFN blocking antibodies 
were used. Importantly, isotype controls did not significantly impede NK cell 
degranulation and results were consistent between the primary and metastatic 
cell line. 
Therefore, JX594 treatment of donor PBMCs activates NK cells to degranulate 
against colorectal cancer target cells.  Despite the low levels of IFN production 
in response to JX-594, NK cell activation is an IFN-dependent process with 
both NK cell phenotypic activation and degranulation being prevented in the 
absence of type I IFN signalling. 
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Figure 5.6 JX-594 activation of NK cells is dependent on type 1 
interferons in PBMCs.  
PBMCs were isolated from whole blood of healthy donor volunteers prior to JX-594 
treatment, PBMCs were treated with control media, IFN-α/IFN-β blocking antibody 
serum and IFNα/β receptor blocking antibodies or IgG2a isotype and control sheep 
serum. Following this pre-incubation, PBMCs were treated with 0, 0.1 and 1pfu/cell 
of JX-594 for 24 hours before being stained with (A) CD3/CD56/CD69-FITC 
antibodies for 30 mins or (B) co-cultured and incubated with SW480 and SW620 
colorectal cell lines (10:1 ratio) for 4 hours prior to assessment of CD107a/b 
expression using flow cytometry. Graphs show mean + SEM for three individual 
donors. Statistical significance is denoted by *p<0.05 (One-way ANOVA).  
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5.6 JX-594 mediated NK cell activation is dependent on 
monocytes in healthy donor PBMCs 
It should be noted that these data examine only an element of the innate 
immune response to oncolytic virus therapy. Hou et al. (2012)290 for example 
suggested VV infection induces monocytes to differentiate into mature 
dendritic cells with enhanced capacity to activate T cells, and activate innate 
and acquired antiviral immunity.  
Interestingly therefore, previous work by the group investigated the primary 
immune cell target for JX-594 and using a GFP-expressing vaccinia virus 
demonstrated that CD14+ monocytes were the predominant cells within 
PBMCs to become infected with JX-594 and hence express the GFP 
transgene (data not shown). Of interest to this work, previous studies have 
demonstrated a role of  CD14+ monocytes in the virus-induced activation of 
NK cells291 and as a result we therefore wished to further explore these 
concepts for JX-594. 
PBMCs from 3 independent healthy donors were collected and using 
magnetic beads CD14+ monocytes were removed. Whole PBMCs and CD14- 
PBMC cell populations from the same donors were treated with 0, 0.1 and 
1pfu/cell of JX-594 for 24 hours before being harvested and NK cell activation 
investigated using CD69 and CD107 degranulation assays. These data 
demonstrates that; 1) in the CD14- population there was no upregulation in 
CD69 expression on NK cells following JX-594 treatment, and 2) that 
degranulation against the two CRC cell targets, SW480 and SW620 was 
significantly reduced (Figure 5.7). Hence, CD14+ monocytes clearly play a role 
in the activation of NK cells within PBMCs in response to JX-594 infection with 
CD69 expression being completely abrogated and degranulation significantly 
reduced. 
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Figure 5.7 JX-594 activation of NK cells is dependent on monocytes in 
PBMC. 
PBMC were isolated from whole blood of healthy donor volunteers by density 
gradient centrifugation and CD14- cells depleted using magnetic beads. CD14+ and 
CD14- PBMCs were treated with 0, 0.1 and 1pfu/cell JX-594 for 24 hours before being 
harvested and (A) stained with CD3/CD56/CD69-FITC for 30 mins or (B) co-cultured 
and incubated with SW480 and SW620 cell lines prior to staining with 
CD3/CD56/CD107a/b-FITC. CD69 and CD107a/b expression, respectively, was 
assessed using flow cytometry. Graphs show mean + SEM for 3 separate healthy 
donors. Statistical significance is denoted by *p<0.05 (One-way ANOVA). 
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As previously demonstrated NK cell activation was dependent on IFN and as 
a direct result of removing CD14+ monocytes from PBMC cell populations, NK 
cell activation was also inhibited. Importantly there was no evidence of 
interferon release in the supernatants depleted of CD14+ monocytes (Figure 
5.8).  
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Figure 5.8 IFN-α production in JX-594 treated whole PBMCs and CD14- 
PBMC population. 
Cell-free supernatants were collected during the experiment described in Figure 5.7. 
Supernatants were analysed by ELISA for the presence of IFN- α. Graphs show 
mean + SEM for 3 individual donors. Statistical significance is denoted by *p<0.05 
(One-way ANOVA). No statistically significant values were observed. 
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5.7 Innate immune characterisation and NK cell activation in 
ex-vivo freshly resected human lymph node tissue 
Having confirmed in PBMCs that JX-594 can activate NK cell in blood we next 
addressed the potential for JX-594 to demonstrate a similar effect in lymph 
nodes. As discussed in Chapter 1, cancer related mortality is intimately linked 
to the progression of disease at diagnosis with the presence of visible lymph 
node disease providing a clear marker of poor prognosis. Occult disease is 
more difficult to assess but with a reported 25% recurrence rate in patients 
with initial node negative staging at the time of diagnosis there is a clear desire 
for novel therapies to target these areas.  
Several studies have described effective transit of virus to tumour draining 
lymph nodes in in vivo models following i.t. injection using various OV’s.292,293 
Indeed using an orthotopic breast cancer mouse model, Gholami and 
colleagues (2012)294 showed that a Lister strain, GFP-expressing VV (GLV-
1h153) could not only be tracked in metastatic lymph nodes 48 hours after a 
single dose i.t. injection but 5 weeks after treatment, the authors were unable 
to find any evidence of metastatic cells within the harvested lymph nodes 
within the treatment group. Untreated controls, however, continued to 
demonstrate detectable metastatic cells.  Clearly, translationally this could 
provide a plethora of exciting new treatment options and the ability of JX-594 
to act by both direct oncolysis and activate an innate immune response at 
these distant tumour locations, rich in immune cells, is of significant interest. 
 
5.7.1 Examination of immune cell components in lymph nodes.  
Access to fresh tissue samples, particularly lymph nodes holds significant 
challenges and to date little is reported in the literature about the phenotypic 
appearance of fresh human lymph nodes samples. Initial work focussed, 
therefore on characterising the cell populations we were able to identify within 
these lymph nodes with a particular interest in NK cells. Lymph Node 
Mononuclear cells (LNMNC) isolated from CRC donor patients were prepared 
by density centrifugation and cell populations identified by flow cytometry 
(Figure 5.9).  
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Figure 5.9 Immune cell populations in lymph nodes. 
Freshly resected lymph node tissue retrieved from the mesentery of patients 
undergoing colorectal resection for malignancy were disaggregated into single cell 
suspensions and cell population assessed by staining with CD3-PERCP, CD3/CD4-
FITC, CD3/CD8-FITC, CD11b-PERCP, CD11c-PE, CD14-PE, CD19-PE, 
CD3/CD56-FITC and CD69-FITC for 30 minutes prior to analysis using flow 
cytometry. Data is representative of at least 3 separate lymph nodes. A) shows a 
representative FSC vs SSC for lymph node biopsies. B) shows representative 
histogram plots for each of the antibody panels used.  
A
B
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Given our previous work in PBMCs, we wanted to see what cell 
populations/markers we could detect in lymph nodes in order to define what 
might be utilised to respond to virus therapy and furthermore identify cell 
populations responsible for possible immune activation. Phenotyping 
experiments identified, as expected, non-tumour LNMNCs did not contain 
monocytes. Perhaps surprisingly CD11b cells were also not detectible; CD11b 
is globally expressed on the surface of neutrophils, monocytes, macrophages 
and NK cells and mediates the inflammatory response by regulating leukocyte 
adhesion and migration. Previous published data describe human lymph 
nodes as locations for immature NK cell populations that express low levels 
of CD11b intergrin would also support this observation.295 The lymph node cell 
population did however, contain CD11c+ and CD19+ cells typically found on 
the surface of DC and B-cells, respectively. CD11c is a type 1 transmembrane 
protein found in high levels on most human DC but also expressed on 
monocytes, macrophages and B cells. CD11c DC are required for 
lymphocytes to traffic towards lymph nodes in vivo and have been implicated 
as likely carriers of pathogens to lymph nodes.296,297 Clearly with respect to 
OVs this may have direct implications with regards virus carriage and access 
to distant disease harbouring sites.  
 
5.8 JX-594 activates NK cells in human, non-tumour, lymph 
nodes 
Studies on human lymph node tissue are scarce, but mouse data suggests 
that NK cells are ‘either normally excluded or at low levels in resting naïve 
lymph nodes but can be rapidly recruited to lymph node draining sites in 
response to immune signalling’.298 It is thought that the primary innate immune 
response causes activated NK cells to kill target cells and/or produce 
inflammatory cytokines such as IFN-g.299 Thereafter, IFN-g production plays 
an important role in T cell priming, inducing CD4+ T cell Th1 differentiation and 
a CD8 cytotoxic response.  Of note, NK cell recruitment to lymph nodes is 
tightly regulated by activation status and requires endogenous IFN-g, although 
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the mechanism by which this controls NK cell recruitment to lymph nodes 
remains unclear.298 
In human tissue, one study identified the presence CD56Bright NK cells in 
human lymph nodes consistent with our data presented below (Figure 5.11). 
The authors demonstrated that the lymph node residing NK cells could be 
stimulated by T-cell derived IL-2, acting through constitutively expressed high 
affinity IL-2 receptors to secrete IFN-g, clearly illustrating the cross talk 
between the innate and adaptive immune response.300 Induction of an innate 
immune response and NK cell activation in the lymph node tissue following 
OV therapy could translate into potential targeted therapeutic effects in 
micrometastases, initiating a focal anti-tumour immune response..  
Having identified cell types present in the LNMNC and demonstrated the 
presence of NK cells (CD3-/CD56+) (Figure 5.10), we further investigated 
whether JX-594 could activate NK cells and trigger an innate immune 
response within the lymph nodes, similar to that seen previously in the blood.  
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Figure 5.10 The Phenotypic appearances of CD3-CD56+ lymphocytes (NK 
cells) and their discrete NK cell subpopulations (CD56Dim and CD56Bright) 
within LNMNCs. 
LNMNCs were prepared from disaggregated fresh lymph node tissue and stained 
with CD3 PerCP and CD56 PE anti-human antibodies. Cells were analysed using 
flow cytometry. (A) denotes a forward scatter (FSC) vs side scatter (SSC) dot plot, 
with the R1 gate incorporating the lymphocyte cell population. (B) Shows CD3 PerCP 
vs CD56 PE expression within the R1 selected cell population. The R2 gates 
surrounds the total NK cell population (CD3-CD56+) with CD56Dim and CD56Bright NK 
Cell populations highlighted. 
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As previously described, CD69 and CD107 staining were utilised as 
representative markers of NK cell activation. Prepared LNMNC cells from 
lymph nodes acquired from the mesentery of colorectal cancer specimens 
were treated with JX-594 (Figure 5.11).  
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Figure 5.11 JX-594 activates NK cells in LNMNCs. 
LNMNCs were prepared from disaggregated fresh lymph node tissue as previously 
described. Isolated LNMNCs were treated with 0, 0.1 and 1pfu/cell of JX-594 for 24 
hours before being harvested and stained with CD69-FITC antibody for 30 mins and 
then washed and fixed with 1% PFA prior to analysis using flow cytometry. Graphs 
show mean + SEM for 3 individual lymph nodes. Statistical significance is denoted 
by *p<0.05 (One-way ANOVA). 
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As a direct result of virus challenge, NK cell activation was observed in non-
tumour bearing lymph nodes, as demonstrated by a significant increase in 
CD69 expression after treatment with 1pfu/cell JX-594. Whilst still significant 
this was less pronounced than that previously demonstrated within PBMCs. 
(Figure 5.3A) 
Similarly, to assess NK cell degranulation, LNMNCs were treated with 
increasing doses of JX-594 and co-cultured with SW480 and SW620 
colorectal cell line targets. Figure 5.13 demonstrates that JX-594-activated 
LNMNC NK cells degranulate against  both SW480 and SW620 cell line 
targets which was significant compared to untreated controls. No significant 
degranulation was observed in the absence of SW480 or SW620 cell targets. 
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Figure 5.12 JX-594-activated LNMNC NK cells degranulate against 
colorectal cell line targets. 
LNMNCs were isolated from disaggregated fresh lymph node tissue obtained from 
CRC patients undergoing surgical resection and treated with 0, 0.1 and 1pfu/cell of 
JX-594 for 24 hours before being harvested. LNMNCs were then co-cultured with 
SW480 and SW620 colorectal cell lines for 4 hours prior to staining with CD107a/b-
FITC antibodies. The percentage of NK cells expressing CD107a/b was quantified 
using flow cytometry and recorded as percentage degranulation. Graphs show mean 
+ SEM for 3 separate lymph node donors. Statistical significance is denoted by 
*p<0.05 (One-way ANOVA). 
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Of note, as with healthy donor PBMC (Figure 5.3) higher levels of 
degranulation were seen against the metastatic colorectal target cell line 
SW620 cells compared with SW480 cells. No statistically significant increase 
was observed in the absence of targets (data not shown). Whilst we 
acknowledge small differences and low levels of degranulation involved, 
purely hypothetically this could present significant translational potential for 
targeting of micrometastasis. 
 
5.9 Cytokines involved in JX-594 activation of NK cells in 
LNMNC. 
To explore the mechanistic process behind the NK cell activation observed 
we analysed the cell free supernatants after infection with JX-594 to quantify 
specific cytokines that may be involved in NK cell activation. In PBMCs, type 
I IFN’s appeared to play a key role in NK cell activation, as demonstrated by 
the production of IFN-α in response to JX-594 infection, and the cessation of 
NK cell activation when assays were performed in the presence of IFN 
blocking (Figure 5.6). 
Unlike in PBMCs, however, LNMNCs did not appear to stimulate the 
production of type 1 IFNs (α/b). At 1pfu/cell JX-594, IFN-α was just detectable 
at very low levels (less than 100pg/ml; Figure 5.13A) and IFN-b was not 
present (data not shown) after treatment with JX-594. GMCSF was secreted 
in a dose-dependent manner, with increased expression associated with 
increasing virus dose; levels were comparable to that seen with PBMCs 
(Figure 5.13C). 
Given previous literature regarding lymph nodes which suggests an important 
role for IFN-Interferon-g in both NK cell recruitment and activation we also 
looked for interferon gamma-induced protein 10 (IP-10). IP-10 (also known as 
C-X-C motif chemokine 10 (CXCL10)) is a small cytokine belonging to the 
alpha chemokine family. It is constitutively expressed at low levels in lymph 
node stroma301 and secreted by various cell types including monocytes, 
fibroblasts  and endothelial cells. IP-10 plays an important role in T-cell 
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trafficking and mediates the IFN-g response. Interestingly, given the absence 
of significant IFN-α or IFN-b, IP-10 was also detected at low levels, although 
levels detected demonstrated wide variability across the repeat experiments 
(Figure 5.13B). 
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Figure 5.13 IFN- α, IP-10 and GMCSF production from JX-594 treated 
LNMNCs. 
Cell-free supernatants were collected from treated LNMNCs and analysed by ELISA 
for the presence of IFN- α, IP-10 and GMCSF. Graphs A & B show mean + SEM for 
3 separate donors. Graph C is data from a single donor. Statistical significance is 
denoted by *p<0.05 (One-way ANOVA). No statistically significant values were 
observed. 
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5.10 JX-594 activation of NK cells in donor LNMNCs is 
independent of type 1 IFNs  
Data from PBMCs demonstrated that despite relatively low levels of Type I 
IFNs identified as a result of JX-594 infection, NK cell activation was indeed 
dependent on type I IFN production.  For example, CD69 expression and NK 
cell CD107 degranulation were both inhibited in the presence of IFN blocking. 
Hypothetically it was anticipated that the same should be true for LNMNC 
response to JX-594 treatment. However, given the unexpectedly low, almost 
undetectable levels of Type I IFN found in the supernatants of infected 
LNMNCs we postulated that IFN may not be the primary mechanism of NK 
cell activation within lymph nodes. To elucidate the importance of IFN for NK 
cell activation in lymph node samples we used interferon blocking experiments 
as previously described to allow direct comparison with data acquired for 
PBMCs. The CD69 and CD107 degranulation assays on LNMNCs in the 
presence and absence of IFN blocking serum antibodies yielded no significant 
reduction in CD69 activation or degranulation.  
Similar levels of CD69 activation (3.6% fold increase from control to 1pfu JX-
594) were observed in response to JX-594 treatment, however, the addition 
of IFN blockade or isotype controls did not inhibit CD69 upregulation in 
response to JX-594, suggesting a mechanism different to that seen in blood, 
and not type I IFN dependent (Figure 5.14A). Likewise, NK cell degranulation, 
was also independent of type 1 IFN with no demonstrable difference in NK 
degranulation seen in the presence or absence of IFN blockade. Of note, this 
was consistent between the SW480 and SW620 target cells with no difference 
seen between the primary and metastatic cell lines (Figure 5.14B). 
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Figure 5.14 JX-594 activation of NK cells is independent on type 1 
interferons in patient LNMNCs. 
LNMNCs were isolated from lymph node samples retrieved from patients undergoing 
colorectal cancer resection prior to JX-594 treatment. LNMNCs were treated with  
control media, IFN-α, IFN-β blocking serum and an IFNα/β receptor blocking antibody 
or IgG2a isotype and control sheep serum. Following this pre-incubation, LNMNCs 
were treated with 0, 0.1 and 1pfu/cell of JX-594 for 24 hours before being stained 
with (A) CD3/CD56/CD69-FITC antibodies or (B) co-culture with SW480 and SW620 
colorectal cell lines (10:1 ratio) for 4 hours prior to assessment of CD107a/b on NK 
cells. Graphs show mean + SEM for 3 separate patient samples. Statistical 
significance is denoted by *p<0.05 (One-way ANOVA). 
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5.11 Reovirus induced NK cell activation in LNMNCs 
As discussed earlier in this chapter, previous work by colleagues in the 
laboratory have largely focused on an alternative virus, Reovirus. Given this 
previous body of work, it was of interest to see if NK cell activation could be 
initiated by Reovirus in lymph nodes in a similar fashion to JX-594.  
As with JX-594, Reovirus resulted in a significant increase in CD69 with 
results largely consistent with those observed for JX-594. Significant NK cell 
activation was observed at lower doses of Reovirus (0.1pfu/cell) resulting in a 
significant increase in CD69 expression (2903.7 - 4422.4mfi; Figure 5.15). 
Similarly, we also examined the ability of Reovirus to promote NK cell 
degranulation within our LN samples. As with JX-594, Reovirus-activated 
LNMNC NK cells resulted in degranulation against colorectal targets in a dose 
dependant fashion. Percentage degranulation against both colorectal cancer 
cell targets were however almost 3-fold greater than those seen with JX-594, 
with similar enhanced levels of degranulation seen in response to both the 
primary and metastatic target cell population (Figure 5.16).  
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Figure 5.15 Reovirus activates NK cells in LNMNCs. 
LNMNCs were prepared from disaggregated fresh lymph node tissue as previously 
described. Isolated LNMNCs were treated with 0, 0.1 and 1pfu/cell of Reovirus for 24 
hours before being harvested and stained with CD69-FITC antibody for 30 mins prior 
to analysis using flow cytometry. Graphs show mean + SEM for 3 individual lymph 
nodes. Statistical significance is denoted by *p<0.05. 
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Figure 5.16 Reovirus-activated LNMNC NK cells degranulate against 
colorectal cell line targets. 
LNMNCs were isolated from disaggregated fresh lymph node tissue from CRC 
patients undergoing surgical resection and treated with 0, 0.1 and 1 pfu/cell of 
Reovirus for 24 hours before being harvested. LNMNCs were then co-cultured with 
SW480 and SW620 colorectal cell lines (10:1 ratio) for 1 hour prior to staining with 
CD107a and b - FITC antibodies in the presence of Brefeldin A for a further 4 hours. 
Percentage of cells expressing CD107a/b was measured using flow cytometry and 
recorded as percentage degranulation. Graphs show mean + SEM for 3 separate 
lymph node donors. Statistical significance is denoted by *p<0.05. 
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Given the levels of NK cell degranulation seen in response to Reovirus it was 
important to also further define the mechanism of Reovirus-induced NK  
degranulation in lymph nodes given the mechanism of action adopted by JX-
594 does not appear to utilise type-1 IFN. In response to Reovirus, significant 
levels of IFN-α were produced (Figure 5.17) consistent with a type 1 IFN 
response. IP-10 was also produced at low levels (Figure 5.17), however no 
GMCSF production (data not shown). 
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Figure 5.17 IFN-α and IP-10 production from Reovirus treated LNMNCs. 
Cell-free supernatants were collected from Reovirus treated LNMNCs and analysed 
by ELISA for the presence of IFN- α, and IP-10. Graphs show mean + SEM for 3 
separate donors. 
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Hypothetically, the high level of IFN-α produced in response to Reovirus in 
LNMNC, in contrast to JX-594, would suggest the mechanism of NK cell 
activation is  likely to be type I IFN dependent as observed in PBMC. Whilst 
beyond the scope of this work, and as a direct result of limited access to further 
lymph node samples, a single preliminary experiment using 10pfu Reovirus, 
was carried out in the presence of interferon block. Surprisingly, in the 
experiment undertaken, IFN blocking yielded no significant reduction in NK 
cell activation or degranulation (Figure 5.18). 
Drawing firm conclusions from single experiments is difficult and further 
repeats would be necessary to corroborate these initial findings, but it seems 
possible that two different mechanisms of action are involved in OV-induced 
NK cell activation in PBMCs and LNMNCs, regardless of the virus chosen. 
OV-induced NK cell activation in PBMCs is type-1 IFN dependent and likely 
controlled by IFN-α, albeit at low levels. In LNMNCs, despite variable IFN 
production depending on the OV chosen, there appears to be no correlation 
between the presence of type 1 IFNs and NK cell activation, in fact, the 
mechanism appears to be independent of type-1 IFNs.  
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Figure 5.18 Reovirus activation of NK cells may be independent of type 
1 interferons in patient LNMNC. 
LNMNC were isolated from lymph node samples retrieved from patients undergoing 
colorectal cancer resection prior to Reovirus treatment. LNMNCs were treated with 
control media, IFN-α, IFN-β blocking serum and an IFNα/β receptor blocking antibody 
or IgG2a isotype and control sheep serum. Following this pre-incubation, LNMNCs 
were treated with 0, 10 pfu/cell Reovirus for 24 hours before being stained with (A) 
CD3/CD56/CD69-FITC antibodies or (B) co-cultured with SW480 and SW620 
colorectal cell lines (10:1 ratio) for 4 hours prior to assessment of CD107a/b on NK 
cells. Graphs show data from a single patient sample.  
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5.12 Discussion 
The initial benefits of OV therapy focussed on their direct oncolytic effects, 
however, more recently modulating OV immune response has been the focus 
of various groups around the world. OV’s have a natural tropism for tumour 
cells, which can be enhanced by genetic modifications to the virus backbone 
resulting in improved cell specificity and supporting anti-tumour immunity. 
Tumour cells also have an impaired antiviral response, demonstrating both a 
diminished IFN response and an increased biological tolerance of viral 
infection making them attractive cancer therapy agents.52 This chapter aimed 
therefore to further define the mechanisms by which JX-594 acts as an 
immunotherapeutic agent.  
The focus of the chapter relates to NK cell activation which has been used by 
our group extensively in previous similar studies as a direct marker of innate 
immune activation and thereafter examined the consequences of associated 
cytokine release. Specific focus was placed on type 1 IFNs, the role of which 
have been reviewed by Biron et al. (1999)40 and Le Bon et al. (2002)302 but 
act to govern a number of immune-regulatory functions that control both the 
innate and adaptive immune response, for example regulating phenotypic and 
functional changes in DC. The production of IFN-α was initially demonstrated 
by Gerosa et al. (1991)303 to induce the upregulation of CD69 expression on 
resting human NK cells and more recent data demonstrated that Reovirus 
infection could induce CD69 expression on NK cells in whole PBMCs in an 
IFN dependent fashion.204 With respect to this, our group has also previously 
demonstrated that RNA viruses, such as Reovirus, oncolytic VSV and 
measles virus activate a generalised inflammatory response following tumour 
cell infection, characterized by the secretion of a range of molecules, in 
addition to the type I IFNs (α and β), including, RANTES, IL-6, IL-8, MIP-1a 
and MIP-1b, which have been shown to be able to regulate innate tumour 
killing.43,206,304,305 
For JX-594, unpublished data reported by my predecessor analysed the 
profile of chemokines and cytokines secreted following JX-594 treatment. JX-
594 infection of CRC cell lines did not result in the secretion of significant 
levels of any of the inflammatory molecules listed above with the exception of 
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IL-6 and GMCSF, where GMCSF is encoded by the virus. However, a dose-
dependent reduction in the classically immunosuppressive cytokines, VEGF 
and IL-10 was observed suggesting that JX-594 can promote a pro-
inflammatory, anti-angiogenic tumour microenvironment (Data not shown; see 
also R Dave unpublished thesis).253 
To progress these data we have demonstrated that JX-594 treatment of 
healthy donor PBMCs activates NK cells to degranulate against colorectal 
cancer target cells. NK cell activation was an IFN-dependent process with 
both activation and degranulation being prevented when IFN signalling was 
abrogated by IFN blocking serum. Interestingly, this occurs despite the 
relatively low levels of IFN production reported in response to JX-594 when 
compared with alternative OV reported in the literature.157,304,306 
Interestingly, previous studies examining the effect of OV (Reovirus) in 
isolated NK cells in vitro, have shown an inability of Reovirus to activate NK 
cells in isolation. Rather it acts to induce phenotypic maturation of 
DC/monocytes and the production of inflammatory cytokines leading to the 
activation of NK cells upon co-culture.157 The effect of JX-594 therefore in 
whole PBMCs is interesting and broadly mimics the response observed by 
both Adair et al. (2013)204 and Parrish et al. (2015)205 seen after Reovirus 
infection of whole PBMCs albeit, with lower IFN production levels. The findings 
further highlight the complex interaction at play in response to virus infection 
of whole PBMCs, with DC, a plethora of inflammatory cytokines and NK cells 
involved in cell-cell cross-talk driving an inflammatory response. Within this 
pathway, IFN-α, secreted from DC, drives an anti-viral response by activating 
other effector cells and propagating the immune response against target 
cells.307  However, various authors have demonstrated, including my 
predecessor for JX-594 (data unpublished) that this anti-viral IFN-α response 
does not completely abrogate direct oncolysis or viral replication.308,309 
Indeed, these mechanisms underly JX-594 inherent tumour selectivity. As a 
result of cellular infection by JX-594, the virus secretes viral proteins from the 
infected cell in order to manipulate pathways that allow it to replicate, spread 
and evade IFN-mediated anti-viral clearance. Two distinct proteins are 
released, vaccinia growth factor (VGF) which activates the EGFR/RAS/MAPK 
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signal transduction pathway driving virus replication and spread and B18R 
which inactivates type 1 IFNs.124 
The other cytokine produced in significant quantities was GMCSF. Initially it 
remained unclear if this increase in GMCSF was as a result of cytokine release 
from activated NK cells or simply as a result of replication of JX-594, which 
has been genetically engineered to encode for GMCSF within PBMCs. VV-
Luciferase treatment of PBMCs, a virus not engineered to encode GMCSF, 
also resulted in a significant, albeit reduced increase in GMCSF. It would 
seem likely therefore that JX-594 stimulates GMCSF production directly from 
immune cells in response to virus challenge, although additional production 
from early phase replication of the virus in PBMCs cannot be discounted.  
Currently, GMCSF is the immune gene that has been inserted most 
successfully into a range of clinical grade OV. Interest stems from its 
underlying ability to generate a potent systemic adaptive anti-tumour immune 
response following expression in tumour cells, this is associated with 
differentiation, maturation and recruitment of DC within the tumour 
microenvironment.271 Numerous clinical trials have now shown clinical benefit 
of this strategy with large scale accumulation of DC seen at injection sites, 
resulting in the processing and presentation of tumour antigens to activate 
tumour-specific T cells.310,311 The findings in this study of both induced and 
encoded GMCSF expression in response to JX-594 infection further supports 
these translational strategies.  
A further interesting observation in this study is that it is evident that CD14+ 
monocytes play a crucial role in the activation of NK cells within PBMCs in 
response to JX-594. As previously mentioned prior work by the group 
demonstrated that CD14+ monocytes were the predominant cell population 
within PBMCs to become infected with JX-594, an observation supported by 
Hou et al. (2012)290 who demonstrated a role of CD14+ monocytes in the virus-
induced activation (VSV, vaccinia, influenza A virus, circulating swine-origin 
virus) of NK cells. Likewise, Sanchez-Puig et al. (2004)312 and Byrd et al 
(2013)313 both conclude that VV infection of peripheral blood leukocytes show 
a strong bias towards the infection of monocytes over alternative immune cell 
populations.  
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In a similar vein to our data, the important relationship between monocytes, 
NK cells and type 1 IFNs in response to virus challenge is consistent with 
recent data published in knock out mice experiments carried out by Lee et al. 
(2017)314. In response to Herpes Simplex Virus Type-2 (HSV-2) infection in 
an in vivo murine model, the authors concluded that type 1 IFN receptor 
signalling in monocytes, not DC’s or NK cells, is essential for NK cell 
activation. In their study, knock-out mice deficient in type 1 IFN signalling 
resulted in ‘significantly lower levels of inflammatory monocytes, deficient  IL-
18 production and lacked NK cell-derived IFN-	𝛾’ following treatment with 
HSV-2. Furthermore, depletion of monocytes (as with our study) resulted in 
complete loss of NK cell activation.314  
Interestingly, CD14+ monocyte dependent NK cell activation in virus treated 
PBMCs has also been reported with Reovirus. Parrish and colleagues 
(2015)205 abrogated CD69 expression and NK cell degranulation in CD14+ 
depleted Chronic Lymphocytic Leukaemia (CLL) patient PBMC following 
Reovirus treatment suggesting monocytes are critical for activation to occur. 
Hypothetically, both our data and previous studies within the group suggest 
that within PBMCs, monocytes take up JX-594 causing a phenotypic shift 
(data not shown) which results in a cascade of events that ultimately leads to 
IFN-α production and NK cell activation. Given the immune response 
demonstrated in PBMCs, one might expect to see similar results in LNMNCs. 
Indeed, JX-594 infection of donor LNMNCs did activate NK cells to 
degranulate against CRC targets, as expected. However, our data does not 
support a role for an IFN dependent system, as with PBMCs, and the 
mechanism of virus activation in lymph nodes remains to be fully elucidated 
and is discussed further below.  
Notable and important differences exist in the phenotyping of LNMNCs when 
compared with PBMCs, namely the lack of monocytes (CD14+ cells) which 
appear critical to the virus response of PBMCs. This is not unexpected for 
lymph nodes in their resting state as typically during infection, monocytes or 
monocyte/derived cells are recruited from the blood into lymph nodes to 
mediate, and promote, an adaptive immune response.315 Vaccinia virus has 
been reported to induce type 1 IFN expression by inflammatory monocytes, 
and recruitment to lymph nodes requires toll-like receptor 2 (TLR2) stimulation 
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by viral ligands in endosomes of virus infected cells. Following recruitment to 
the lymph nodes, monocytes differentiate along distinct pathways based on 
distinct pathogen-derived ligands.316 Indeed only eighteen hours after VV 
infection, different subsets of DC can be identified characterised in part by 
increased cell surface expression of the DC maturation marker CD83, and is 
associated with rapid disappearance of CD14+ cells.290  
Within the lymph nodes, the main initiators of a cellular immune response are 
thought to be antigen presenting cells (APC) which act to present processed 
viral antigens to naïve T cells in the draining lymph nodes. Of these APC, DC 
are reported to be the most important in stimulating T-cell proliferation. In 
murine lymph nodes several phenotypically distinct DC populations exist but 
consistent with our data all are CD11c+.317 Interestingly a review by Colonna 
et al. (2002) demonstrated that CD11c+ DC’s secreted large amounts of type 
1 IFN in vitro following infection with HSV-1 in both humans and mice.318 This 
is at odds to the minimal IFN production seen in response to JX-594 but is 
consistent with the IFN production observed following Reovirus treatment. 
Hypothetically, this may reflect different virus acting on different DC subsets, 
i.e. plasmayctoid DC or conventional DC both of which express a different 
array of TLR.316  
To examine potential reasons for the differences observed between both the 
JX-594 and Reovirus and PBMC and LN responses, it is important to explore 
human NK cell biology in more detail. Human NK cells, as previously 
discussed are identified by CD56 expression and the absence of the T cell 
marker CD3. CD56 NK cells can be sub-classified further into CD56Dim and 
CD56Bright which can be found in different quantities depending on tissue type 
examined. The CD56Dim subset are largely found in the blood and are 
characterised by high cytotoxicity and low cytokine production, in keeping with 
our PBMC findings which demonstrate low levels of CD56Bright in phenotyping 
studies (Figure 5.1) and low levels of cytokine production in response to NK 
cell activation. Conversely, CD56Bright NK cells are largely found in lymph node 
tissues, and are reported to show low cytotoxicity, and produce large amounts 
of cytokines, specifically IFN-𝛾,319 not examined in this study. Our phenotyping 
of lymph nodes certainly demonstrated an increased proportion of CD56Bright 
when compared with PBMC data and perhaps suggests OV-induced NK cell 
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activation is exerting its effect via two different subpopulations of NK cell in 
the two different tissue types, as reviewed by Zwirner et al. (2017)320. 
Different cell types and cytokine release is supported by a previous study 
examining NK cells in mice and human lymph nodes by Watt et al. (2008)298. 
The authors identified mature NK cells to be recruited preferentially into 
draining lymph nodes following DC challenge in a tightly regulated IFN-𝛾 -
dependent mechanism. Thereafter, DC induced NK cell activation was 
reported to produce IFN-𝛾 which played an important role in inducing Th1 
responses. Several reports suggest a tightly coordinated network involving 
DC, T cell and NK cells which act within the local LN microenvironment to 
determine an immune response.321–323 Interestingly, consistent with these 
findings, Rajani et al. (2015) 324 also demonstrated an adaptive T cell 
response in LN following Reovirus treatment. In mice treated with i.t. Reovirus, 
an IFN−𝛾 memory recall response to B16 tumour lysates was detected in 
pooled splenocytes and lymph nodes suggestive of Reovirus priming anti-
tumour T-cell responses.  
Furthermore, Hayakawa et al. (2008)321 examined the effect of prior NK cell 
activation with two molecules, poly(I:C) and α-GalCer on NK cell recruitment 
to draining LN.  Poly(I:C) and α-GalCer are known to be type I and type II IFN 
dependent in their mechanism of action, however acted to diminish NK cell 
recruitment to draining LN whilst downregulating expression of the activated 
NK cell chemokine receptor, CXCR3. The authors hypothesise that reduced 
CXCR3 expression may be driven by the cell microenvironment to avoid any 
undesired contribution that pre-activated NK cells may play during T cell 
priming. It is clear from these studies, as with our data that NK cell biology in 
the lymph nodes may act through different mechanism to that utilised by 
PBMCs. In this study, we did not look at IFN−𝛾, however the literature 
suggests that IFN−𝛾 plays a pivotal role in coordinating both NK cell 
recruitment and activation in lymph nodes and this would therefore be an 
interesting continuation of this work. As previously stated, confirming a 
different mechanism by which OV-induced immune priming can act between 
PBMCs and LNMNCs could open the window to the targeting of 
micrometastatic disease in lymph nodes in addition to the blood.  
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Whilst much work remains examining the wider immune response to systemic 
virus and the potential anti-tumour effects, this could hold the key to treating 
non-resectable microscopic disease. It is likely that multiple other effectors, 
not examined here also play a role in driving innate immune responses, an 
example being neutrophils which are reported to contribute to the innate anti-
tumour efficacy of other oncolytic viruses (Reviewed by Choi et al. (2016))325. 
In addition, our preliminary data with Reovirus showed that Reovirus is also 
capable of activating LNMNC NK cells and as observed for PBMC, was more 
efficient than JX-594 at inducing IFN-𝛼 and activating NK cell populations. 
Reovirus anti-tumour efficacy is widely reported to depend upon a potent anti-
tumour immune response mediated through the activation of DC to stimulate 
NK cells and T cell mediated cytotoxicity.43,157,324,326 Our preliminary findings, 
suggest improved type 1 IFN release from LNMNC as a result of Reovirus 
treatment with significantly higher levels of IFN-𝛼 recorded compared with JX-
594. However, as observed for JX-594 NK cell activation did not appear to be 
type-1 IFN dependent in LNMNCs in the pilot experiment performed.  
This study may also provide the basis for exploring further combination 
strategies to treat micrometastatic disease, for example, the use of OV with 
immune checkpoint inhibitors. Rajani et al. (2015)324 reported a significantly 
improved survival benefit in mice treated with a combination of Reovirus and 
anti-PD-1 antibody compared with either PBS controls or single agent 
treatment. Preliminary phenotyping experiments in our LNMNC population 
(data not shown) showed significant levels of PD-1 and PDL-1 and as such 
the potential for translational combination strategies in the clinical setting must 
be considered promising and provides an area of interest to explore further in 
more detail in future experiments.324 
It is clear from these studies that JX-594 is able to alter both phenotypic and 
functional aspects of NK cell activity acting via different mechanisms in the 
blood and lymph nodes. These different mechanistic processes may allow 
translational opportunities with JX-594 targeting tumour cells in both blood and 
lymph node tissue. Indeed, if low levels of virus can access any non-resected 
tissue, activation of an innate immune response at specific tissue sites may 
provide sufficient therapy to treat this micrometastatic disease and our data 
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suggests that JX-594 holds promise as a novel treatment modality. Moreover, 
direct tumour-specific lysis, transgene expression and the induction of tumour 
specific innate immunity means that it may provide a multi-pronged, and 
selective attack, against the tumour at various disease sites. 
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Chapter 6  
Conclusion 
As discussed colorectal cancer remains a significant clinical problem. By 2030 
CRC globally is estimated to be diagnosed in 2.2 million new cases per year 
and account for 1.1 million deaths, an increase of 60%.3 Nonetheless bowel 
cancer survival has undoubtedly improved.  In the UK alone survival has more 
than doubled in the last 40 years (22%-57%), however these figures remain 
dependent on stage of disease at diagnosis, patient demographics, comorbid 
state and tumour biology.327  
In part, improved survival has transpired as a result of now established 
treatments such as anti-EGFR antibodies (Cetuximab, Panitumumab, and 
GA201). Unfortunately they are currently only offered to about 50% of CRC 
patients, based on identification of appropriate genetic susceptibility; 
disappointingly only 10-20% of patients obtain objective clinical responses 
with KRAS, BRAF and PI3KCA mutations (causing constitutively activated 
EGFR signalling) implicated in this cellular resistance. Newer classes of 
anticancer agents include oncolytic viruses (T-VEC and HSV-1) which have 
been approved by regulatory bodies for mainstream use in the treatment of 
inoperable melanoma, and BH3-mimetic (Navitoclax) which continue to 
develop as experimental agents in phase II clinical trials. 
The laboratory has a broad breath of experience with respect to delineating 
the cytotoxic and immune potential of a variety of oncolytic viruses in a range 
of tumour types and as such this study set out to explore the potential for OV 
involvement in combination with alternative immune-mediated therapies. 
Furthermore, viral effects in areas other than the tumour itself and its 
microenvironment may also be therapeutically important.  This is particularly 
the case in organs which can harbour micrometastases such as lymph nodes, 
which may potentially be targeted and cleared by appropriate activation of an 
innate and adaptive immune response. An alternative OV, JX-594 was 
therefore chosen to investigate if it could preferentially replicate, and kill, CRC 
at micrometastastic sites, and activate and induce an innate immune response 
in both the blood and lymph nodes. 
- 187 - 
This thesis examined the ability of Reovirus and JX-594 to kill a range of CRC 
cell lines regardless of their EGFR/KRAS/BRAF/PI3K mutational phenotype. 
Variable levels of cytotoxicity were demonstrated against cells with different 
mutational profiles with some cell lines demonstrating consistent dose-
dependent, time dependent killing (SW480, SW620) and other cell lines 
completely resistant to OV treatment (LIM1899). However, no correlation 
between mutational status and OV-induced death was elicited.  
Before exploring treatments in combination, the cytotoxic potential of ABT-263 
and Cetuximab in isolation was examined. Consistent with data that reports 
up to 50% of cancer cell lines are resistant to ABT-263 because of variable 
expression of pro vs anti-apoptotic molecules, our data also elicited a mixed 
response. Some cell lines tested were completely resistant whilst others 
showed time-dependent, dose-dependent increases in cytotoxicity. Once 
again, no correlation was seen between killing and cell line mutational status 
although the WT cell line, Colo320, was least sensitive suggesting a potential 
requirement for positive mutational status to allow ABT-263 cytotoxic death. 
Despite positive results with monotherapies, the effect of combining Reovirus 
and ABT-263 was disappointing. A single cell line (SW620) elicited increased 
cell death as a direct result of using both treatments in combination however, 
statistical analysis revealed only additive effects.  
Cetuximab induces its anti-cancer effect by two distinct mechanisms; 1) 
antagonism of EGFR binding preventing pro-survival and proliferation signals, 
and 2) immune-mediated ADCC. Irrespective of EGFR signalling mutations, 
ADCC should occur and Reovirus immune activation of monocytes, 
neutrophils and NK cells, as demonstrated previously by the group might 
potentiate this antibody-induced ADCC.328 Interestingly, regardless of EGFR 
cell surface expression or KRAS/BRAF/PI3K mutational status cetuximab 
induced no direct cytotoxicity against the selected CRC cell lines, although we 
were unable to test this model specifically against an EGFR positive, RAS wild 
type cell line, which has been reported by other groups to be sensitive to direct 
killing by cetuximab. Despite the lack of direct killing we did demonstrate 
preliminary evidence that pre-treatment of PBMCs with Reovirus, and 
resultant NK cell activation, did increase cetuximab-mediated ADCC in a 
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KRAS mutant cell line (SW480). Further work is needed to validate this data 
fully but certainly provides promise and direction for future experimentation.  
JX-594 like Reovirus can kill target cells by direct oncolyis, replicate within 
CRC cell lines, and induce a pro-inflammatory, anti-angiogenic tumour 
microenvironment by promoting immune cell recruitment to stimulate an 
innate and adaptive immune response. However, VV-induced death 
mechanisms in CRC remain poorly understood and similarly the effects of VV 
on distant tissues, not related to the primary tumour, remain to be elucidated. 
These areas of study are however important given that targeting 
micrometastatic disease, in for example the blood and lymph nodes, with 
novel treatment strategies such as combinations of anti-EGFR antibodies and 
OV might prevent recurrence and the development of non-resectable 
disseminated disease.  
Significantly, JX-594 infection has been shown to be associated with increase 
caspase-3 expression in previous work by the group. Caspase-3 is an 
important protein used in apoptosis and as such JX-594 was expected to, at 
least in part, kill by this mechanism. Despite the upregulation of these 
markers, and having confirmed JX-594 could induce direct killing in our panel 
of cell lines, we were unable to elicit any attenuation of VV-induced cytotoxicity 
using a pan-caspase inhibitor. Similarly, necroptosis inhibitors had no effect 
on JX-594-mediated death, which along with the absence of HMGB1 in post-
treatment cell free supernatants was suggestive that necrosis and necroptosis 
were also not the primary mechanisms of action. The final mechanism of cell 
death investigated was autophagy, a process which VV has been shown to 
interfere with in ovarian cancer cell lines. In the CRC cell lines used in this 
study, no evidence of autophagy was demonstrated. Therefore, whilst it is 
clear that JX-594 induces significant cell oncolysis, the exact mechanism 
remains to be identified. It would seem likely that cell death is a coordinated, 
multi-faceted process involving parts of each pathway investigated and as 
such beyond the scope of this work to delineate further. 
It is now well understood that for a virus to be an effective therapeutic agent, 
it must be highly immunogenic and stimulate an innate and adaptive immune 
response. Indeed, even if systemic delivery yields relatively low levels of virus 
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to non-tumour tissue, such as blood and lymph nodes, activation of an innate 
immune response may be sufficient to provide adequate therapy against 
CTCs and micrometastatic disease. We therefore first examined the innate 
effects of JX-594 on blood, which would be readily accessed at high dose 
following intravenous administration and which can harbour circulating tumour 
cells, a feature of CRC associated with poor prognosis. Virus treated NK cells 
from donor blood demonstrated CD69 activation, NK cell degranulation and 
increased cytotoxicity against CRC cell line targets. This was dependent on 
IFN production and the presence of CD14+ monocytes. The relatively low 
levels of IFN-a and absence of IFN-b contrasts with Reovirus which produced 
relatively high levels of type-I IFNs. It is likely that this may be due to proteins 
such as B18R, encoded by VV, whose role is to blunt the infected cells IFN 
response. High levels of GMCSF were also seen following JX-594 treatment. 
Taken together the findings demonstrate the ability of JX-594 to infect 
monocytes within PBMC, leading to IFN-a mediated NK cell activation for 
potential killing of CTC’s. 
The study then addressed whether JX-594 mediated innate immune activation 
may have therapeutic effects in LN tissue. Data pertaining to the examination 
of fresh human lymph nodes using ex vivo models is relatively scarce in the 
literature, presumably because of the challenge of accessing samples. Initial 
work therefore determined the phenotypic appearance of lymph node tissue 
and identifiable cell populations. Not surprisingly, LNMNCs did not contain 
monocytes and CD14 was absent. NK cells were however identified, along 
with the presence of CD11c, which is implicated as a likely carrier of 
pathogens to lymph nodes, which as discussed raises the potential for virus 
carriage to distant disease harbouring sites. 
Having identified NK cells in LNMNCs, we repeated PBMC experimental 
protocols. Again virus treated LNMNC demonstrated CD69 activation, 
degranulation and increased cytotoxicity against CRC targets. Interestingly 
however this was a type-I IFN independent process with CD69 expression and 
NK cell CD107 degranulation not abrogated by the presence if IFN blocking. 
In addition, there was almost undetectable levels of type 1 IFN found in the 
cell free supernatant. Interestingly, similar results were observed in a 
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preliminary experiment using Reovirus treated LNMNC despite the production 
of high levels of IFN-a. 
This work opens the door to several areas of interest for continuing work. 
Defining the mechanism behind LNMNC viral induced NK cell activation, and 
validating the preliminary finding for Reovirus induced activation, will help 
delineate treatment strategies further. Exploration of IFN-g would also provide 
an important extension of this work.  
Furthermore, this study may also provide the basis for examining alternative 
OV combination strategies for example with immune checkpoint inhibitors 
given the significant levels of PD-1 and PDL-1 found in our LNMNC 
population. Anti-PD-1 antibody inhibitors are the focus of promising recent 
research and have been shown to improve survival in in vivo mouse models 
when combined with Reovirus.324 Given the findings from our LNMNC 
populations examining this combination would certainly be a promising 
experimental avenue to explore. 
Indeed the arrival of the first two clinical grade PD-1 checkpoint inhibitors, 
Nivolumab and Pembrolizumab for the treatment of advanced melanoma and 
non-small cell lung cancer have shown significant promise in the field of 
immuno-oncology and as such are beginning to change the landscape of 
available treatment strategies for advanced disease.329 As a result of these 
novel molecules, exploring combination strategies holds understandable 
appeal and as such the field of immuno-oncology continues to pursue the ideal 
combination to enhance patient outcomes. It is however, becoming apparent 
that this process is complicated with potential significant safety concerns 
associated with certain tested strategies. Pre-clinical testing of combined 
immune checkpoint blockade with a PD-1 inhibitor and CTLA-4 inhibitor for 
the treatment of various cancer types has demonstrated unprecedented 
efficacy, however is associated with a considerable toxic profile and high 
incidence of adverse drug reaction raising significant concerns about 
safety.330As such the challenges remain clear, and balancing improved 
treatment efficacy with toxicity is vital. Novel combination strategies clearly 
hold great promise, and as such the potential for immune checkpoint inhibitors 
- 191 - 
in combination with oncolytic virus provides an exciting avenue of further 
research. 
Whilst there continues to be significant focus on immune checkpoints other 
areas of development and research include small molecule agents that 
modulate the tumour immune microenvironment such as CSF1R, IDO1, A2AR 
and KIR, cell therapies that engineer immune cells such as T cells to directly 
attack cancer cells (e.g. anti-CD19 CAR-T) and cancer vaccines that induce 
antigen specific antitumour immunity (e.g. sipuleucel-T).331 Indeed the field is 
broad with currently 940 clinical-stage immuno-oncology agents including 
oncolytic viruses registered modulating 271 different targets.329  
Immunomodulatory targets continue to be approved as the standard of care 
for many advanced tumour types, however with such a crowded and diverse 
molecular profile available some authors have recently questioned the 
efficiency of resources available to test all these agents effectively. Indeed the 
therapeutic milieu available to scientists and clinicians has been reported to 
be overwhelming to even the most experienced investigators, with limited 
availability of patients to register for clinical trials and as such may be delaying 
future innovation and clinical development.331 Without doubt, progress 
continues to be rapid however the challenges remain multifaceted moving 
forward. Exploring combination strategies, controlling adverse effects and 
toxicity and targeting tumours that don’t respond as yet to immunotherapy all 
hold potential for future research. As an aside, there is increasing calls for the 
development of collaborative working practices within academic institutions, 
biotech companies and pharmaceutical organisations as a way of bringing 
promising cancer immunotherapies to patients, sooner rather than later which 
must be the goal of any research study within this field.  
In summary, it is evident from this work that both JX-594 and Reovirus hold 
promise as novel treatment modalities both as a monotherapy and in 
combination with adjuvant therapies. Both viruses tested can alter the 
phenotypic and functional aspects of NK cell activity via different mechanisms 
in the blood and lymph nodes. Moreover, direct tumour-specific lysis, 
transgene expression, the induction of tumour specific innate immunity and 
the potential to modulate other immunotherapies, means that these viruses 
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may be able to provide multi-faceted and selective targeted therapy against 
tumour at both primary and distant locations. 
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